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ABSTRACT
Epithelial cells interact w ith their surrounding extracellular m atrix via 
integrin receptors. Signals generated in  this way control epithelial cell 
m igration, proliferation and apoptosis. Changes in the extracellular m atrix, 
integrin expression and protease secretion occur in  w ound healing and cancer 
and thus these system s are thought to play a crucial role in  such processes. 
We hypothesise that the interactions betw een these key players affect 
epithelial cell behaviour. We have utilised a variety of epithelial cells 
including norm al prim ary cells and lines w ith m anipulated integrin 
expression to investigate this further.
Epithelial cells are commonly grown in  m edium  containing additives such as 
hydrocortisone, EGF, insulin and cholera toxin. W hen epithelial cell are 
cultured in  m edium  w ithout additives they adopt a more m esenchymal 
phenotype. This w as show n to be due to the absence of EGF which resulted 
in a dow n-regulation of the cell-cell adhesion molecule e-cadherin.
Experim ents w ere perform ed exam ining the interaction of epithelial cells w ith 
a variety of fibronectin fragments. The adhesion of norm al keratinocytes and 
cell lines expressing low (Cl) and high (VB6) levels of the 06 integrin subunit 
w as unaffected on the 120kDa fibronectin fragm ent w hen com pared to the 
full length molecule. M otility has been followed using w ound assays and
Transwell® m igration assays. The latter show ed th at m igration w as 
significantly increased on the 120kDa fragm ent but only in the VB6 cells. This 
m ay be achieved through the up-regulation of m atrix m etalloproteinase 9 
(MMP-9) which is increased in the supernatant from  VB6 cells plated on 
120kDa fragm ent In vitro this fragm ent can be generated by incubating full 
length fibronectin w ith purified MMP-9.
Imm unohistochem ical studies using oral squam ous cell carcinoma tissue 
indicate that these interactions m ay occur in vivo w ith fibronectin, (36 integrin 
and MMPs all being located at the invading tum our fro n t
We have thus identified an im portant feedback loop w here expression of the 
(36 integrin subunit which is only seen in w ound healing and cancer enhances 
the m otility of and MMP secretion by epithelial cells in  contact w ith the 
120kDa fibronectin fragm ent These enzym es can then further degrade 
fibronectin to generate additional fragm ents. If it were possible to distinguish 
this fragm ent from  the parent molecule im m unologically it could prove to be 
a valuable m arker of aggressive OSCC being indicative of a num ber of pro- 
tum ourigenic processes.
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CHAPTER 1
INTRODUCTION
1.1 STATEMENT OF THE PROBLEM
The environm ent that surrounds cells is altered in w ound healing and 
carcinogenesis resulting in  signals and cues that influence cellular behaviour 
such as gene expression and motility. These alterations may include the 
expression of new  extracellular m atrix (ECM) proteins and the m odification 
of those already p resen t This can occur by the action of proteolytic enzymes 
to produce bioactive fragments. In this way molecules that in other 
circumstances are inert and innocuous m ay present them selves as inducing a 
pathological phenotype.
Previous studies have been carried out on fragm ents of ECM molecules, but 
few if any have devoted their attention to fragm ents of fibronectin. Given the 
abundance of fibronectin in the ECM it is plausible that it may have an 
im portant role. Bioactive fragm ents of fibronectin may be crucial in the 
process of carcinogenesis by inducing expression of other molecules such as 
proteases and cell adhesion molecules. Detailed exam ination of the interplay 
between ECM fragm ents, their receptors (integrins) and m atrix m odifying 
proteases m ay identify common pathw ays which could provide novel ideas
for therapy or may help identify m arkers of aggressive disease. The challenge 
is to identify these key pathw ays in complex interactions that occur 
tem porally and spatially between num erous molecules and cells in vivo.
1.2 OVERVIEW
1.2.1 O ral Epithelium
The oral epithelium  is the tissue that covers the oral mucosa, underneath 
which is connective tissue (CT). Like other epithelia in  the body it is m ade up 
of a large num ber of cells, the keratinocytes, closely attached to one another to 
form  a continuous barrier. The prim ary function of oral keratinocytes reflects 
the function of the oral epithelium , that is, to provide a barrier betw een the 
outside environm ent and the deeper tissues. They therefore serve as 
protective and selective barriers through which certain substances may pass.
1.22 O ral Cancer
Oral squam ous cell carcinoma (OSCC) is the commonest of all head and neck 
tum ours accounting for over 90% of m outh malignancies, and is the sixth 
m ost common hum an m alignancy (De Vicente 2002). The 5-year survival rate 
for oral cancer is less than 50% and has not im proved in more than two 
decades (Lippman & Hong 2001). Carcinogenesis is a m ultistep process. There 
are three m ain sequential steps: initiation, prom otion and progression.
Clinically, norm al tissue first becomes hyperplastic, then dysplastic, followed 
by the form ation of a carcinoma in  situ, defined as a lesion that does no t 
extend beyond the basem ent membrane; subsequently it develops into an  
invasive carcinoma and finally m etastasizes to distant sites by way of blood 
or lym ph. A t a m olecular level, norm al cells first become precancerous, then 
undergo irreversible DNA changes (im m ortalization of cancer cells), and 
finally penetrate the basem ent membrane and spread. Tum our invasiveness is 
a distinct characteristic of tum our progression. Once the cells spread beyond 
the basem ent membrane, they form  an invasive front that interacts w ith the 
connective tissue beneath. Tum our cells characteristically exhibit altered cell- 
to-ECM interactions. They rem odel the ECM to facilitate cell m igration by 
increased and modified production of proteases or inhibition of control 
mechanisms. Of vital im portance to this m odel is the participation of a family 
of cell-adhesion molecules known as integiins, which link the cells to the 
molecules in  the ECM and provide com m unication channels. Changes in  their 
profile, localization and signalling is a tra it of cancer progression (Kassis et al.
2001).
1.3 THE EXTRACELLULAR MATRIX
The developm ent and function of oral keratinocytes, like all other cells in the 
body, depends on the interactions w ith molecules in their environment. The
I n t r o d u c t i o n
ECM not only provides mechanical support but also influences cell 
behaviour. M olecules that regulate cellular developm ent and function include 
grow th and differentiation factors, cell adhesion molecules and components 
of the ECM (Kreis & Vale 1993). D uring rem odelling, w hether physiologically 
or pathologically, new signals are generated betw een the cells and their 
environm ent, particularly the basem ent membranes (BM) (Ortega & W erb
2002).
1.3.1. The Basem ent M em brane
Oral keratinocytes rest on a thin m at of specialized ECM know n as basem ent 
mem brane (BM) that separates them  from  the underlying connective tissue 
(Raitz el al. 2003). The BM varies in  com position in  a tissue-specific way as 
well as during repair and developm ent The BM serves as a structural scaffold 
and certain components have been identified as regulators of biological 
activities such as cell growth, m igration and differentiation (Erickson & 
Couchm an 2000). Furtherm ore, it is able to determ ine cell polarity and 
influence cell m etabolism  (Erickson & Couchman 2000). Under the electron 
microscope it consists of two distinct layers; the lamina lucida directly beneath 
the keratinocytes, and the lamina densa just below this. In some cases a third 
layer m ay be found consisting prim arily of collagen fibrils adjacent to the CT, 
and this is know n as lamina fibroreticularis. The com position of the BM varies 
from  tissue to tissue bu t the constant com ponents are lam inins, entactin- 
1 /n idogen-l, type IV collagen and heparin sulphate proteoglycans (Erickson
& Couchm an 2000). Anchored to the underlying CT are type VII collagen 
fibrils (Alberts et al. 1994).
During tum ourigenesis the first barrier to be broken through is the BM. A 
prim ary neoplastic mass can not invade and m etastasize to d istant loci 
w ithout first penetrating the supporting BM. By com promising the division 
between epithelium  and connective tissue, the first sign of aggressiveness is 
established.
1.3.2 Extracellular M atrix Proteins
The extracellular m atrix is composed of a large num ber of molecules. The 
major com ponents include collagens, fibronectin, vitronectin and laminins. 
The signalling properties of the ECM depend on the organization of its 
constituent molecules (Lukashev & W erb 1998). The ECM is increasingly 
im plicated in malignancy via two mechanisms: enzymatic degradation, and 
the failure of cells to synthesize and assemble the m ain ECM com ponents 
(Raitz et al. 2003).
1.3.3 Extracellular M atrix Fragments
All the constituent proteins m aking up the extracellular m atrix can be 
degraded to sm aller fragm ents. This may be as part of a turnover process or 
may be a specific mechanism whereby smaller bioactive fragm ents are
__________________    Int roduct ion
generated that carry out distinct and precise functions dissim ilar from  the 
parent molecule (Yamada 2000).
1.3.3.1 Collagens and their fragments
Collagens are a large family of glycoproteins. M any forms are found 
throughout the tissues. Collagens type I and HI are the major interstitial, 
fibrillar collagens that are found in m ost connective tissues. Collagen types IV 
and VII are located in the BM. Extensive studies have been carried out on 
collagen fragm ents and their im plication in  both norm al physiological 
processes such as embryogenesis and w ound healing, and pathological 
processes such as carcinogenesis (O'Toole 2001; Ortega & W erb 2002) (Table 
1.1).
Collagen type I, II and HI, are triple helices m ade up  of polypeptide chains of 
about 95 kDa, which are quite resistant to degradation by m ost proteolytic 
enzymes except collagenases. These proteases belong to the m atrix 
m etalloproteinases (MMP) family and are able to cleave all three chains into 
fragm ents approxim ately 75% and 25% of the total length, a t specific sites 
between amino acid residues 775 and 776 (Stringa et al. 2000). All of these 
effects are thought to be m ediated via integrals (Pilcher et al. 1997; M essent et 
al. 1998; Stringa et al. 2000).
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Collagen IV, found in all basem ent membranes, regulates cell adhesion and 
m igration. The non-collagenous C-terminal fragm ent (NCI) of type IV 
collagen has been identified as a circulating fragm ent in serum. This fragm ent 
(also a by-product of collagen XV and XVTII degradation) is involved in  the 
regulation of angiogenesis and other m orphogenetic processes (Ortega & 
W erb 2002; Ham ano et al. 2003).
COLLAGENS 
Collagen I
Collagen U
Collagen IV
Collagen VU7 
Collagen XIV 
Collagen XV
Collagen XVIII
FRAGMENTS 
•Trimer Carboxyl 
Propeptide 
•Various fragments
•Various fragments
•C-propeptide or 
Chondrocakin 
•NCI and 7S domains 
•NCI domain 
•a l NCI, arresten 
•a2 NCI, canstatin 
•a3 NCI, turns ta tin 
•a6N C l
•NCI domain vastatin
• N-terminal fragment
•NCI
•Restin
•NCI
•Endostatin
BIOLOGICAL FUNCTIONS 
Chemotactic for endothelial cells
Chemotactic for dermal fibroblasts 
and peripheral monocytes 
Inhibit collagen synthesis and MMP 
secretion by chondrocytes.
Cartilage calcification
Inhibit morphogenesis
Promote axonal growth
Anti-angiogenic
Anti-angiogenic
Anti-angiogenic
Anti-angiogenic
Angiogenic
Chemotactic for neutrophils
AntHmgiogenc
Anti-angiogenic
Induce migration of neural and non- 
neural cells.
Anti-angiogenic, inhibit branching 
Morphogenesis
Table 1.1 Biological functions of various collagen fragments (Ortega & Werb 2002).
I n t r o d i u  turn
1.3.3.2 Laminins and their fragments
Laminins constitute a family of ECM molecules that are associated w ith BM. 
They have been found to affect adhesion, m igration, grow th and the 
differentiation of cells (Kreis & Vale 1993). Proteolytic degradation of 
Laminin-5 generates fragm ents of 160 kDa and 105 kDa that can influence cell 
adhesion and m igration. Such fragm ents have been detected in hum an 
fibrosarcomas, rodent skin carcinoma (Gilles et al. 2001; Hirosaki et al. 2002), 
rem odelling mam m ary glands and epithelial neoplasia (Koshikawa et al. 
2000).
1.4 F1BRONECTINS
Fibronectins (FN) are glycoproteins of high m olecular w eight found in m any 
extracellular matrices and in blood plasm a. FN can be divided into soluble 
plasm a FN (pFN) and insoluble cellular FN (cFN). Plasma FN is m ainly 
synthesized in the liver by hepatocytes whereas cFN is synthesized locally by 
cells in the ECM. Cellular FN consists of a larger and more heterogeneous 
group of FN isoforms that are both cell-type-specific and species-specific 
(Pankov & Yamada 2002). FN can influence cell adhesion, m orphology, 
m igration, differentiation and cytoskeletal organization (M agnusson & 
M osher 1998). Fibronectin is especially abundant in die ECM of embryonic 
and regenerating or injured tissues, although it can be found in m ost ECM,
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including basem ent membranes. It interacts w ith cells through integrins 
linking the ECM to the intracellular cytoskeleton and signalling pathw ays 
(M agnusson & M osher 1998).
1.4.1 Structure
FN exists as a soluble protom eric form  in m icrom olar concentrations in  blood 
plasm a and as an insoluble m ultim eric form  in  the ECM (Kreis & Vale 1993). 
Soluble FN is a dim eric glycoprotein of two nearly identical 210-250kDa 
subunits linked covalently near their C-term inus by a pair of disulfide bonds 
(Pankov & Yamada 2002) (Figure 1.1). Each subunit of the FN molecule is 
m ade up  of a series of repeating units which in tu rn  form  structural and 
functional dom ains which m ediate binding to cell surface receptors or other 
ECM molecules. The different FN isoforms arise by alternative splicing of the 
transcript of a single gene (M agnusson & M osher 1998).
Each FN subunit is m ade up of three types of repeating m odules, type I, type 
II and type HL There are 12 type I m odules (each around 40-45 amino acids 
long, clustered in 3 groups), 2 type II m odules (each 60 amino acids long) and 
15-17 type HI m odules depending on the splicing (about 90 amino adds long). 
Furtherm ore, there is a variable (V or IIICS) sequence that is not homologous 
to other parts of FN. Type I and II m odules each contain the 2 disulphide 
bonds and together account for approxim ately 90% of the FN sequence 
(Pankov & Yamada 2002).
C O O H
Fibrin/
Heparin
Collagen/
Gelatin
Disulphide bonds
RGD Heparin Fibrin
O O H
11-15 19-mi IU8-UI10
Fibrin/ Gelatin/
heparin collagen integrin heparin
I |-----------------------1 I-------- 1 l--------------1
COOH
SS
 "-------- '■______________ i I I
29kDa 45kDa FNfrg 120kDa FN frg
FN frg °
B
0 Type I module
0 Type II module
0 Type III module
□ Variable sequence
Figure 1.1 Dimeric structure of FN (A). Structure of the fragments (B).
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There are 2 cysteines per subun it The 2 FN type ID m odules that are subject 
to alternative slicing are called extradom ain A (ED-A) and extradom ain B 
(ED-B). Plasma FN synthesized in  the liver by hepatocytes contains neither 
ED-A nor ED-B and only one of the subunits contains the V region. On the 
other hand, cellular FN which is synthesized locally in the tissues contains 
variable am ounts of either or both ED-A and ED-B and alm ost all the subunits 
contain the V region (Kreis & Vale 1993; M agnusson & M osher 1998). FNs 
may contain 4-9% carbohydrates depending on the cell source. Glycosylation 
sites are either N-linked or O-linked and reside in  type HI repeats and the 
collagen-binding domain. Such glycosylation appears to stabilise FN against 
hydrolysis and m ay alter its affinity to different substrates.
Circulating soluble FN is relatively unreactive w ith surrounding cells. As it is 
deposited, conform ational changes in the molecule support cell attachm ent, 
spreading and the form ation of m any focal contacts w ith the cells. This 
increased adhesiveness is known as "surface activation of pFN" and can be 
explained by the increased availability of the RGD-containing 10th Type ID 
repeat (Ugarova et al. 1995).
1.4.2 Fibronectin variants
A lternative splicing in three different regions, EDA, EDB and V give rise to up 
to 20 different mRNA in a cell-specific m anner (Srebrow et al. 2002). The m ain 
type of splicing occurs in  the central portion of repeat HL The exon is either
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used or skipped leading to the inclusion or exclusion of 2 type HI repeats, 
EDB betw een repeats III7 -Ills, and EDA between repeats III11-III12- This type 
of ED splicing is found in m any vertebrates including hum an. A second type 
of splicing involves the V or IIICS region. The structural variations in this 
region are m ore complex and species dependent In general, this region can be 
either partially or completely included or excluded. In hum an FN there can be 
five different V region variants. A third  type of splicing is found in cartilage 
w here the whole V region and the FN III15 and FN I10 repeats are missing 
(Pankov & Yamada 2002).
Such changes in alternative splicing of the mRNAs occur as a result of 
stim ulation by grow th factors, cytokines, hormones and stress stimuli. Cell- 
ECM interactions initiate a dynamic flow of inform ation that regulates m any 
im portant processes throughout developm ent Among them  is cell m igration 
during embryogenesis, morphogenesis during organ form ation, and the 
m odulation of grow th, survival and differentiation of m any specialized cell 
types (Srebrow et al. 2002).
Both EDA and EDB-containing FNs are expressed predom inantly during 
embryogenesis. Their expression is also increased during w ound healing. 
EDA-containing FN has been associated w ith the regulation of cell adhesion, 
proliferation and differentiation. EDB-containing FN seems to have a role in 
angiogenesis (Liao et al. 2002). A study on epithelial cells showed that
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m igrating cells change the type of FN secreted to an EDA-containing FN 
despite producing lesser am ounts. This clearly shows that in many cases the 
characteristics of the FN m ay be a stronger stim ulus than the am ount 
produced (Inoue et al. 2001).
1.4.3 Fibronectin receptors
One of the m ost im portant families of proteins that bind to FN are the 
integrins which m ediate cell-to-FN binding and serve to trigger function- 
specific intra-cellular pathw ays. A large num ber of integrin heterodim ers 
bind to FN including the classic FN receptor a5 p i integrin. FN has several 
integrin-recognition sequences, the best know n of which is the RGD sequence 
in fflio (Pankov & Yamada 2002). RGD peptides can compete w ith this 
binding and block integrin-m ediated cell adhesion to FN (M agnusson & 
M osher 1998). RGD sequences occur in other molecules such as vitronectin, 
tenascin and TGF-p latency-associated-peptide (LAP) and these also m ediate 
adhesions to integrin receptors (Thomas et al. 2002). Integrins that bind to this 
region include a5 p i, a3p l, av p l, avp3 and avp6. The binding of a5 p l to FN 
is synergized by m odules 1118-1119, specifically the Pro-His-Ser-Arg-Asn 
(PHSRN) synergy sequence in III9 (Pankov & Yamada 2002). Binding to the 
a5p i integrin can also occur a t the N -term inal region containing repeats I1-9 
and IIi^. This region can trigger intra-cellular signals different from those 
triggered by the interaction w ith the RGD sequence (Akiyama & Yamada 
1995).
Several sites from  the COOH-terminal to the RGD sequence interact w ith the 
cell surface. This region, known as the heparin-binding dom ain (HBD, III12-14) 
can attach to heparin sulphate proteoglycans and chondroitin sulphate 
proteoglycans. The III14 also has a low affinity for the a4 p l integrin. Further 
towards the COOH-terminal from  the HBD, along the alternatively spliced 
IIICS or V region are the a4 p i binding sites CS-1 and CS-5, of which the CS-1 
has the higher affinity. This site is also recognized by the a4p7 integrin 
(H uhtala et al. 1995).
There are other cell-recognition sequences along the FN molecule known as 
LDV and REDV that bind to the a4 p l and a4p7 integrins. They are found on 
the alternatively spliced V region. The a4 p i integrin, as w ell as the a9 p i have 
been identified to bind to the EDA segm ent of FN. Since this segment of FN is 
alternatively spliced, it generates a novel m otif for a9 p l (which finds no other 
binding site on the molecule) and an additional site for a4 p i (Liao et al. 2002; 
Pankov & Yamada 2002).
FN has m any other adhesive sites for various substances including fibrin, 
heparin, collagen/ gelatin which make it an im portant molecule not only in 
cell-ECM binding (Akiyama & Yamada 1995). Two major heparin-binding 
sites are H eparin II, which has high affinity and is located at the C-terminus, 
and H eparin I, w ith weaker affinity located a t the N-term inus. H eparin II 
binds to chondroitin sulphate and H eparin I contains a staphylococcus-
aureus-binding dom ain which enables this molecule to interact w ith bacteria. 
A recently described dom ain in  the V region which binds to 
glycosaminoglycans (named "H eparin" at the V-region) may potentiate cell 
adhesion (Pankov & Yamada 2002).
The collagen binding dom ains in FN are located at repeats h - 9  and IIi^. As it 
binds more effectively to denatured collagen (gelatin) it is thought to be 
im portant in  the interaction w ith denatured collagenous m aterials from  blood 
than to m ediating cell adhesion to collagen (Pankov & Yamada 2002). Fibrin I 
and Fibrin II are the major fibrin-binding sites in  FN located at the N- 
term inus. This interaction w ith fibrin is im portant in  the clotting mechanism 
of blood (Pankov & Yamada 2002).
1.4.4 Fibronectin m atrix assem bly
FN m atrices are deposited both spatially and tem porally in  a defined pattern 
utilising both the soluble and insoluble FNs. This assembly occurs in cell- 
m ediated co-ordinated steps, the first of which is the binding of FN to the cell 
surface via the interaction w ith the N -term inus 70 kDa region of the molecule. 
This cell-bound FN is converted into a stable m ultim er by the form ation of 
disulphide bonds as the FN molecules interact (Hocking et al. 2000). In 
addition, the NH2-term inal 29-kDa dom ain is required for assembly of a 
fibrillar FN matrix. It has fibrin- and weak heparin-binding activities and 
binds weakly to the cell surface (Huhtala et al. 1995).
Integrins and LAMMs (molecules of large apparent molecular mass) are 
integral to FN m atrix assembly (M agnusson & M osher 1998). Most of the 
binding activity that directs FN to assembly is in  the 70-kDa region of FN. The 
specific integrins required in m atrix assembly is dependent on the substrate to 
which assembly cells are adherent to. The m ain integrin responsible for 
m atrix assembly is a5 p l although other FN binding integrins can initiate the 
process, including avfB which recognises the 10* type HI m odule, and a3p l 
integrin which acts indirectly by binding first to entactin which then binds to 
FN (Wu et al. 1995; M agnusson & M osher 1998).
Ligation of integrins on the cell surface to the ECM induces the clustering of 
actin and actin-binding proteins to focal adhesions and mechanically couples 
the ECM w ith the actin cytoskeleton. FN polym erization is thus critical in 
triggering cytoskeletal tension generation necessary for cell contractility 
(Hocking et al. 2000).
1.4.5 Fibronectin fragm ents
Soluble FN in its compact conformation reacts poorly w ith cells. However, 
proteolysis reveals adhesive properties that are latent in the intact molecule 
(Ugarova et al. 1995). This occurs by the exposure of various biologically 
active dom ains that are sterically hindered in the intact molecule. Fibronectin 
may exist as a variety of m olecular w eight fragm ents in the ECM, many 
possessing differing bioactivities. Elevated levels of FN fragm ents have been
found in various pathological conditions such as in the synovial fluids of 
arthritic patients and in gingival crevicular fluid in patients w ith periodontitis 
(Kapila et al. 19%; H uynh et al. 2002; Gemba et al. 2002). W hen found as 
peptides, the cell-binding sites of FN can function in  several different ways: 
(a) they may mimic the intact molecule, (b) they may act as a competitive 
inhibitor, (c) they may augm ent integrin signalling and activate cell-to-cell 
adhesiveness in  certain cell types. Bearing this in  m ind, some fragm ents may 
be utilised in  tissue engineering and w ound repair or alternatively may be 
used to inhibit unw anted effects such as tum our cell invasion and m etastasis 
(Kapila et al. 19%; H uynh et al. 2002).
1.4.5.1 Cell-binding fragment
The 120kDa FN fragm ent contains the cell-binding region of FN (RGD). This 
region has shown to bind to the a5 p i integrin, and also to the a3 p l integrin. 
Such fragm ent is formed in vivo by the action of proteases and is 
m anufactured commercially by the action of chym otrypsin (Akiyama & 
Yamada 1995). An im portant observation was m ade w hen com paring the 
effect of pre-incubating the cells w ith anti-a5pi and -a 3 p l antibodies as 
opposed to adding them  to the cells after they are exposed to them. It was 
shown that pre-incubating the cells yielded the desired inhibitory effect 
whereas adding the antibodies after the cells were exposed to the fragm ents 
had little or no effect This may be explained by the fact that once the cells are
exposed to the fragm ents the binding sites are fully occupied leaving no 
opportunity for antibodies to bind (Livant et al. 2000).
It has been shown that the 120kDa fragm ent elicits different responses 
compared to the intact molecule. These include increased expression of 
collagenase, strom elysin and the serine protease urokinase in  hum an 
periodontal ligam ent cells (Kapila et al. 19%), and increased collagenase, 
stromelysin-1 and gelatinase expression in  rabbit synovial fibroblasts 
(H uhtala et al. 1995). O ther studies have show n that this cell-binding fragm ent 
increased the release of pro-stromelysin-1 and the release of urokinase-type 
plasm inogen activator (uPA) but not the tissue-type (tPA) in  cultures of 
bovine chondrocytes (Xie et al. 1994; Bewsey et al. 19%). In mammary 
epithelial cell lines the 120kDa FN fragm ent reduced cell num bers and 
induced apoptosis and matrix degrading protease activity (Schedin et al. 
2000). In w ound healing studies the cell-binding fragm ent stim ulated 
monocytes and fibroblast chemotaxis through the dermis, increased the 
release of MMPs by fibroblasts and stim ulated monocyte differentiation into 
inflam m atory m acrophages (Livant et al. 2000) (Table 1.2).
1.4.5.2 Amino-terminal fragment
The 29kDa am ino-term inal heparin-binding FN fragm ent has been found to 
possess potent chondrolytic effects and may be im plicated in  the cartilage 
degradation of arthritis. In cartilage explant cultures it was found to elevate
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MMP production, enhance rates of proteoglycan loss and suppress 
proteoglycan synthesis (Gemba et al. 2002). In cultured hum an articular 
cartilage it was also found to increase levels of tum our necrosis factor-a, 
interleukin-1 p (IL-lp) and IL l-a (Gemba et al. 2002). It has also been 
im plicated in prom oting cell m otility in soft tissue sarcomas (Liu et al. 1998) 
(Table 1.2).
The influence of a num ber of FN fragm ents including the 29kDa, the 50kDa 
gelatin-binding, the 140kDa integrin-binding fragm ent and the 35kDa 
carboxyl-terminal heparin-binding fragm ent on the release of prostaglandins 
(PG) in the synovial fluid of osteoarthritis (OA) and rheum atoid arthritis (RA) 
has been studied. Specific fragm ent combinations resulted in up  to 23-fold 
increase in  PG release (Homandberg et al. 1992). This 29kDa amino term inal 
fragm ent may work in synergy, w ith combinations producing increased 
response as com pared to individual fragm ents (Hom andberg et al. 1992).
1.4.5.3 PHSRN peptide
This peptide sequence found on repeat III9 prom otes specific a5p l integrin 
binding to FN and is therefore also known as the "synergy site" (Yamada 
2000; Pankov & Yamada 2002). In a study using sea urchins as in  vitro 
invasion substrates, the PHSRN sequence of pFN was found to stim ulate 
ECM invasion by both keratinocytes and fibroblasts (Table 1.2). This peptide, 
in an acetylated and am idated form  was show n in  this study to be more
potent than its non-acetylated counterpart and the 120kDa cell-binding FN 
fragm ent The presence of this peptide in  solution has also been shown to 
stim ulate dissociation of adherent cells from  the substratum  (Livant et al. 
2000; Yamada 2000).
1.4.5.4 EDA and EDB fragments
Previous studies indicate that the presence of EDB dom ain in  certain cell- 
binding FN fragm ents may increase cell spreading and adhesion. This was 
not observed w ith the EDB fragm ent alone suggesting that it either simply 
provides an additional integrin binding site, or that w hen present, it generates 
conform ational modifications in the other domains possibly im proving access 
to integrin-binding sites (Hashimoto-Uoshima et al. 1997) (Table 1.2). O ther 
groups have attributed this same synergistic property to the EDA dom ain 
(Chen & Culp 19%).
FRAGMENT SIZE
Cell-binding 120kDa
fragment:
Ammo-terminal 29kDa 
fragment
PHSRN synergy Peptide 
sequence:
EDA/EDB domains: Peptides
EFFECT
• |  collagenases, stromelysin and
PA production by human periodontal 
ligament cells (Kapila et al. 19%).
• |  collagenases, stromelysin-1 and 
gelatinases by rabbit synovial fibroblasts 
(Huhtala et al. 1995).
• t release of pro-stromelysin-1 and uPA in 
cultures of bovine chondrocytes (Xie et al. 1994;
Bewsey et al. 19%).
• f matrix degrading proteins and 
reduction in apoptosis in mammary 
epithelial cells (Schedin et al. 2000).
• Stimulation of monocyte and fibroblast 
chemotaxis, increased MMP release by 
fibroblasts and stimulation of monocyte 
differentiation in wounds (livant et al. 2000).
• t MMP production, increased 
proteoglycans loss and suppression of 
proteoglycans synthesis by chondrocytes 
in arthritic patients (Gemba et al. 2002).
• t  levels of tumour necrosis factor-a, 
interieukin-lp (IL-ip) and ILl-a in human 
articular cartilage (Gemba et al. 2002).
• t cell motility in soft tissue sarcomas (Liu e al. 1998).
• Promotion of a5pi binding to RGD 
(Yamada 2000; Pankov & Yamada 2002).
• Stimulation of ECM invasion by keratino­
cytes and fibroblasts (Livant et al. 2000; Yamada 2000).
• t  cell spreading and adhesion
(Chen & Culp 19%; Hashimoto-Uoshima et al. 1997).
Table 1.2 Various FN fragments and their effects.
1.5 CELL-ADHESION MOLECULES
The structure and organization of body tissues is dependent on preservation 
of contact between cells and their neighbours and between cells and the ECM 
(Garrod 1993; Pignatelli 1998). Adhesion molecules are responsible for cell 
stability, and contribute to their m orphology, differentiation, m otility and 
internal signalling (Eversole 1996). There are four know n families of cell- 
adhesion molecules: the cadherins, the im m unoglobulin superfam ily, 
integrins and selectins (Garrod 1993). Mouse knock-out experim ents have 
confirmed the necessity for cadherins and integrins in  stable cell-cell and cell- 
m atrix adhesion (Pignatelli 1998).
1.5.1 Cadherins
Cadherins are calcium -dependent cell adhesion molecules responsible for 
cell-to-cell adhesion (Pecina-Slaus 2003). They play a key role in calcium- 
dependent cell-cell interactions and act not only to establish tight cell-cell 
adhesion but also to define adhesive properties of cells (Wheelock & Johnson 
2003). Cadherins constitute a large family of transm em brane glycoproteins 
that can be divided into subfamilies based on molecular features (Alberts et al. 
1994; W heelock & Johnson 2003). The classical cadherins expressed by 
keratinocytes are E- and P-cadherins (Bagutti et al. 1998). P-cadherin, along 
w ith integrins is expressed predom inantly in the basal layer of stratified 
epithelium , while E-cadherin is expressed in all living cell layers (Bagutti et al.
1998). During developm ent the expression of each subtype is 
spatiotem porally regulated so as to be correlated w ith m orphogenetic events 
dining cell adhesion processes. They are therefore im portant in cell 
recognition, adhesion, sorting and signalling. D isruption of cadherin function 
has serious and significant im plications in  disease conditions including cancer 
(Wheelock & Johnson 2003).
The epithelial cadherin E-cadherin (also known as uvom orulin) appears very 
early in  developm ent and is die best characterized cadherin (Garrod 1993). E- 
cadherins may be found clustered in continuous adhesion belts, known as 
zonulae adherens, which encircle the cell apicolaterally. Such adhesion belts 
are held together by interacting extra-cellular dom ains of E-cadherins. E- 
cadherins m ay also be found grouped in desmosomes, buttonlike points of 
intercellular contacts (Alberts et al. 1994). Cadherins bind by a homophilic 
mechanism, where a cadherin molecule on one cell binds to a cadherin 
molecule on another (Garrod 1993). Recently however, E-cadherin has also 
shown to be a ligand for two integrins, aEp7 and a2pi; the form er is 
im portant in the retention of intraepithelial lymphocytes in mucosal tissue 
while the latter helps contribute to the organization of epithelial m ultilayers 
(Pecina-Slaus 2003).
1.5.1.1 Structure o f E-cadherin
Cadherins constitute a large family of transm em brane glycoproteins 
composed of about 700-750 amino ad d  residues (Alberts et al. 1994; Wheelock 
& Johnson 2003). Proteins are considered members of the cadherin family if 
they have one or more cadherin repeats; these repeats are independently 
folding conserved sequences of approxim ately 110 amino ad d s (Behrens 1999; 
Pedna-Slaus 2003; Wheelock & Johnson 2003). C aldum  is essential for the 
optim al adhesive function of E-cadherins and their protection against 
protease digestion. The caldum  ions bind to specific residues in each cadherin 
repeat to w arrant its proper folding and to give rigidity upon the extracellular 
dom ain (Guilford 1999; Wheelock & Johnson 2003). The intracellular dom ain 
of the molecule is linked to the cell cytoskeleton via the intracellular 
attachm ent proteins a-, either (3- or y- catenins, vinculin, a-actinin and 
plakoglobin (Garrod 1993; Pignatelli 1998; Pecina-Slaus 2003) (Figure 1.2). 
Beta and y- catenins share homology and bind to a specific dom ain at the E- 
cadherin C-terminus; the a-catenins then links the bound (3- or y-catenin to 
the actin cytoskeleton (Guilford 1999; Pedna-Slaus 2003). In this way, an 
extensive trancellular netw ork is formed (Alberts et al. 1994). In the absence of 
catenins, cadherins are unable to function (Garrod 1993; Alberts et al. 1994).
1.5.1.2 E-Cadkerin and tissue development
During embryogenesis, tissues require the coordination of cellular processes, 
including polarization, adhesion, aggregation, segregation, differentiation
and m igration (Pignatelli 1998; Guilford 1999; Pecina-Slaus 2003; Wheelock & 
Johnson 2003). The expression of specific adhesion proteins is vital not only to 
normal developm ent but also for the m aintenance of norm al tissue structure 
and integrity (Guilford 1999; Wheelock & Johnson 2003). Different cadherin 
family members are expressed in specific spatiotem poral patterns during 
developm ent and are im portant regulators of m orphogenesis and tissue 
form ation (Behrens 1999; Wheelock & Johnson 2003).
The establishm ent of cellular polarity occurs in the earliest stages of 
developm ent and is m ediated by E-cadherin. Furtherm ore, E-cadherin 
constitutes a major cellular adhesion/ recognition system  that grants cells the 
ability to sort from  one another. W hen a group of cells separates from an 
existing cell layer the segregating cells express qualitatively or quantitatively 
altered sets of cadherins. This may then turn  off or on some cadherin genes 
(Wheelock & Johnson 2003). Such gene silencing in E-cadherin expression has 
been associated w ith hyperm ethylation of the CpG islands, found in prom oter 
regions of regulatory genes in both breast and prostate carcinomas (Graff et al. 
1995; Auerkari 2005).
1.5.13 E-cadherin in cancer
Decreased expression of E-cadherin is seen as one of the m ain molecular 
events involved in  cell-cell adhesion system dysfunction, triggering cancer 
invasion and m etastasis (Pecina-Slaus 2003). M any studies have shown E-
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Figure 1.2 The structure of cadherins (taken after Alberts et al. 1994).
cadherin to be a tum our suppressor molecule (Pecina-Slaus 2003; Wheelock & 
Johnson 2003) and its dow nregulation was found to correlate w ith poor 
prognosis (Guilford 1999; Q uaranta 2002). Both in vitro and in vivo studies 
have shown that by inhibiting E-cadherin activity w ith function-perturbing 
antibodies norm al epithelial cells were changed into invasive ones (Guilford 
1999; Wheelock & Johnson 2003). Conversely, invasive E-cadherin negative 
carcinoma cells were converted to non-invasive cells by exogenous expression 
of E-cadherin (Wheelock & Johnson 2003). As epithelial cells progress through 
the process of carcinogenesis, they change from  an epithelial to a 
mesenchymal phenotype exhibiting a more m otile and dynamic character. A 
hallm ark of such transition is the decreased expression of E-cadherin (Behrens 
1999; W heelock & Johnson 2003).
The dow nregulation of E-cadherin can occur via gene m utation; however the 
majority of carcinomas lack such m utation. Since by immunohistochemical 
studies there is apparent loss of E-cadherin in  m ost tum ours, it seems that 
tum our cells m ust downregulate the activity of E-cadherin in order to invade 
the surrounding tissues (Behrens 1999; Wheelock & Johnson 2003) (Figure 
1.3). This mechanism of gene silencing has been docum ented (as already 
m entioned) and therefore such loss of E-cadherin does not necessarily involve 
irreversible genetic alteration (Auerkari 2005; Graff et al. 1995).
Figure 1.3 E-cadherin expression in normal and malignant oral epithelium. Cells 
exhibit continuous E-cadherin expression in normal epithelium (A). Epithelial tumour 
nests showing areas of discontinued E-cadherin expression (short arrows) and areas of 
persistent E-cadherin expression (longer arrow) denoting some down-regulation of 
this cell-adhesion molecules in carcinomas (B) (Bagutti et al. 1998).
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Alternatively, E-cadherin function can be disrupted by upsetting the
connection between the cadherin and the cytoskeleton. For example,
m utations in p-catenin disturb the binding to a-catenin resulting in a non­
adhesive phenotype. M utations in the gene that encodes a-catenin inactivate 
E-cadherin function by not allowing the cadherin complex to associate w ith 
the cytoskeleton (Wheelock & Johnson 2003).
Some studies have dem onstrated the reappearance of E-cadherin expression 
in m etastatic cells. Such reestablishm ent of cellular contact may prevent 
apoptosis and enhance tum our cell adhesion at the m etastatic site (Guilford 
1999) therefore guaranteeing the tum our's im m ortality (Pecina-Slaus 2003).
1.5.2 Integrins
Integrins are one of the largest families of cell-adhesion molecules providing 
attachm ent between the cell and the surrounding ECM. They are 
transm em brane proteins that connect the ECM to the cell's cortical
cytoskeleton and trigger num erous intra-cellular pathw ays (Alberts et al.
1994). They m ediate cell adhesion, spreading, migration, proliferation and 
differentiation (Alberts et al. 1994; Hynes 2002). It has been shown that the 
composition and organization of the ECM can regulate die expression of 
genes and this is thought to occur through integrin engagem ent (H uhtala et al. 
1995; Aplin et al. 1998). Integrin expression is altered in tum ours and
expression varies both between different tum ours and in different regions in 
the same tum our (Bagutti et al. 1998).
1.5.2.1 Structure and function
Integrins are heterodim ers m ade up  of two noncovalently associated 
transm em brane glycoprotein subunits called a  and p, both of which 
contribute to the binding of the m atrix protein (Thomas et al. 1997; Aplin et al. 
1998; Giancotti & Rouslahti 1999). Both subunits consist of a large extra­
cellular domain, a transm em brane dom ain and a short cytoplasmic domain 
(Thomas et al. 1997). The a  chain contains several cation binding regions and 
is usually quite long varying between 120-180kDa (Hynes 1992) (Figure 1.4). 
The binding of integrins to their ligands depends on extracellular divalent 
cations, some requiring Mg++ and others requiring Ca++ (Alberts et al. 1994; 
Thomas et al. 1997). All integrins except a6p4 integrin bind to the actin-based 
m icrofilament system (Hynes 2002). The cytoplasmic tail of the p subunit 
binds intracellularly to both talin and a-actinin and in so doing initiates the 
assembly of a complex of intracellular attachm ent proteins that link the 
integrin to actin filaments in the cell cortex. If the p-chain were missing, the 
integrin w ould be able to retain some ability to bind to the ECM but w ould 
loose its ability to trigger cellular responses (Hynes 2002). This 
communication is bi-directional; the ECM binding may influence the 
organization of the cell's cytoskeleton and the cell's cytoskeleton may in turn  
influence die orientation of secreted ECM proteins (Alberts et al. 1994). The p4
subunit differs from the others in the size of the cytoplasmic domain; being 
much larger it interacts w ith the interm ediate filam ents instead of actin 
(Hynes 2002).
To date 8-p and 18-a subunits have been described combining to form 25 
distinct integrins (Hynes 2002) (Figure 1.5). Integrins recognize short peptide 
motifs, such as RGD on ECM proteins. Some integrins bind to just one 
substrate and others have the ability to bind to several. Furtherm ore, integrin 
receptors often exhibit overlap in their ligand-binding specificity (Aplin et al. 
1998; Boudreau & Jones 1999).
1.5.2.2 Integrin activation
Most integrins are not constantly active; they can be expressed on cell surfaces 
in an inactive state in which they do not bind to ECM ligands or generate an 
intracellular signal (for example integrins on cell surfaces of circulating 
platelets and w hite cells) (Hynes 2002). But such tight regulation is not 
exclusive to blood cells; integrin activation is essential for normal 
developm ent during processes such as cell m igration, proliferation and ECM 
assembly (Calderwood 2004). Many cells may regulate integrin activity in a 
tem poral and spatial fashion (Hynes 2002).
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Figure 1.4 Structure of integrins (taken after Alberts et al. 1994).
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Integrin activation is achieved by rapid, reversible changes in the 
conformation of the extracellular dom ains of the integrin structure 
(Calderwood 2004). M embrane-proximal regions of both a  and (3 tails contain 
a much conserved sequence, the deletion of which leads to integrin activation. 
Furthermore, deletion of both a  and p membrane-proximal regions also leads 
to integrin activation (Calderwood 2004).
1.5.2.3 Integrin signalling
Integrins act as integrators of the ECM and cytoskeleton of cells (Boudreau & 
Jones 1999); as they bind to the ECM they cluster in a site on the cell 
membrane and associate w ith cytoskeletal and signalling complexes that 
enhance the assembly of actin filaments or keratin filam ents and their 
associated proteins namely vinculin, talin, paxillin, a-actinin and tensin 
(Aplin et al. 1998; Boudreau & Jones 1999). This causes the reorganization of 
actin filam ents into large stress fibres which in tu rn  causes more integrin 
clustering (Figure 1.6). Integrins transduce signals and activate a num ber of 
signalling pathw ays including the non-receptor protein tyrosine kinase (PTK), 
m itogen-activated protein kinase (MAPK), Rho family of small guanine 
nucleotide binding proteins and protein kinase C (PKQ (Boudreau & Jones 
1999; Giancotti & Ruoslahti 1999). Such signalling pathw ays then lead to 
alterations in  cell shape, gene expression and cell behaviour (Boudreau & 
Jones 1999).
Focal Adhesion Kinase (FAK) is a member of the PTK family and is found to 
co-localize w ith ECM-bound integrins to induce integrin clustering(Aplin et 
al. 1998; Giancotti & Rouslahti 1999) (Figure 1.6). It plays a critical role in 
integrin-m ediated signalling and is a common theme in m ultiple signal 
transduction pathways (Aplin et al. 1998). FAK tyrosine phosphorylation in 
reaction to cellular adhesion to ECM proteins has been shown in a variety of 
cells (Aplin et al. 1998). It interacts directly or through the cytoskeletal 
proteins talin and paxillin w ith the cytoplasmic tail of the integrin P subunit 
(Giancotti & Ruoslahti 1999). In addition to integrin-m ediated events, FAK 
tyrosine phosphorylation is increased through non-integrin cell surface 
receptors including growth factor receptor tyrosine kinases and G-protein- 
coupled receptors (Aplin et al. 1998).
Activation of FAK is achieved w hen the Tyr-397 site is exposed to 
phosphorylation and this happens during the association of the N -term inal 
end of FAK w ith the tail of the p subunit of the integrins (Schlaepfer & H unter
1998). FAK is unable to phosphorylate other substrates directly but integrin- 
induced autophosphorylation of FAK enables it to interact with 
docking/ adaptor proteins such as paxillin, tensin, G rb2/Son of Sevenless 
(SOS) which in turn  activate downstream  signalling m ediators including Src, 
Ras and Raf (Aplin et al. 1998; Schlaepfer & H unter 1998; Boudreau & Jones
1999) (Figure 1.7). Generally, FAK activation is associated w ith signals that 
regulate growth, cell transform ation and suppression of apoptosis
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Figure 1.6 Matrix binding advocates integrin clustering and association with the 
cytoskeleton (taken after Giancotti & Ruoslahti 1999). As integrins cluster in response 
to interactions with the ECM, FAK is recruited and signalling is initiated via the 
actin cytoskeleton.
(Aplin et al. 1998; Boudreau & Jones 1999). There is a lot of evidence to 
suggest the convergence of integrin and grow th factor signalling pathways at 
the level of FAK (Boudreau & Jones 1999) seen by the recruitm ent of growth 
factor receptors into the focal adhesion complexes. A lternative to activating 
FAK some p i and av integrins also activate the tyrosine kinase Fyn and 
through it the adapter protein She. In this pathway, rather than acting 
through talin and paxillin, caveolin-1 seems to function as a membrane 
adapter coupling die integrin a  subunit to Fyn. It is probable that both FAK 
and She contribute to the activation of the Ras-extracellular signal-regulated 
kinase (ERK) MAPK cascade w hen Shc-linked integrins bind to the ECM 
(Giancotti & Ruoslahti 1999).
MAP kinases act as convergence point for various receptor-initiated growth- 
signalling events initiated at the plasm a membrane (Ahmed et al 2002). 
Extracellular signal-regulated kinases (ERKs) include a sub-family of MAPs. 
MAPK can be activated by FAK indirectly w hen the C-terminal of the FAK 
molecule causes the Grb2 adaptor protein recruitm ent which then directly 
activates ERK2/MAPK pathw ay (Schlaepfer & H unter 1998; Li et al. 2003). 
During this process, engagem ent of integrins by ECM induces FAK 
autophosphorylation which then leads to FAK association w ith and tyrosine 
phosphorylation by Src (Aplin et al. 1998). Scr-mediated phosphorylation of 
FAK encourages the direct binding of Grb2 adapter protein to Tyr925 of FAK. 
This may also prom ote the form ation of a FAK-Grb2/Shc complex which is
independent of Tyr925 phosphorylation. However, both mechanisms result in 
the recruitm ent of SOS to the juxtamembrane complex and the subsequent 
activation of Ras which then activates Raf (Aplin et al. 1998). Integrin- 
activated ERK translocates to the nucleus and activates transcription factors 
such as Elkl and c-Myc. This activation induces gene-related responses to 
ECM adhesion binding. Such integrin-m ediated signalling acts in synergy 
w ith growth factor signalling in m ediating DNA changes at the level of MAP 
kinases (Schlaepfer & H unter 1998).
Which of the pathways predom inates in contribution depends on cell type 
and maybe on how far the adhesion process has progressed. In many cell 
types She seems to be in charge of the initial high-level activation of ERK 
upon cell adhesion. The more slowly activated FAK may then sustain ERK 
activation (Giancotti & Ruoslahti 1999).
Many integrin-stim ulated intracellular signalling pathw ays are similar to 
those triggered by growth factor receptors and are very closely coupled w ith 
them  Integrin aggregation and association w ith the cytoskeleton appear to 
give rise to integrin-grow th factor receptor complexes (Giancotti & Ruoslahti 
1999). In order for the cells to respond to growth factors such as epithelial 
growth factor (EGF), platelet derived grow th factor (PDGF) and thrombin, 
they need to be adherent to a substrate via integrins. Not only does this result 
in the activation or near-activation of growth receptors, but also enables cross-
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Figure 1.7 FAK pathway via a chain of the integrin. FAK is phosphorylated by its 
association with integrins, enabling it to interact with docking/adaptor proteins 
such as paxillin, tens in, Grb2/SOS, which in turn activate downstream signalling 
mediators such as Scr, RAS, JNK (taken after Giancotti & Ruoslahti 1999).
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talk between integrins and growth factor receptors (Giancotti & Ruoslahti 
1999; Hynes 2002).
1.5.2.4 Eyithelial integrins
The main integrins expressed by the oral epithelium  are those of the p i 
family, along w ith a6p4 and avp5 (Thomas et al. 1997). Epithelial integrins are 
involved in  cell-cell interactions, cell-ECM interactions, cell m igration, cell 
stratification and term inal differentiation (Thomas et al. 1997) (Table 1.3). In 
normal hum an epithelium  integrins are expressed very strongly by the basal 
keratinocytes but may also be found in the suprabasal layers. Integrins are 
expressed in a discrete polarized m anner being situated mostly in an apico- 
lateral distribution. The a6p4 integrin is localized in hemidesmosomes in the 
basal aspect of basal keratinocytes and binds to Laminin-1 and -5 (Zam brano 
et al. 1995). The a2p i and a3p l integrins on the other hand appear to m ediate 
cell-cell contact as they are found on the lateral aspects of cells.
Integrin expression is changed in m alignant cells compared to their normal 
counterparts (Thomas et al. 1997). In m alignant melanomas the avp3 integrin 
is expressed and is found to m odulate expression of proteolytic enzymes by 
the tum our cells (Thomas et al. 1997). Most p i integrins are expressed in 
elevated am ounts during w ound healing, hyperproliferative disease and 
carcinomas (Zam brano et al. 1995). Carcinomas exhibit variable loss of 
expression of a3p i, a2pi and a5p i (Thomas et al. 1997). Such altered integrin
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expression seems to be involved in several aspects of neoplastic growth, 
invasion and metastasis. The expression of the a6p4 integrin is increased in 
some tum ours such as squamous, bladder and gastric carcinoma, m aintained 
in breast and colorectal tum ours and newly expressed in  thyroid carcinomas. 
However, the localization changes from the polarized hemidesmosomes, to 
actin-association at the leading edge under lam ellopodia and filipodia 
(Mercurio & Rabinovitz 2001). The loss or increased expression of integrins 
may physically modify the adhesive properties of cells as w ell as rendering 
them  unresponsive to the regulatory signals transm itted through the receptor. 
These alterations may lead to uncontrolled growth, proliferation and 
m igration (Thomas et al. 1997).
INTEGRINS: UGANDS:
a2(3l Collagen type I and IV, Laminin
a301 Laminin-1 and -5, Collagens, Fibronectin
a501 Fibronectin
0604 Laminin-1 and-5
avp5 Vitronectin
av06 Fibronectin, Tenasdn, Vitronectin and Latent TGF-0
Table 1.3 Epithelial integrins and their ligands (Thomas et al. 1997; Li et al. 2003). 
I.5.2.5. The a5pl integrin
This epithelial integrin is not always detectable in  healthy adult epiderm al 
cells (Zambruno et al. 1995). However, it becomes highly expressed on the
!nt ivdiu lion
surfaces of keratinocytes during active w ound healing, in cell culture and in 
carcinomas (Zambruno et al. 1995). The a5p i is a known FN receptor, 
recognizing the RGD sequence, and is particularly im portant in epithelial 
m igration (Livant et al. 2000). Studies suggest that the 120kDa FN fragment- 
a5p i interaction provides an inductive signal for MMP expression; this may 
be overridden by additional signal(s) arising from the interactions of 
domain(s) of FN outside the central cell-binding region (H uhtala et al. 1995). 
This integrin has been closely linked to tum our grow th factor-pl (TGF-pl). 
During w ound healing, TGF-pl strongly upregulates a5p i integrins and 
promotes keratinocyte m igration (Zambruno et al. 1995). This could be 
achieved through FN binding. This increased expression of the a5 p i integrin 
during w ound healing could classify it as an emergency receptor that 
enhances cell m igration and aids in the healing process (Zambruno et al. 1995) 
(See the w ound healing and keratinocytes m igration section).
1.5.2.6 The avp6 integrin
The avp6 integrin is a receptor for FN that is not detectable on keratinocytes 
under norm al conditions. It is increased significantly in w ound healing, oral 
epithelial dysplasia and oral squamous cell carcinoma (Huang et al. 1998; Li et 
al. 2003). In such conditions the avp6 integrin is expressed at the leading edge 
of w ound sections and at the interface between tum our cells and adjacent 
strom a (Huang et al. 1998). Its expression is maximal in  the w ound healing 
process w hen the m igrating edges of the lesion have joined and correlates
w ith the tim e w hen FN and tenascin are actively synthesized (Clark et al. 
19%; Haapasalm i et al. 1996). Several studies have shown that high expression 
of avp6 integrin correlates w ith the acquisition of a more m alignant 
phenotype w ith increased cell m igration and cell invasion (Thomas et al. 
2001). This m igration is enhanced on FN and tenascin (Huang et al. 1998; 
Thomas et al. 2002). Other studies have suggested that m atrix modifying 
proteases are upregulated by keratinocytes plated on FN in an avp6 
dependent m anner (Agrez et al. 1994; Thomas et al. 2001a). It seems that av(36 
does not affect the ability of the cells to adhere to FN, but rather increases cell 
m igration on FN and cell invasion through reconstituted basem ent membrane 
preparations (matrigel). Recent studies have scrutinized the relation between 
avp6 and TGF-pl and 3. M ature TGF-P rem ains associated w ith it latency- 
associated-peptide (LAP) and the avp6 integrin interacts w ith both TGF- 
p l/L A P  and TGF-P3/LAP via the RGD sequence (Thomas et al. 2002). All 
these studies conclude that the avp6 integrin in oral squamous cell carcinoma 
is associated w ith a more m alignant phenotype, characterized by increased 
invasiveness and metastasis (Li et al. 2003).
1.5.2.7Fibronectin and avp6 inteprin in tumours
W hen the avp6 integrin couples w ith FN it activates the Fyn signalling 
pathw ay (Li et al. 2003). Once the p6 associates w ith Fyn, FAK is recruited and 
a functional complex is formed. This in turn  activates She and links it to the 
Raf-ERK/  MAPK pathw ay im plicated w ith increased expression of MMPs (Li
et al. 2003). Activation of the Src family kinase Fyn promotes oral SCC cell 
proliferation and metastasis (Li et al. 2003).
Expression of av(36 integrin prom otes cell m igration on FN rather than 
adhesion to FN. Since interaction of the avp6 integrin w ith FN-mediated Fyn 
activation occurs sim ultaneously w ith cell m igration, it seems that SCC cells 
initially adhere to FN using other FN receptors such as a5p i or av p i. Such 
adhesion w ithin 60 m inutes does not activate Fyn, however, w hen SCC cells 
rem ain adherent to FN p6 is activated and commences the cascade of 
signalling that prom otes cell m igration (Li et al. 2003).
1.6 PROTEASES
A regulated turnover of ECM is essential for norm al biological processes such 
as developm ent The molecules of the ECM can be broken-down by extra­
cellular proteolytic enzymes that are secreted locally by die surrounding cells. 
Furtherm ore, localized degradation of the ECM is essential for cells to migrate 
during w ound healing and in cancer (Vassalli & Pepper 1994).
There is a delicate balance between proteases and their inhibitors which 
creates an equilibrium  of production and degradation of ECM components. 
During development, w ound healing and during tum ourigenesis this balance
may be disrupted leading to more breakdown than production. This is 
particularly im portant w ith regard to tum ours as proteases give cancers some 
of their defining characteristics. However, evidence suggests that m ost of the 
increased protease production associated w ith m alignant tum ours comes 
from the host strom a rather than from  the cancer cells themselves (Edwards & 
M urphy 1998). Tumour cell invasion consists of three main steps: 1 )- 
attachm ent of tum our cells to the basem ent membrane, 2)- localized 
proteolytic degradation of the basem ent membrane and 3)- m igration of 
tum our cells through the generated defects (Stetler-Stevenson & Yu 2001; Itoh 
& Nagase 2002) (Figure 1.8). The serine protease plasm inogen 
activator/plasm in system and the matrix m etalloproteinases (MMPs) are the 
two protease system s thought to be the m ost im portant in ECM modification. 
In tum ours, interaction between the cancer cells and their surrounding strom a 
regulate the production of these proteases (Vassalli & Pepper 1994; Edwards 
& M urphy 1998).
1.6.1 M atrix m etalloproteinases
MMPs are thought to play an im portant role in embryonic development, 
morphogenesis and tissue remodelling. However, excessive or inappropriate 
expression of MMPs may contribute to the pathogenesis of many tissue 
destructive processes including arthritis, m ultiple sclerosis and 
cardiovascular disease and is essential for growth, invasion and metastasis of 
m alignant tum ours (Shapiro 1998; Reunanen & Kahari 2002).
Degradation of the ECM is the crucial first step in the mechanism of tum our 
cell invasion and MMPs are thought to be involved in this process (Stetler- 
Stevenson & Yu 2001). In addition, MMPs may directly influence metastatic 
tum our growth (Stetler-Stevenson & Yu 2001). However, MMPs not only 
break-down ECM molecules through proteolysis, but also expose cryptic sites 
of ECM proteins which may stim ulate specific biological activities (Itoh & 
Nagase 2002). Their activity is in  turn  regulated by tissue inhibitors of 
m etalloproteinases (TIMPs) and plasm a inhibitor a 2-macroglobulin (Itoh & 
Nagase 2002).
1.6.1.1 Types o f matrix metalloproteinases
MMPs are a large family of zinc-containing metalloenzymes that are able to 
cleave m ost ECM proteins (Nagase & W oessner 1999; Stetler-Stevenson & Yu
2001). They can be subdivided into two m ain groups: soluble MMPs and 
m embrane-type MMPs (MT-MMPs) (Table 1.4). The soluble MMPs can be 
subdivided according to substrate specificity into the interstitial collagenases, 
gelatinases, stromelysins and metalloelastases (Itoh & Nagase 2002).
Collagenases: Collagens type I, II, HI and IV are cleaved by collagenases-1 
(MMP-1), collagenases-2 (MMP-8) and collagenases-3 (MMP-13). Collagenase- 
1 is secreted dining embryonic development, w ound repair and tum ours, and 
is the only MMP unable to cleave the basem ent membrane. It is secreted by 
basal keratinocytes and is pivotal in keratinocytes m igration on type I
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Figure 1.8 Steps in cellular invasion: A- Attachment, B- Proteolysis and 
C- Invasion (taken after Stetler-Stevenson & Yu 2001).
collagen (Reunanen & Kahari 2002). Collagenase-2 is synthesized and stored 
by polym orphonuclear leukocytes m aturing in bone marrow as well as by 
articular cartilage chondrocytes (Reunanen & Kahari 2002). Collagenase-3 is 
expressed w hen rapid rem odelling is needed and has wide substrate 
specificity. It is expressed dining embryonic development, inflammatory 
conditions, w ound healing and m alignant tum ours (Reunanen & Kahari 
2002).
Gelatinases: Gelatinase-A (MMP-2, 72-kDa gelatinase) and Gelatinase-B
(MMP-9, 92-kDa gelatinase) contain three FN-type II repeats in the catalytic 
dom ain and are molecules that cleave components of the basem ent membrane 
and are im portant in conditions w hen basem ent membrane disruption is 
necessary, such as inflammatory conditions where w hite blood cells are 
required. They are also expressed in elevated am ounts in malignancies and 
correlate w ith tum our spread and poor prognosis (Reunanen & Kahari 2002).
Stromelvsins and stromelvsin-like MMPs: Stromelysin-1 (MMP-3) and 
stromelysin-2 (MMP-10) are expressed by keratinocytes and fibroblasts and 
both have a w ide spectrum  of substrate specificity. MMP-3 is expressed by 
strom al cells during mammary gland developm ent and is an inducer of 
apoptosis and proliferation depending on the differentiation status of the cell. 
It also activates latent MMP-1. Stromelysin-3 (MMP-11) is expressed in 
invasive tum ours and correlated w ith poor prognosis in breast cancer cases. It
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is secreted by fibroblasts. M acrophages continually express macrophage 
metalloelastase (MMP-12) during pathologies such as atherosclerotic lesions, 
as well as by tum our cells in cutaneous SCCs (Reunanen & Kahari 2002).
Matrilvsins: The smallest MMPs are m atrilysin and matrilysin-2 (MMP-7 and 
MMP-26 respectively), lacking the hinge region and hem opexin domain. They 
have w ide substrate specificity and are secreted by m any epithelial cell types 
(Reunanen & Kahari 2002).
Membrane-tvpe MMPs: M embrane-type MMPs are bound to the membrane by 
a transm em brane dom ain near the C-terminus except for MT4-MMP and 
MT6-MMP which are anchored by glycosylphosphatidylinositol (GPI)- 
anchor. There are six members in this group; MT1-MMP (MMP-14), MT2- 
MMP (MMP-15), MI3-MMP (MMP-16), MT4-MMP (MMP-17), MT-5-MMP 
(MMP-24) and MT6-MMP (MMP-25). M embrane-type MMPs play a role in 
cell-matrix interactions and cell invasion. MT1-, MT3-, MT5- and MT6-MMPs 
activate pro-MMP2 and MT1- and MT2-MMPs activate pro-MMP13. These 
activations form  a cascade of events im portant in the degradation of ECM. 
MT1-MMP is w idely expressed in norm al tissues as well as in tum ours. It can 
cleave a num ber of ECM proteins (Table 1.4). MT2-MMP is expressed in 
placenta, testis, colon, intestine, pancreas, kidney, lung, heart and skeletal 
muscle. MT3-MMP is found in brain, placenta, heart and certain m alignant 
melanomas. MT4-MMP is expressed in brain, leukocytes, colon, ovary, testis
and breast carcinoma. MT5-MMP is predom inantly expressed in kidney, 
pancreas, lung and brain tissues, especially brain tum ours. Finally, MT6-MMP 
is expressed specifically by peripheral blood leukocytes and in lung and 
spleen tissue (Reunanen & Kahari 2002).
O ther MMPs include MMP-19 which is found in high am ounts in acutely 
inflamed synovial cavities; MMP-28 may sometimes be found in basal 
keratinocytes at the w ound edge; MMP-20, enamelysin has an expression 
pattern restricted to ameloblasts and odontoblasts of developing teeth. It is 
im portant in ECM remodelling during tooth developm ent and was found to 
degrade amelogenin, aggrecan and cartilage oligometric matrix protein 
(Reunanen & Kahari 2002).
1.6.1.2 Structure and activation o f MMPs
MMPs have a multi-domain structure; all share common dom ain structures 
including a signal sequence, a propeptide, a catalytic dom ain containing the 
Zn-binding site, and a hemopexin-like dom ain (Stetler-Stevenson & Yu 2001). 
The signal peptide found at the N term inal of the molecule, directs the 
secretion of the proenzyme. The propeptide contains a highly conserved 
sequence in  which the cysteine forms a covalent bond w ith the zinc ion and a 
cysteine switch that m aintains the proMMP in latent form. The catalytic 
dom ain is m ade of two modules separated by a deep active site cleft w ith zinc 
ion at the bottom. The binding of the catalytic zinc is coordinated by three
ENZYME 
Soluble types: 
Collagenases:
• Interstitial collagenases 
(collagmases-1)
• Neutrophil collagenases 
(collagenases-2)
• CoUagenase-3
Gelatinases:
•  Gelatinase A
•  Gelatinase B
Stromelysins:
• Stromelysin-1
• Stromelysin-2
Matrilysins:
•  M atrilyisn-1
•  M atrilysin-2
Others:
• Stromelysin 3
• Metalloelastase
• No name
• Enamelysin
• CA-MMP
• No name
MMP SUBSTRATE
MMP-1 Collagens I, II, III, VII, VIE, X and XI, gelatin, 
entactin, tenasdun, aggrecan, FN, vitronectin, 
casein.
MMP-8 Collagens I, II and III, aggrecan.
MMP-13 Collagens I, II, III, IV, DC, X  XTV, gelatin, FN, 
aggrecan, casein.
MMP-2 Collagens I, II, El, IV, V, VII and X, gelatin, FN, 
laminin, aggrecan, elastin, vitronectin, tenascin. 
MMP-9 Collagens IV, V, XI, XIV, elastin, aggrecan, 
decorin, laminin, FN.
MMP-3 Collagens III, IV, V, DC, X, and XI, gelatin,
aggrecan, elastin, FN, vitronectin, laminin, 
entactin, tenascin, decorin.
MMP-10 Collagens El, IV and V, gelatin, FN, elastin,
aggrecan, casein, pro-MMP-1, pro-MMP-2, pro- 
MMP-9, pro-TNFa.
MMP-7 Collagen IV, gelatin, aggrecan, link protein, 
elastin, FN, vitronectin, laminin, entactin, decorin, 
tenascin, casein, pro-MMP-1, pro-MMP-2, pro- 
MMP-9, pro-TNFa.
MMP-26 FN, fibrinogen, vitronectin, gelatin.
MMP-11
MMP-12 Ealstin, collagor IV, gelatin, FN, vitronectin, 
laminin, entactin, aggrecan.
MMP-19 Collagen type IV, laminin, FN, gelatin, aggrecan. 
MMP-20 Amerogenin 
MMP-23 Gelatin 
MMP-27 Not known
• Eptiysin 
Membrane types: 
Transmembrane:
• MT1-MMP
• MT2-MMP
*MT3-MMP
• MT5-MMP
GPl-anchored:
• MT4-MMP
• MT6-MMP
MMP-28 Casein
MMP-14 ProMMP-2, proMMP-13, collagens I, II and III, 
gelatin, FN, vitronectin, laminin-1 and -5.
MMP-15 proMMP-2, laminin, FN, tenascin, entactin, 
aggrecan, perlecan.
MMP-16 proMMP-2, collagen III, FN.
MMP-24 proMMP-2, gelatin
MMP-17 Fibrinogen, fibrin, proTNFa.
MMP-25 Collagen IV, gelatin, fibrinogen, FN.
Table 1.4 Mammalian MMPs (Itoh & Nagase 2002).
histidine residues and is essential for the proteolytic activity of the MMP 
(Reunanen & Kahari 2002). At the C term inus, a proline-rich pivot region 
links the catalytic dom ain w ith the C-terminal hemopexin domain. This 
domain is a highly conserved one containing four repeats showing similarity 
to hemopexin plasm a protein. The ends of the dom ain are connected by a 
disulfide bridge (Figure 1.9 (A)) (Reunanen & Kahari 2002). MMP-2 and 
MMP-9 have, in addition, a gelatin-binding dom ain that contains three FN- 
type II repeats (Stetler-Stevenson & Yu 2001).
M embrane-type MMPs are further subdivided into transm em brane type, 
which contain a transmembrane dom ain and a short cytoplasmic tail at the C- 
term inus, and glycosylphosphatidylinositol (GPI)-anchored type which have 
a hydrophobic GPI-anchoring signal sequence at the C-terminus (Itoh & 
Nagase 2002). MT-MMPs contain a carboxy-terminal transm em brane domain 
after the hemopexin domain and reside on the cell surface (Stetler-Stevenson 
& Yu 2001) (Figure 1.9 (B)).
All MMPs are synthesized as inactive zymogens, w ith the exception of 
stromelysin-3 (MMP-11) and MT-MMPs, and are activated by a variety of 
proteases including plasmin, uPA and other MMPs (Nagase & W oessner 
1999; Stetler-Stevenson & Yu 2001; Reunanen & Kahari 2002). Furthermore, 
w ith the exception of MMP-11, -23 and-28, all soluble MMPs are activated 
extracellularly by proteinases (Itoh & Nagase 2002). MMPs -11, -23 and -28 are
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Figure 1.9 Conserved structure of MMPs (A) and doman structure of MMPs (B).
PC: pro-hormone convertase, cys arrays: cys array domain,TM/CP: transmembrane 
and cytoplasmic domain (taken after Reunanen & Kahari 2002; Itoh & Nagase 2002).
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activated intracellnlarly and secreted as active molecules (Itoh & Nagase
2002). Extracellular activation occurs by the modification of the bond between 
a conserved cysteine sulfhydryl group and the catalytic zinc in the active site 
which yields the release of the prodom ain and liberation of the active site for 
catalysis. Intracellular activation occurs by a furin-dependent cleavage of a 
conserved sequence found between the prodom ain and the catalytic domain 
(Stetler-Stevenson & Yu 2001). MMP activity is controlled by anchoring them 
to the cell surface therefore localizing their activity to the pericellular space 
(Reunanen & Kahari 2002). At the transcription level MMPs expression is 
regulated by growth factors, cytokines, chemical agents like phorbol esters, 
physical stess, oncogenic transform ation, cell-cell and cell-ECM interactions 
(Reunanen & Kahari 2002).
1.6.1.3 Tissue inhibitors o f metalloproteinases (TIMPs)
Once activated MMPs are regulated by either TIMPs in  the ECM or by <12- 
m acroglobulin in the plasma. Four TIMPs have been described, all ranging 
between 21-29kDa in size and consisting of conserved cysteine residues that 
form 6 intram olecular disulfide bonds. Three of these bonds are located in the 
N-terminal dom ain which also contains the M MP-inhibitory site and the C- 
term inal dom ain is involved in other binding interactions (Stetler-Stevenson 
& Yu 2001).
i n t r o d i k ’t i o n
TIMPs have other biological functions distinct from the inactivation of MMPs 
(Nagase & W oessner 1999). TTMP-l and TIMP-2 both exhibit mitogenic 
activities on various cell types and their over-expression inhibits tum our cell 
growth. TIMP-2 inhibits basic fibroblast growth factor-induced hum an 
endothelial cell growth (Nagase & W oessner 1999). TTMP-l seems to stim ulate 
the production of MMP-1 and may participate in  cell growth. TTMP-3, by 
stabilizing TNF-a receptors induces apoptosis of hum an colon carcinoma cell 
lines (Nagase & W oessner 1999).
1.6.1.4 Functions o f MMPs in pathologic conditions and tumours 
As previously mentioned, MMPs are expressed in both physiologic and 
pathologic conditions. Collagenases are highly expressed during chronic 
ulcers, rheum atoid arthritis, gingival wounds, periodontitis and osteoarthritis 
(Reunanen & Kahari 2002). Stromelysins are found during chronic wound 
healing and stromelysin-1 deficient mice showed im paired derm al wound 
contraction (Bullard et td. 1999). Gelatinases play a vital role in w ound healing 
as they degrade the basement membrane to enable cells, such as T 
lymphocytes to migrate through to various sites. Deletion of MMP-2 in  mice 
leads to im paired macrophage recruitm ent (Hautamaki et al. 1997). MT1- 
MMP deficient mice show severe defects in skeletal developm ent and 
angiogenesis and activation of pro-MMP-2 is deficient (Reunanen & Kahari 
2002).
In t r o d  l i d i i  mi
Matrix metalloproteinases also play a critical role in tum our growth and 
metastasis. By degrading the ECM they promote tum our growth and spread 
and play a role in  enhancing angiogenesis (Reunanen & Kahari). 
Collagenases, stromelysins, gelatinases and MT-MMPs have all been 
im plicated to play im portant roles in tum ourigenesis. MMP-11 deficient mice 
showed reduced chemical-induced tum ourigenesis suggesting a role for this 
MMP in cancer cell survival (Masson et al. 19%; Bullard et al. 1999). 
Gelatinase-A and -B deficient mice show reduced angiogenesis, tum our 
progression, im paired m etastasis formation and tum our growth (Itoh et al. 
1998; Itoh & Nagase 2002). Many studies have established a positive 
correlation between MMP expression and the invasive and metastatic 
potential of tum ours including colon, lung, head and neck, basal cell, breast, 
thyroid, prostate, ovarian and gastric carcinomas (W estermarck & Kahari
1999).
1.6.1.5 MMP inhibitors in clinical trials
Because of the significant role MMPs play in tum our progression, it would 
seem that targeting them could offer an effective therapy. Both endogenous 
MMP inhibitors (TIMPs) and synthetic inhibitors have been tested as potential 
treatm ent agents. Preclinical trials have been encouraging in that these 
inhibitors were able to block tum our cell invasion in vitro and in  vivo (Brown 
1997). Clinical trials have not been as successful on account of the lack of good 
bioavailability and the broad spectrum  of these inhibitors (Brown 1998;
Nelson et al. 2000). Ideally, selective inhibitors aim ing at specific MMPs are 
desirable. However, encouragingly it was found that they can nonetheless be 
adm inistered as adjuncts of conventional cytotoxic therapy (Brown 1997).
1.6.2 The plasm inogen activator system
The PA system is a cascade of serine proteases and which is initiated by 
plasminogen activators, of which there are two types, urokinase type (uPA) 
and tissue type (tPA). These act on the proenzyme plasm inogen to form active 
plasmin. Plasmin is able to breakdow n a num ber of molecules such as FN, 
laminin, vitronectin, proteoglycans and fibrin and can activate latent 
collagenases (Stoppelli 2005). This activity is controlled by the action of 
plasm inogen activator inhibitors (PAIs) and alpha-2-antiplasm in (Preissner et 
al. 2000) (Figure 1.10). This system is not only im portant in fibrin dissolution 
and the maintenance of vascular patency but also in norm al tissue 
remodelling, ECM degradation, and cell m igration (Stoppelli 2005). Studies 
have shown that lack of any of its components can severely delay or im pair 
w ound healing and developm ent (Vassalli & Pepper 1994; F.llis 1997; Edwards 
& M urphy 1998). UPA is relatively widely expressed by a variety of tissues 
and cells including proximal and distal kidney tubules, sub-epithelial 
fibroblasts in the gastrointestinal tract, bladder urothelium , ovarian granulosa 
cells and blood plasma. In pathologic situations such as invasive cancer, 
w ound healing and activated leukocytes uPA is upregulated (Ellis & Dano 
1991). TPA expressed by endothelium  but very few other cell types. Vascular
smooth muscle cells express significant levels following vascular injury (Ellis 
1997). It is now well established that elevated levels of uPA, PAI-1 and uPAR 
correlate w ith poor prognosis in tum ours (Andreasen et al. 1997). This system 
plays an im portant role in tissue regeneration, w ound healing, immune 
responses, angiogenesis and cancer invasion (Stoppelli 2005).
1.62.1. uPA
uPA was first discovered in hum an urine, hence the term  urokinase. The 
interaction w ith its specific cellular receptor urokinase plasm inogen activator 
receptor (uPAR) leads to plasm a membrane localization and catalytic 
amplification (Vassalli & Pepper 1994; Ellis 1997). uPA is a serine protease 
that consists of tw o disulfide bridge-linked polypeptide chains. Therein are 
contained three functionally independent domains: a)- the serine proteinase 
domain, b)- the amino-terminal growth factor-like dom ain (containing the 
uPAR binding site) and c)- the single kringle dom ain (Andreasen et al. 1997; 
Reuning et al. 1998b) (Figure 1.10). The inactive precursor of uPA secreted by 
the cells as pro-uPA is a one-chain zymogen form w ith several-hundred-fold 
lower activity than the two-chain active uPA (Andreasen et al. 1997). The 
activation of pro-uP A to uPA is catalysed by several proteinases including 
plasmin, plasm a kallikrein, blood coagulation factor Xlla, cathepsin B, 
cathepsin L and nerve growth factor-y (Reuning et al. 1998a). uPA has a 
restricted substate specificity and plasm inogen is the m ain substrate. Other 
molecules w ith sequences similar to plasm inogen which may be substrates for
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uPA include hepatocyte grow th factor (HGF), uPAR and macrophage- 
stim ulating factor (MSF) (Vassalli & Pepper 1994; Andreasen et al. 1997; Ellis 
1997; Preissner et al. 2000). uPA has been found to be able to degrade ECM 
molecules such as FN independent of plasm in activity, and to activate other 
ECM-degrading enzymes such as MMPs (Reuning et al. 1998a).
1.6.22 uPAR
Membrane receptors of the PA system mediate plasminogem activation at the 
cell surface, thus focusing proteolysis a t the pericellular environm ent 
(Stoppelli 2005). The urokinase receptor binds uPA w ith high affinity and is 
found on the surface of many cells including tum our cells. Many studies have 
found a correlation between the expression of uPAR and the m igratory and 
invasive potential of tum our cells (Preissner et al. 2000). uPAR is a glycolipid- 
anchored membrane protein consisting of three homologous independently 
folded dom ains (dom ainl,2 and 3) (Andreasen et al. 1997) (Figure 1.10). It is 
anchored to the plasm a membrane by a GPI moiety and this renders it quite 
mobile on the plasm a membrane (Preissner et al. 2000). Studies have shown 
that uPAR distribution on m igratory cells is different from  stationary cells in 
that uPAR expression is clustered at the leading edge (Reuning et al. 1998a). 
uPAR may also be found in solution and differs from the cell-bound uPAR by 
the absence of the GPI dom ain (Andreasen et al. 1997). uPAR binds to the N- 
term inal growth factor-like dom ain of uPA (Andreasen et al. 1997). Other 
ligands of uPAR include vitronectin (to which it binds w ith high affinity), P2
integrins and p i integrins (Andreasen et al. 1997). Through such alternative 
interactions uPAR has been linked w ith chemotaxis, adhesion and 
intracellular signal transduction cascades (Preissner et al. 2000).
Both uPA and pro-uP A bind to uPAR. Upon binding, pro-uP A is more 
susceptible to activation by proteases including plasm in (Reuning et al. 
1998a). Evidence suggests that intracellular signals are initiated by the 
binding of uPA to uPAR which is independent of plasm in generation 
(Andreasen et al. 1997).
1.6.2.3 tPA
In contrast w ith uPA, tPA is secreted proteolytically active. The major role for 
tPA is in vascular biology. However, the finding of a specific tPA receptor in 
neuronal cells has implicated it to play a role in  neural plasticity (EUis 1997). 
The stim ulation of tPA activity is dependent on the sim ultaneous cellular 
binding of plasm inogen (Ellis 1997).
1.6.2.4 Plasminogen activator inhibitors (PAI-1 and -2)
PAI-1 and PAI-2 belong to the serpin superfamily and inhibit the catalytic 
activity of both uPA and tPA (Andreasen et al.1997). PAI-1 is synthesized by 
endothelial cells in  high concentrations and by m ost neoplastic cells. PAI2 is 
synthesized by macrophages (Stoppelli 2005). Both PAI-1 and -2 regulate the 
activity of uPA by forming a complex w ith it that renders it inactive. PAI-1
can also bind to uPAR-bound uPA and this ternary complex prom pts its rapid 
internalization and is followed by the degradation of uPA and PAI-1 by 
lysosomes and the recycling of uPAR back to the cell surface (Reuning et al. 
1998a).
1.6.2.5 Plasmin
Plasmin is a broad-spectrum  protease which may break down the ECM 
directly or indirectly by activating various MMPs (Ellis & Dano 1991; Vassalli 
& Pepper 1994; Preissner et al. 2000). Plasmin consists of two disulfide bridge- 
linked polypeptide chains, the C term inal consisting of a serine protease 
dom ain responsible for the catalytic activity and the N term inal consisting of 
5 so-called kringle domains (Andreasen et al. 1997). These domains are 
responsible for the interaction between plasm in, plasm inogen and the cell 
surface (Figure 1.10). Plasminogen can be cleaved into plasm in by the 
catalytic action of uPA, tPA and certain bacterial proteins (Andreasen et al.
1997).
1.6.2.6 pFN as substrtate for uPA
Studies have shown limited digestion of pFN by uPA (Gold et al. 1989). This 
type of ECM degradation is independent of plasmin. uPA was found to cleave 
the dimeric form of pFN into its two monomers, 220kDa each. However, 
smaller molecular w eight fragments were also observed.
membrane
Figure 1.10 Domain structure of pro-uPA (A), plasminogen (B) and uPAR (C) 
where SPD is the serine protein domain, K is the Kringle domain, and G is 
the growth-factor domain (taken after Andearsen et al. 1997).
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1.7 THE EPITHELIAL CELL
The epithelial cell is the basic com ponent of the epithelium. Epithelial cells 
differ from other cells in the body in their content of tonofilaments and 
desomosomes (Ten Cate 1998). Tonofilaments are fibrous proteins that belong 
to a family of interm ediate filam ents known as cytokeratins and are im portant 
structural components w ithin the cell W hen aggregated they form  bundles 
known as tonofibrils. It is this cytokeratin that gives the epithelial cell the 
alternative name of keratinocyte. The other characteristic component of 
epithelial cells is the desmosome. This structure is an area bordering the cell 
membranes of adjacent cells and consists of an attachm ent plaque into which 
the tonofilaments insert W hen the cell borders the connective tissue, the 
specialized structures are known as hemidesmosomes. Together, the 
tonofilaments, desomosomes and hemidesmosomes form the mechanical 
linkage that distributes and dissipates forces applied on the cells (Ten Cate
1998).
There are two other junctions found apically between epithelial cells, the 
zonula adherens and the zonula occludens. The former is characterized by 
cadherin-m ediated cell-cell adhesion and the latter by tight junction proteins 
such as occluding and the cytoplasmic plaque proteins ZO-1 and ZO-2 
(Sander & Collard 1999; Evers et al. 2000). Tight junctions between cells and
the underlying basement membrane characterize epithelial tissues (Sander & 
Collard 1999).
1.7.1 The Cvtoskeleton
The cytoskeleton is an elaborate network of protein filaments found 
throughout the cytoplasm It is a highly dynamic structure that is 
continuously reorganized as the cell changes shape, divides and responds to 
outside stimuli (Bray et d. 1998). The cytoskeleton is responsible for 
movements such as crawling of cells along a surface, contraction of muscle 
cells and changes in cell shape. Furthermore, the cytoskeleton provides an 
intracellular channel system for transport and signalling. The main 
components of the cytoskeleton are the intermediate filaments, the 
microtubules and the actin filaments. The intermediate filaments are a type of 
fibrous proteins whose main function is to help the cell withstand mechanical 
stresses, for example when stretched. Microtubules and actin are made of 
tubulin and actin respectively. Microtubules are stiff hollow protein tubes 
that can be assembled and disassembled as required. They grow out of the 
centrosome to create the tracks that guide chromosomes during cell mitosis. 
They can also form permanent structures such as cilia and flagella (Bray et d .
1.7.2 Cell migration
Generally, epithelial cells are non-migratory. However, under certain 
circumstances they become motile and when this happens they undergo some 
form of mesenchymal transition by losing some epithelial characteristics such 
as polarity and cell-cell adhesion (Quaranta 2002). Cell migration can be both 
physiologic and pathologic. An example of physiologic migration is that of 
the basal cells in normal epithelium maturating and moving up towards the 
surface (Ten Cate 1998). Migration is also an integral part of both wound 
healing and cancer (Kassis et al. 2001). During wound healing epithelial cells 
migrate from the edges of the wound in a process called re-epithelialization 
(Hakkinen et al. 2000). Epithelial cells dissolve their hemidesmosomal 
connections and detach from the basement membrane in order to rapidly 
migrate over the wounded surface. An attribute of migrating cells is their 
ability to focus proteolysis at the leading edge of the epithelium (Hakkinen et 
al. 2000). Studies have shown die localization of urokinase type plasminogen 
activator receptor on the cell membrane at the advancing edge (Reuning et al. 
1998a). Furthermore, other studies have shown increased expression of matrix 
metalloproteinase-9, matrix metalloproteinase-1 and matrix 
metalloproteinase-10 by migrating keratinocytes (Hakkinen et al. 2000). In 
carcinomas a similar process occurs. Malignant cells are known to attach to 
the basement membrane, secrete proteolytic enzymes and breach the barrier 
to penetrate the connective tissue beneath (Kassis et al. 2001) (Figure 1.8). 
These mutated migratory carcinoma cells also exhibit a very mesenchymal
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phenotype and loose cadherin mediated cell-cell adhesion (Behrens 1999; 
Mercurio & Rabinovitz 2001; Wheelock & Johnson 2003). Needless to say this 
type of transition is associated with the most aggressive cancers (Mercurio & 
Rabinovitz 2001). The process of cell migration involves dynamic and 
coordinated interactions among ECM receptors, growth factor receptors and 
the actin cytoskeleton (Mercurio & Rabinovitz 2001). When growth factor 
receptors interact with the provisional ECM a cascade of events is triggered 
resulting in localized actin polymerization in the direction of cell movement 
Traction forces are also established that help propel the cell forward 
(Mercurio & Rabinovitz 2001). Changes in the profile, localization and 
signalling of cell adhesion molecules such as integrins and cadherins is the 
hallmark of cancer progression (Evers et al. 2000; Kassis et al. 2001).
1.7.2.1 Epithelial cell migration modes
There are several morphogenetic movements that are relevant to epithelial 
migration and they include: sheet migration, tube migration, ingression, 
invagination and delamination. In order for these movements to occur there is 
the need for the downregulation of cell-cell adhesion and for the transition of 
epithelial cells to a more mesenchymal form (Quaranta 2002).
During sheet migration, the epithelia cover or envelop a tissue. It is a common 
mechanism during normal tissue development, wound healing and cancer 
invasion. When individual epithelial cells detach from the sheet and enter the
underlying stroma it is referred to as ingression (Quaranta 2002) and this is 
commonly seen during the migration of carcinoma cells through basement 
membranes. Invagination involves the formation of furrows, tubes or 
glandular structures by groups of epithelial cells within a flat epithelium and 
tube migration includes the formation and remodelling of glandular structures 
and secretory epithelia (Quaranta 2002) (Figure 1.11).
Such migratory mechanisms are often expressed by epithelial cells during 
normal physiologic processes such as embryonic development and tissue 
remodelling, or during pathologies such as wound repair and carcinogenesis 
(Quaranta 2002).
1.7.2.2 The dynamics o f cell migration
Migration is facilitated by loss of cell-cell adhesion. This is achieved by loss in 
function and mutation of molecules mediating interactions such as E-cadherin 
and the catenins (Evers et al. 2000; Mercurio & Rabinovitz 2001). This is 
concurrent with the down regulation of hemidesmosomes despite the fact that 
in many cases the expression of the a6^4 integrin is maintained. However, 
this integrin is found in altered localizations such as lamellipodia (Kassis et al. 
2001; Mercurio & Rabinovitz 2001). Such coordinated alterations are in many 
instances regulated by growth factors such as EGF, HGF and TGFa (Mercurio 
& Rabinovitz 2001).
Sheet migration
Tube migration
q  I q
Ingression
Invagination
Figure 1.11 Schematic representation of epithelial movement 
(taken after Quaranta 2002).
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The first step in cell motility involves the extension of the cell membrane via 
lamellipodia in any given direction (Kassis et al. 2001). If the lamellipodia is 
stabilized by adhesion molecules to the substratum, the actin polymerization 
generates protrusions at the edge of the cell which are followed by contraction 
of the actin network with associated myosin fibres (Kassis et al. 2001; 
Mercurio & Rabinovitz 2001). The actinmyosin system thus generates forces 
that are transmitted to the substrate creating the traction needed to produce 
forward movement resulting in the translocation of the cell body (Mercurio & 
Rabinovitz 2001). When this is followed by the detachment of the trailing 
edge of the cell, the process of motility is complete (Kassis et al. 2001). The key 
players in this process are the integrins. Integrins not only mediate the 
dynamic formation of adhesion contacts but also anchor the cell to the 
substratum and detach at the trailing edge (Mercurio & Rabinovitz 2001) 
(Figure 1.12). Concurrently, integrin-mediated adhesion at die rear of the 
migrating cell must be disrupted to permit forward movement (Mercurio & 
Rabinovitz 2001). Findings suggest that tumour cells shed integrins as they 
migrate through three-dimensional matrices, and this happens at the 
intracellular face of the cell membrane (Kassis et al. 2001). An important 
integrin involved in the active movement of cells is the a6p4 integrin which is 
found to anchor filopodia to the ECM (Mercurio & Rabinovitz 2001). These 
stabilized filopodia then act as traction tracks for myosin and assist the 
formation of a spreading edge (Mercurio & Rabinovitz 2001). Similarly, the
E-cadherin complexes
Cytoskeletal " 
reorganization
ProtrusionContraction
Adhesion
Figure 1.12 Dynamics of epithelial cell motility (taken after Evers et al. 2000 and 
Kassis et al 2001). In preparation to movement cells downregulate their expression 
of E-cadherin complexes, relaxing the cell-cell adhesion. Cells extend protrusions 
in the form of lamellopodia and filipodia, adhesion is formed at the leading edge 
anchoring the cell to the stroma via cell-adhesion molecules such as integrins.
This generates forces that cause cytoskeletal reorganization followed by contraction 
and the release of the trailing edge. In this way, bodily movement of the cell is 
achieved.
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a6(M integrin has been found localized at the base of lamellae in carcinoma 
cells migrating over ECM (Mercurio & Rabinovitz 2001).
1.7.2.3 Signalling in cell migration
Integrins work in synchrony with growth factors in regulating the signalling 
pathways that control cytoskeletal dynamics and migration (Mercurio & 
Rabinovitz 2001). Abnormalities in signalling pathways involved in the 
regulation of cell-migration, cell-cell and cell-ECM interactions contribute to 
cell migration (Sander & Collard 1999). Such cytoskeletal changes have been 
found to be regulated by a family of small Rho-like GTPases that include 
Cdc42Hs, Racl and RhoA (Sander & Collard 1999). Activation of RhoA is 
correlated with the assembly of stress fibres and focal adhesions; it plays a 
dual role with regards to cell-cell adhesion and motility. The activation of 
Cdc42Hs and Racl on the other hand is associated with the formation of 
lamellipodia and filopodia (Sander & Collard 1999; Evers et al. 2000). The 
epithelioid or migratory phenotype of the cells is determined by the balance 
of Rho and Rac activities. Cellular response to Racl activation, whether 
towards migration or not is determined in great part by signalling via 
integrin-ECM interactions (Sander & Collard 1999), and may be responsible 
for the loosening of intercellular adhesiveness due to functional disturbance 
of E-cadherin mediated cell-cell contacts (Evers et al. 2000).
Rac activation is controversial in that it may promote cell-cell adhesion and 
thus decrease migration or promote it. Its effect is dependent upon integrin 
signalling which is in turn dependent on cell-ECM interactions (Evers et al. 
2000). Furthermore, there is cross-talk between Rac and Rho signalling; Rac 
activation leads to inactivation of Rho but the opposite is not true, suggesting 
unidirectional signalling (Evers et al. 2000).
1.8 SUMMARY:
The de novo expression of the avp6 integrin is of particular importance in both 
wound healing and tumourigenesis. This integrin establishes novel 
interaction between activated keratinocytes, tum our cells and their 
environment Fibronectin is found in abundance in tissues and can be broken 
down to smaller, active fragments. Such fragments elicit responses unlike the 
parent molecule and could induce a more malignant phenotype. The av(36 
integrin binds to the RGD sequence present in fibronectin and its cell-binding 
fragm ent The expression of this integrin may therefore produce altered 
responses when it interacts with specific fibronectin fragments.
1.9 GENERAL AIMS:
The aim of this thesis is to investigate the interaction between various FN 
fragments and av(36-positive cells. Our choice of cell lines reflects our interest 
in the av(36 integrin, a de novo expressed integrin present in activated 
keratinocytes and tumour cells. The VB6 cells are a cell line transfected with 
the (36 integrin while the C l are the null transfectant. Both cell lines are in 
essence the same except in their (36-integrin expression (Thomas et al. 1997). 
This particular integrin is known to bind to FN via the RGD sequence 
contained in the fibronectin repeat IIIio. This makes die comparison between 
the intact molecule and the 120kDa FN cell-binding fragment interesting as 
both contain this sequence. The RGD sequence is known to bind to both the 
a5|31 and av(36 integrins and both these integrins are involved in cell 
migration. We aim to assess if this fragment evokes different effects on the 
two cell lines.
The p6 positive cells have been shown to produce more proteases than 
negative counterparts (Agrez et al. 1999). Our work will look at the secretion 
of the serine protease uPA and matrix metalloproteinases MMP-2 and -9. 
Such proteases have already been studied in relation to both wound healing 
and neoplasia and their expression often correlates with a more aggressive 
phenotype (Schedin et al. 2000; Davidson et al. 1999; Andreasen et al. 1997). 
Protease secretion may therefore be an important factor influencing the 
behaviour of our cell lines. Furthermore, it is important to evaluate the ability
of such proteases in generating the cell-binding FN fragment from the intact 
molecule. This may prove crucial in the loop implicating (36 positive cells in 
the production of specific fragments that elicit a pro-migratory response. In 
vivo correlation of (36, proteases and substrate could provide further evidence 
to the hypothesis we are proposing.
In order for us to draw credible conclusions from our results the repertoire of 
the critical cell-adhesion molecules expressed by both cell lines has to be 
evaluated. This will enable us to associate possible effects elicited by the FN 
fragments to the expression of a particular integrin. The assessment of high 
(36-integrin expression by the VB6 cells is crucial to our work. Furthermore, 
the establishment of the optimal medium of growth for our experiments is 
equally important. Most keratinocyte growth media contain fibronectin that 
may obscure the effects of the matrix proteins added by us in the various 
assays. In order to draw plausible conclusions, the effect of such "extrinsic" 
fibronectin must be kept to a minimum while growing the cells in a medium 
that does not jeopardize their growth or cell-adhesion molecule expression.
M a i v T i a i s  a n d  M e t h o d s
CHAPTER 2
MATERIALS AND METHODS
2.1 CELL CULTURE
The cell lines used in this study are the VB6 and C l as tumour cells, and the 
UPs and normal human keratinocytes (NHK). VB6 and C l are derived from a 
parental squamous cell carcinoma cell line, H357 (Prime et al. 1990) which is 
av-negative (Figure 2.1). This was transfected with av cDNA to create the av- 
positive cell line, V3 (Jones et al. 1996) which express mainly avp5. The V3 cell 
line was further transfected with [36 to yield the av(36-positive cell line (VB6). 
C l are the null transfectants of V3 (Thomas et al. 1997). NHK cells were 
provided by Cancer Research UK and were obtained from foreskin. UPs are 
normal keratinocytes immortalized for tissue culture by transfecting them 
with a viral oncogene, simian virus 40 (SV40) (Pei et al. 1991). Like NHKs, 
they express little av(36 and a5pl. All cells were grown and maintained in 
keratinocyte growth medium (KGM) in a humidified incubator at 37°C and 
5% CO2 (Appendix 1).
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Figure 2.1 Diagrammatic representation of Cl and VB6 transfection.
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2.1.1 Cell culture passage
All cell manipulations were carried out in a class II laminar flow cabinet to 
provide a sterile environment where growth medium was aspirated and the 
cell layer was washed twice with PBS containing ImM  calcium chloride and 
ImM magnesium chloride. Cells were then covered with 1ml 0.05%Trypsin- 
0.02% EDTA (Invitrogen Corporation, Gibco™, Pailsey,UK) in order to harvest 
the cells. The flask(s) were incubated for approximately 10 minutes at 37°C to 
allow the trypsin to digest the cell-attachment to the plastic. This action was 
terminated by adding 2-3 ml KGM and transferring the cell-KGM mixture 
into 15ml centrifuge tubes. Following centrifugation at 230G for 5 minutes the 
KGM was aspirated carefully so as not to disturb the cell pellet and fresh 
medium added. The cell suspension was agitated to disperse the pellet and 
the cell number estimated using a haemocytometer. Cells were then seeded at 
varying densities in 80cm2 flasks.
2.1.2 Counting the cells
During routine passage, after re-suspending the cells in known amounts of 
fresh medium and prior to seeding, 8pl of cell-containing medium was 
aspirated and placed under the coverslip of a haemocytometer. The cell 
containing medium fills the chamber by capillary action. The chamber is 
viewed under a phase-contrast microscope and the cells counted. The 
concentration is equal to the number in each 4 x 4  grid xlO4 /m l.
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2.1.3 Freezing cell stocks
In order to maintain a supply of cell stocks, the cells were routinely frozen 
and stored in liquid nitrogen. During routine passage, after centrifugation the 
cells were counted and re-suspended in cold KGM containing 10% 
dimethylsulphoxide (DMSO), (Sigma-Aldrich Co Ltd., Dorset, UK). They 
were then transferred in cryovials at 1 million cells per 1ml medium and 
stored overnight at -80°C. The following day they were transferred to liquid 
nitrogen.
2.1.4 Thawing cell stocks
Cells were taken out of liquid nitrogen and the vials held in a 37°C water bath 
for rapid de-frosting. The cells were then transferred in a tube containing 
fresh medium, were centrifuged and the supernatant was then discarded. 
Cells were resuspended and seeded in flasks in approximately 14ml of KGM 
and incubated at 37°C.
2.1.5 Cell sorting 
Rationale
This technique employs the use of magnetic beads designed for cell 
separation with any subclass of mouse IgG. Dynabeads bind to specific cell 
surface antigens via the primary mouse IgG used; target cells form rosettes 
with the Dynabeads Pan Mouse IgG (Figure 3.1) and these can then be
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separated by applying a magnet (Dynal® Magnetic Particle Concentrator, 
Dynal Biotech) (Figure 2.2).
Procedure
Cells were grown to full confluency, trypsinized, resuspended in KGM and 
placed in 1.5ml microtubes (Sarstedt Ltd., Leicester, UK). The primary 
antibody, monoclonal mouse anti-p6 (R6G9, Chemicon International) was 
added and left for 30 minutes on ice. One hundred pi of Dynabeads 
suspension (Dynabeads® Pan Mouse IgG, Dynal Biotech) was added to 900pl 
KGM and washed twice by passing them along the magnet and discarding 
the medium. After incubation the cells were washed twice and spun at 690G 
for 3 minutes. Cells were resuspended in 300pl KGM and 20pl of Dynabeads 
solution was added to each tube. Cells were left on ice for 30 minutes with 5 
minute interval shaking. After incubation the cells were washed six times as 
described above, resuspended in KGM and seeded in 6-well plates (Nunc™ 
VWR International). Once confluent the cells were transferred to cell culture 
flasks.
Figure 2.2 Dynal® Magnetic Particle Concentrator.
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2.1.6 Proliferation assays
Proliferation assays were carried out using CellTiter 96® A Q u e o u s  One Solution 
Cell Proliferation Assay (Promega UK, Southampton, UK) a colorimetric 
assay that indirectly measures viable cells. The MTS tetrazolium compound in 
the assay is bioreduced by dehydrogenase enzymes in live cells to give a 
coloured formazan bi-product soluble in tissue culture medium. The colour 
intensity in the medium is then measured at 490nm absorbance and plotted 
against a standard curve.
Using 96-well plates (Nunc™, VWR International, Dorset, UK) previously 
coated for 1 hour with matrix protein at 37°C, cells were seeded at a density of 
30X104 in triplicate and allowed to attach for 1 hour at 37°C. Cells were 
washed with PBS containing ImM  calcium chloride and ImM  magnesium 
chloride, lOOpl SFM was added to each well and the plate returned to the 
incubator for a further hour. Twenty pi of MTS solution (Cell Titer 96® 
Aqueous One Solution Cell proliferation Assay, Promega UK) was added to 
the medium and the plates were incubated at 37°C for 1 hour in the dark. 
Following incubation the absorbance at 490nm was determined using a Plate 
Reader 340 ATTC (SLT Labinstruments, Austria). The number of cells was 
calculated by comparison to the standard curve.
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2.1.7 Flow Cytometry
Flow cytometry is a method used to measure certain physical and chemical 
characteristics of cells or particles as they travel in suspension one by one past 
a sensing point. A modem flow cytometer consists of a light source, collection 
optics and a computer to translate signals into data (Figure 2.3). In the 
majority of cytometers the light source of choice is a laser which emits 
coherent light at a specified wavelength. The scattered and emitted 
fluorescent light is collected by two lenses and by a series of optics enabling
Figure 2.3 A Flow Cytometer connected to a computer for data analysis 
(http://w ings.buffalo.edu/ smbs/confocal/flow_cytometry.htm).
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Figure 2.4 Graphic representation of Flow Cytometry data. The first two graphs are 
dot plots representing cell populations and the relative homogeneity of the sample. 
The lower line graphs represent forward and side scatter (side scatter being 
represented in this instance) denoting size and complexity of the cells. The same line 
graph is used to view fluorescence, representing the molecule studied (e.g. integrins).
specific bands of fluorescence to be measured. The light intensity of a cell or 
particle is detected by photomultiplier tube (PMT) which converts it via an 
amplifier to a voltage. Such data can be displayed using either a linear or a 
logarithmic scale (Figure 2.4). This method permits us to measure physical 
characteristics such as cell size, shape and internal complexity as well as any 
cell component (Vallan & Wider 2004).
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Procedure
Cells were trypsinized as previously described and resuspended in 10% FCS 
(PAA Laboratories GmbH, Yeovil, UK) in PBS (Invitrogen Corporation, 
Gibco™) at a concentration of 5-lOxlO5 cells per tube. Cells were centrifuged 
at 230G for 3 minutes and divided into 2 falcon tubes (BD Falcon™ tubes, BD 
Biosciences, Cowley, UK) per molecule to be tested, one positive and one 
negative (control). After the last washing the medium was discarded and 
primary antibodies introduced into an approximately 100-200pl of remaining 
medium and cells. The cells were left on ice for 1 hour after which medium 
(10%FCS in PBS) was added and they were spun again at 230G for 3 minutes. 
This washing step was repeated three times prior to adding the secondary 
antibody, rabbit anti-mouse FITC (Dako Cytomation, Ely, UK) at a 
concentration of 20pg/ ml for 30-60 minutes on ice and in the dark. 10% FCS 
in PBS was added and the cells were washed three times before being taken to 
the flow cytometers for analysis. Analysis was carried out using FACscan 
(Becton Dickinson Immunocytometry Systems, Oxford, UK) which was in 
turn connected to an apple Macintosh computer fitted with Cellquest 
software set to aquire 104 events.
2.2 MOTILITY ASSAYS
2.2.1 Migration Assays
Haptotactic cell migration was measured using polycarbonate Transwell® 
inserts (Coming Costar, Poole, UK). The underside of these inserts was coated 
with the matrix protein to be tested diluted in PBS (Figure 2.5). The inserts 
were coated in 250pl of this solution for 60 minutes at 37°C. Inserts were then 
blocked with migration buffer consisting of DMEM and F12 (Appendix 1) in a 
3:1 ratio with 0.5% BSA (Sigma-Aldrich Co Ltd.). Six hundred pi of this buffer 
was placed in new wells in a 24 well plate and lOOpl of the same buffer in the 
top compartment to ensure the polycarbonate membrane was totally 
immersed. The inserts were incubated at 37°C for 1 hour.
Cells were trypsinized, counted and resuspended in migration buffer at 
lmillion cells per 1ml medium. The migration buffer in the upper 
compartment of the inserts was then removed and replaced with lOOpl of cell- 
containing medium to give a seeding density of 100,000 cells per insert. The 
inserts were incubated at 37°C for 4 hours. The inserts were then fixed in 10% 
formalin for 10 minutes followed by staining in 0.5% crystal violet in 10% 
ethanol for 10 minutes. They were rinsed briefly in water and the cells in the 
upper surface removed with a cotton bud. Membranes were allowed to dry 
overnight, cut and mounted on a slide with DPX. Cells were counted with 
phase-contrast microscopy and the number per high power field recorded.
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Figure 2.5 Haptotactic cell migration measured using polycarbonate Transwells ®. 
The underside Transwell® is coated with the matrix protein, cells are seeded in the 
upper compartment and are allowed to migrate over a period of time.
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2.2.2 W ound Assays
Cells were grown to just below full confluence, trypsinized and seeded at 105 
in 24 well plates. The cells were left overnight to reach maximal confluence 
then two denuded strips ('wounds') were created in each well with a pipette 
tip (PI000, Anachem Ltd., Bedfordshire, UK) in the form of a cross. Cells were 
once again washed with PBS to remove loosened cells. Care was taken to 
ensure the width of the wound was as constant as possible and only "similar" 
wounds were studied. Three images were taken at time zero (To) for each well 
using a Leica DMIRB inverted microscope linked to a computer running the 
Leica software FW4000 (Leica Microsystems UK Ltd., Bucks Milton Keynes, 
UK). The cells were then incubated for 4 hours at 37°C. Three images for each 
well were taken at Ti at the same position in the well using the cross mark for 
orientation. The distance migrated by the cells was assessed by subtracting Ti 
from To (See Figure 2.6) using Scion Image (Scion Corporation, Maryland, 
USA).
2.2.3 Adhesion Assays
Using a 96 well plate triplicate wells were coated with lOOpl of various matrix 
proteins to give a final dilution of lOpg/ml, for one hour at 37°C. The plate 
was washed once with PBS and blocked with 0.5% BSA in PBS for one hour at 
37°C. Cells were washed in PBS, trypsinized and resuspended in serum-free 
medium (SFM). 30,000 cells were plated per well and left for one hour at 37°C.
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Figure 2.6 Schematic representation of a high power field image of a wound in a well 
plate. At To (A) the distance between the edges of the wound is measured at various 
points and a mean is obtained. The same procedure is then carried out at Ti (B).
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This plate was then set aside. The plate with the samples to be tested was then 
washed in PBS containing 1.3mM CaCh and 0.5mM MgCh twice. lOOpl of 
SFM was added to the wells and the plate was returned to the incubator for 
one hour.
At this point 20pl of MTS (CellTiter 96® Aqueous One Solution Cell 
proliferation Assay, Promega UK) was added to both plates which were then 
returned to the incubator for a further 60 minutes. The absorbance was 
measured at 490nm and the number of adherent cells calculated by 
comparison to the standard curve adjusted to cell numbers.
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2.3 PROTEASE SECRETION ASSAYS
2.3.1 Plasminogen Activator Assay
This assay measures the concentration of PA in the conditioned medium of 
cells using a chromogenic substrate. The PA cleaves the plasminogen present 
in the reaction mixture to form the active enzyme plasmin. This reacts with 
the chromogenic substrate to release a colorimetric molecule (pNA) whose 
concentration can be measured at 405nm (Figure 2.7).
PA
Plasminogen
Chromogenic substrate
Measured at 405nm
Figure 2.7 Diagrammatic representation of plasminogen activator assay.
Procedure
Cells were trypsinized as previously described and seeded in 6- or 24-well 
plates (Nunc™, VWR International) for 4 hours in KGM to enable the cells to
attach, then after washing with PBS the medium was changed to SFM and the
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cells were left overnight. The following day the supernatant was collected, 
cleared by centrifugation at 1150G for 5 minutes and kept on ice for analysis. 
Standard solutions were obtained by preparing a number of serial dilutions of 
uPA (Chemicon International) in 50mM Tris/lOOmM NaCl/0.01% Tween 80 
(pH 7.4) and placed in 96-well plates (Nunc™, VWR International). Samples 
were also prepared in 0.01% Tris/Tween 80. Chromogenic substrate S-2251 
(Chromogenix, Quadratech, Epson, UK) was added to all the wells at a final 
concentration of 2.5pg/m l and the reaction was activated by adding Glu- 
plasminogen (Enzyme Research Laboratories, Swansea, UK) at a final 
concentration of 160nM. The plate was incubated for 90 minutes at 37°C and 
the absorbance was then measured at 405nm using the Plate Reader 340 
ATTC (SLT Labinstruments). The concentration of uPA was assessed by 
interpolation from the standard curve.
2.3.2 ID  Gel electrophoresis and Western Blot
The term electrophoresis describes the migration of molecules under the 
influence of an electric field through a colloid matrix. The degree of migration 
is dependent on the molecules' molecular weight. The larger molecules move 
through the matrix with more difficulty whereas the smaller molecules are 
more dynamic. Resulting molecular bands show and depending on their 
location an approximate molecular weight may be deduced by use of known 
molecular markers.
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Figure 2.8 Apparatus used during vertical electrophoresis (www.bio-rad.com)
Procedure
Protein Assay:
The Bio-Rad DC Protein Assay (Biorad, Hemel Hempstead, UK) was used 
according to the manufacturer's instructions, to determine the protein 
concentration in each sample. This assay is based on a colorimetric reaction 
between the protein in the sample and the copper tartrate and folin reagent in 
the buffer. The reaction yields a characteristic blue colour with maximal 
absorbance at 750nm. The protein level in cell supernatants was estimated by 
comparison to standard solutions of BSA. In this way samples containing the 
same amounts of protein can be subjected to electrophoresis.
Sodium Dodecyl Sulphate polvacrilamide gel electrophoresis (SDS-PAGE): 
Supernatants containing lOpg total proteins were diluted in non-reducing 
sample buffer (Appendix 1) and subjected to SDS-PAGE electrophoresis using
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a 10% acrylamide (Flowgen Bioscience Ltd., Nottingham, UK) resolving gel 
and 4% stacking gel (Appendix 1) in the appropriate apparatus (Figure 2.8). 
Molecular weight markers (Amersham Life Science, Little Chalfont, UK) were 
also loaded. Gels were run for 10 minutes at 100 volts, then 140 volts for 1 
hour. After running the gel the assembly was dismantled and the gel carefully 
removed and stained using Commassie Blue stain (Appendix 1).
Membrane transfer:
Proteins were transferred to a nitrocellulose membrane (Opitban, Schleicher 
& Schuell, London, UK) overnight at 140V using a mini Trans-Blot cell 
assembly (Biorad). Once the transfer was complete the blot was incubated in 
blocking solution (5% dried milk in 0.05% tween20/PBS) for 1 hour with 
agitation. The blot was rinsed in PBS/0.05% Tween20 and incubated with 
primary antibody for 1 hour with agitation. The blot was rinsed three times in 
PBS/0.05% Tween20/0.1%BSA for 10 minutes each, incubated with secondary 
antibody polyclonal goat anti-mouse IgG, final conc. 0.3pg (Dako Ltd.) for 1 
hour before repeating the three washing steps.
Development o f  the membrane
Specifically bound antibody was detected using enhanced chemiluminescence 
(ECL) according to the manufacturer's instructions (Amersham Life Science). 
In the dark room under safe light, 2ml of the ECL reagent mixture was 
pipetted over the blot and left for 1 minute. The blot was then wrapped in
cling film, placed in a cassette and exposed to radiographic film for varying 
lengths of time ranging from 15 seconds to 1 minute. The film was then 
immersed in developer followed by fixer and then washed in water and 
dried.
2.3.3 Zvmography
Gelatin zymography is a technique that involves electrophoresis of secreted 
proteases (in this case, MMP-2 and MMP-9) through polyacrylamide gels 
containing the enzyme substrate gelatin. Following electrophoresis the SDS in 
the gel is removed by washing in 2.5%Triton-X (Appendix 1) to allow the 
enzyme to renature and degrade the protein substrate. The gel is then stained 
with commassie blue and the bands of proteolytic activity can be assessed as 
clear bands of lysis against a blue background.
Procedure
Gels containing 12% polyacrylamide and 10% gelatin (Sigma-Aldrich 
Company Ltd.) (Appendix 1) were prepared and equal volume samples (20pl) 
were loaded into the wells along with molecular weight standards 
(Kaleidoscope Prestained Standard, Bio Rad). The gels were run with IX Tris- 
Glycine SDS Running Buffer (Appendix 1) at 120V for approximately 1 hour. 
The rim is completed once the bromophenol blue tracking dye reaches the 
bottom of the gel. The gel is then washed twice in Renaturing Buffer 
(Appendix 1) for 30 minutes with gentle agitation at 37°C to remove
remaining SDS and then incubated in Zymogram Developing Buffer 
(Appendix 1) overnight again at 37°C. The following day the gels are stained 
with 0.5% Commassie Blue R-250 in 40% methanol, 10% acetic acid for up to 
12 hours. The gel was then de-stained for 1 hour at room temperature until 
the clear lysis bands show. An image of the gel was taken by use of the Alpha 
imager 1220 version 5.5 (Alpha Innotech Corp™, USA). The images were then 
analysed using Scion Image (Scion Corporation).
2.4 IMMUNOHISTOCHEMISTRY
2.4.1 Indirect Immunofluorescence
Indirect immunofluorescence is a procedure carried out on cells or tissue 
sections whereby an antibody is used to link a cellular antigen specifically to a 
stain that can be more readily seen with a microscope. This procedure 
involves the detection of the antibody by fluorescence. A molecule known to 
fluoresce is attached to the antibody and is detected using UV light
Procedure
Cells were seeded at a density of 104 overnight in Defined Keratinocyte 
serum-free medium (Invitrogen Corporation, Gibco™) on 13mm cover slips 
(Nunc™, VWR International Ltd.) placed inside 24-well plates (Nunc™, VWR 
International). The following day the cells were washed with PBS (Invitrogen 
Corporation, Gibco™) and fixed with 4% paraformaldehyde in PBS for 10 
minutes at room temperature. After rinsing once with PBS they were treated 
with 0.1% TritonX-100 in PBS for 5 minutes at room temperature and were 
rinsed in PBS once more. Blocking was carried out with 0.1% sodium 
azide/ 0.1% BSA in PBS (0.1/0.1 solution) for 20 minutes at room temperature. 
Following the blocking step, the primary antibodies were added for one hour 
at 4°C (see chapter 6 for antibodies and concentrations). Negative controls 
were left without primary antibodies at this stage, in PBS to avoid the cells 
drying out. The cover slips were rinsed three times with 0.1/0.1 solution and 
the secondary antibody added, goat anti-mouse IgG FITC/Alexa-488
(Molecular Probes-Invitrogen Ltd., Paisley, UK) at a concentration of 20pg/ ml 
for 30 minutes at room temperature in a dark environment Cells were rinsed 
once and washed three times with 0.1/0.1 solution. A solution containing 4',6- 
Diamidino-2-phenyindole, dilactate (DAPI) and phalloidin-TRITC (Sigma- 
Aldrich Company Ltd.) at concentrations of 50pg/m l in 0.1/0.1 solution, was 
added for 10 minutes at room temperature and in the dark. After rinsing once 
and washing three times, each cover slip was dipped in distilled water 
(dH2 0 ), drained and mounted face down onto glass slides with anti-fade 
mountant, glycerol/PBS (Citifluor Ltd., London, UK). Slides were viewed 
using a Confocal Inverted Laser Scanning microscope (Zeiss Axiovert 200M, 
Welwyn Garden City, UK) and images collected digitally.
2.4.2 Immunohistochemistrv 
Coating o f slides
A number of primary antibodies require some form of antigen retrieval for 
optimal binding to an antigen on a tissue section. Two methods can be used, 
heat and enzymatic retrieval. When using heat to retrieve the antigen, the 
slides used m ust be coated with APES (3-Aminopropyltriethoxysilane) to 
avoid the detachment of the section under the high pressure and heat. Slides 
are soaked in hot soapy water for about 10 minutes. They are rinsed in hot 
running water for another 10 minutes and then rinsed in 2 changes of 
deionised water for a few seconds each time. They are rinsed in Industrial
Methylated Spirit, IMS (Tennants Distribution Ltd., Manchester, UK) for a 
few seconds and dried in the oven at 40°C for 1 hour. Once dry the slides are 
dipped in 5% APES (Sigma-Aldrich Company Ltd.) in IMS for about 15-20 
seconds, rinsed in IMS for a minute, rinsed in 2 changes of deionised water 
for 15-20 seconds each time and dried in the oven at 40°C overnight
Antigen retrieval
In our work we carried out both types of antigen retrieval. Heat-mediated 
antigen retrieval was necessary for cFN staining whereas beta-6 integrin and 
cytokeratin required enzymatic retrieval by Pepsin (Zymed® Laboratories, 
Cambridge, UK) and Chymotrypsin (Sigma-Aldrich Company Ltd.) 
respectively for 5 minutes at room temperature.
Heat-mediated antigen retrieval:
In this procedure sections are cooked under pressure for 2 minutes in 2 litres 
of Citrate/HCL buffer (Appendix 1) at a PH of 6.0.
Procedure
Sections were dewaxed twice in xylene (Solmedia Lab Suppliers, Romford, 
UK) for 5 minutes each time. They were then rehydrated through decreasing 
concentrations of alcohol, 100%, 95% and 50% ethanol twice for 2 minutes 
each time. They were then immersed in distilled water for 2 minutes. 
Following antigen retrieval the sections were encircled with a PAP pen 
(Zymed® Laboratories). Endogenous peroxidase was then blocked using
peroxidase-blocking solution (ChemMate, Peroxidase-Blocking Solution, 
Dako Cytomation). Primary antibodies were applied for one hour at room 
temperature.
The sections were washed twice in Tris buffered saline (TBS), (Appendix 1) 
following which the secondary antibody was added (ChemMate™ DAKO 
Envision™/HRP, Rabbit/Mouse, Sigma-Aldrich), for one hour. Slides were 
again washed twice in TBS and diaminobenzidine tetrahydrochloride (DAB) 
added for 10 minutes. Specimens were washed with TBS followed by warm 
tap water and they were then stained with Mayer's haematoxylin (Appendix 
1) for nuclear counterstain. They were washed once again with water and 
then rehydrated with ascending concentrations of alcohol, 50%, 95% and 
100% ethanol followed by xylene, and they were finally mounted using 
Permount (Fisher Scientific, Loughborough, UK) and observed under the 
microscope.
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2.5 STATISTICAL ANALYSIS
Data is expressed as the mean + /-  standard deviation of a given number of 
values. Where needed, statistical analysis was carried out using non- 
parametric analysis of variance (ANOVA) to compare multiple groups. 
Comparisons were by Kruskal-Wallis Test between 3 groups or more, and the 
Mann-Whitney Test between 2 groups. Significance was set at 5% and a p 
value of <0.05 was considered significant.
Chapter 3
CHAPTER 3
CHARACTERIZATION OF CELL LINES AND OPTIMIZATION OF 
CULTURE CONDITIONS
3.1 INTRODUCTION
Cells receive multiple cues from the environment they are in, which 
influences their phenotype and gene expression. Cell adhesion molecules 
such as integrins and cadherins mediate such environmental cues and are 
important determinants of cell morphology and behaviour. Cadherins are 
spatiotemporally regulated to correlate with specific morphogenetic and 
developmental events. It is not uncommon for tumour cells to downregulate 
their expression of E-cadherins as they change to a more mesenchymal 
phenotype. In fact, E-cadherin expression has been considered a prognostic 
marker of greater differentiation (Wheelock & Johnson 2003). There is 
established cross-talk between cadherins, integrins and their surrounding 
ECM that leads to the activation or inactivation of signalling pathways.
When studying the effect of a particular molecule on cell behaviour it is vital 
to optimize the culture conditions. The extra cellular matrix is a delicate 
balance of many molecules, cations and pH, and minor changes can influence 
responses in the cells. Baseline characterization was performed to establish 
the expression of cell adhesion molecules in relation to different medium 
constituents. Data contained within the ECM is vital for differentiative
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decisions and normal cellular homeostasis, while inappropriate changes in 
both its structure and information content lead to disease states such as 
neoplasia (Streuli 1999). In cell culture the cells are surrounded by medium 
that contains many of the molecules found in vivo. Although the composition 
of the media is formulated to mimic as much as possible the tissue fluid and 
ECM, these two entities are not necessarily the same. Establishment of the 
most appropriate medium is therefore of importance since variations can 
influence cell behaviour, such as migration and differentiation.
Migration of various cells is determined by variables such as their origin, 
adhesion receptor function and the environment they are in including the 
nature of the ECM (Murphy & Gavrilovic 1999). Loss of specific components 
of the ECM has been found to affect the differentiation of specific cell types 
(Bissell & Nelson 1999). When normal keratinocytes are placed in suspension 
they are stimulated to undergo terminal differentiation and this can be 
partially inhibited by the addition of certain ECM molecules or anti-pi 
antibodies into the medium, inducing cell adhesion. This suggests that 
adhesion normally suppresses terminal differentiation (Levy et al. 2000). 
Furthermore, cues provided by molecules in the media can regulate the 
expression of cell adhesion molecules, either inducing or inhibiting them. 
There appears a dynamic competition between integrins and cadherins for 
polymerized actin microfilaments (Weaver et al. 1997) and certain cues in the 
ECM microenvironment in vivo, or medium in culture, influence the balance
Chapter 3
one way or another. Determining cell adhesion molecule expression of the 
cells prior to experiments is necessary to establish the effects of the 
manipulation of medium constituents.
The avp6 integrin is expressed de novo and is an indicator of a more 
aggressive cell phenotype (Thomas et al. 2001a). E-cadherin expression on the 
other hand is lost in the more aggressive lesions (Christofori 2003). The VB6 
cell line used in this work expresses high amounts of the av(J6 integrin 
whereas the C l being their null transfectant express minimal amounts (see 
section 2.1). Studies on VB6 have found them to be more migratory and 
produce more proteases than their C l counterparts (Thomas et al. 2001b) 
particularly when seeded on ECM molecules such as FN.
3.2 OBJECTIVES
To confirm the cell adhesion profile of the cell lines to be used in studies 
described within this thesis and to assess whether the cell adhesion molecules 
expressed by the cells are influenced by specific media components. 
Furthermore, we aim to establish if any change observed by manipulating 
medium additives is reversible and to investigate which particular cell- 
adhesion molecule is affected.
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3.3 MATERIALS AND METHODS
3.3.1 Fluorescence Activated Cell Sorter (FACS)
Cells were grown in 25cm2 culture flasks (Nunc™, VWR International) 
overnight at 37°C in KGM. They were trypsinized and resuspended in 10% 
FCS in PBS and centrifuged for 3 minutes at 230G at a concentration of about 
5-lOxlO5 cells per tube. The supernatant was discarded and primary 
antibodies added:
• Monoclonal mouse anti-p6 (R6G9, Chemicon International)
• Monoclonal mouse anti-E-cadherin (Clone HECD-1, Abeam Ltd, 
Cambridge, UK)
• Monoclonal mouse anti-a5 (P1D6, Chemicon International)
at concentrations of lOpg/ml, for one hour on ice. Five hundred pi of 10% 
FCS in PBS was added and the tubes were washed twice before adding the 
secondary antibody, FITC-conjugated rabbit anti-mouse immunoglobulin 
(Dako Cytomation) at concentration of 20pg/m l for 30-60 minutes on ice and 
away from light. Cells were washed three times as described above and then 
subjected to FACS analysis (FACscan, Becton Dickinson Immunocytometry 
Systems). The FACscan was in turn connected to an apple Macintosh 
computer fitted with Cellquest software set to aquire 104 events.
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3.3.2 Cell sorting by magnetic beads 
Rationale
During the preliminary integrin-profiling of the cell lines, a mixed population 
of VB6 was observed (figure 3.2 A) indicating that some cells were expressing 
the p6-integrin while others were not. This is a common finding in transfected 
cell lines where some cells either loose the expression of the transfected 
molecule or cells that from the start failed to be transfected grow and divide 
and subsequently form a sub-population. Whatever the reason, seeing that the 
P6 integrin was pivotal to our work, the VB6 were sorted to isolate the p6 
positive population from the p6 negative one (Figure 3.1). This ensured a 
homogeneous population of p-6 expressing cell lines (Figure 3.2 B). The VB6 
cells were sorted using magnetic beads according to the manufacturer's 
instruction (Dynal Biotech®, Wirral, UK). Cells were trypsinized and sorted 
as described in section 2.1.5.
Figure 3.1 Sorted VB6 exhibiting the Dynabeads on their surface appeared as 
rosettes.
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3.3.3 Growth of cells in various media
VB6 and C l cell lines were grown in specified media (Table 3.1) for a duration 
of at least 5 days that included at least one passage, but averaged two. Media
were made up, filtered and stored in sterile containers at 4°C.
MEDIUM Constituents:
KGM DMEM, F12, FCS, insulin, EGF,
Penicillin/Streptom ycin, adenine, cholera toxin, 
Fungizone, Hydrocortisone.
AFM DMEM, F12, FCS, Penicillin/Streptom ycin, 
Fungizone.
AFM-A DMEM, F12, FCS, Penicillin/Streptom ycin, 
Fungizone, insulin.
AFM-B DMEM, FI2, FCS, Penicillin/Streptom ycin, 
Fungizone, EGF.
AFM-C DMEM, F12, FCS, Penicillin/Streptom ycin, 
Fungizone, cholera toxin.
AFM-D DMEM, F12, FCS, Penicillin/Streptom ycin, 
Fungizone, adenine.
AFM-E DMEM, F12, FCS, Penicillin/Streptom ycin, 
Fungizone, hydrocortisone.
SFM DMEM, F12, Penicillin/ streptomycin. Fungizone
SFM-A DMEM, F12, P enicillin/ streptomycin. Fungizone, 
insulin.
SFM-B DMEM, FI2, Penicillin/streptom ycin. Fungizone,
EGF.
SFM-C DMEM, F12, Penicillin/streptom ycin. Fungizone,
cholera toxin.
SFM-D DMEM, F12, Penicillin/streptom ycin, Fungizone,
adenine.
SFM-E DMEM, F12, Penicillin/streptom ycin. Fungizone,
hydrocortisone.
KGM + C a~ KGM+ O.lmM Ca++
Table 3.1 A list of the various media used.
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3.3.4 Western Blot Analysis
Cells were grown in 80cm2 cell culture flasks (Nunc™, VWR International) in 
KGM and AFM for a minimum of 5 days and two passages. After washing 
with PBS, 150pl of lysis buffer (Appendix 1) containing protease inhibitors 
(Sigma-Aldrich Company Ltd.) was added to each flasks which were then left 
on ice for one hour. Cells were scraped off using cell scrapers (Nunc™, VWR 
International) and collected in 1.5ml microtubes (Sarstedt Ltd.). Protein assay 
(see section 2.3.3.1) was carried out to standardize the amount of protein to be 
loaded on the gels. SDS polyacrylamide gel electrophoresis was carried out as 
previously described (section 2.3.3). Mouse anti-E-Cad (Clone HECD-1, 
Abeam Ltd., Cambridge, UK) was used as a primary antibody at a 
concentration of 1.8pg/ml, and goat anti-mouse HRP (Biosource, Nivelles, 
Belgium) was used as secondary antibody.
3.3.5 Indirect Immunofluorescence
VB6 cells grown in KGM and AFM were seeded in defined keratinocytes SFM 
at a concentration of 104/  ml on glass cover slips in a 24-well plate. Cells to be 
stained for avp6 integrin were left overnight at 37°C and those to be stained 
for E-Cadherin for 48hrs at 37°C. The primary antibodies used were mouse 
anti-E-Cad (d o n e  HECD-1, Abeam Ltd.) at a concentration of 1.8fil/ml, and 
mouse anti-p6 integrin (R6G9, Chemicon International, Chandler's ford, UK) 
at a concentration of 10pg/ml. The experiment was carried out as previously 
described (section 2.4.1).
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3.4 RESULTS
3.4.1 Characterization of integrin expression by various cell lines
The cells used in this study were analysed by performing a baseline integrin 
profile. Prior to sorting, VB6 cells showed weak expression of (36 integrin. 
The FACs analysis showed two peaks with a wide base indicating a wide 
range of (36 expression of weakly expressing cells and strongly expressing 
cells. This was resolved after sorting as shown by a clear peak of positive 
expression (Figure 3.2).
C l and VB6 were profiled for their a5pi and av(36 integrin (for FACs analysis 
see Appendix 2). Whenever possible normal hum an keratinocytes (NHK) 
were also profiled and when unavailable the normal keratinocyte cell line UP, 
which has a similar phenotype, was used (Pei et al. 1991). Expression of the 
a5pl integrin was similar in NHK, C l and VB6, whereas expression of the 
avp6 integrin was low in C l and NHK but high in VB6 (Figure 3.3, 3.4, 3.5 
and 3.6).
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Figure 3.2 Beta-6 integrin expression in VB6 cells. The concise dot plots denote 
homogeneity in the cell population. In the first graph the green area denotes 
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3.4.2 Morphology of C l and VB6 changes w hen grown in growth medium 
devoid of additives
Keratinocyte growth medium (KGM) contains serum and this in turn contains 
FN. When testing the possible effect of FN or the fragments on the cell, the FN 
in the medium posed as a potentially interfering factor. It would be difficult 
to ascertain the effect of the added FN and fragments under these 
circumstances. Bearing in mind that cells also have the ability to synthesize 
endogenous FN, it seemed important to reduce additional sources of FN as 
much as possible. The cells were therefore seeded and grow the cells in 
additive-free medium (AFM) and serum-free medium (SFM) to reduce the 
effect of unwanted exogenous FN to as low as possible. C l and VB6 grown in 
SFM and AFM, as opposed to those grown in KGM, were observed to exhibit 
a changed morphology and a resemblance to normal hum an keratinocytes in 
their growth pattern under light microscopy (Figure 3.7). Cells appeared more 
epithelioid in their growth and spreading pattern. A cell-adhesion molecule 
profile was run to confirm whether this morphologic change was associated 
with a change in cell-adhesion molecules expression. Flow Cytometry 
analysis showed a very subtle difference in E-cadherin profile (Figures 3.8,3.9 
and 3.10). Additives were added one at a time to observe when the cells 
reverted back to their original form. Normal morphology was restored when 
EGF was added back to the medium (Figure 3.7 (C)). Western blot for E- 
cadherin was carried out on lysates of VB6 grown in KGM and AFM (a 
protein assay was carried out previously to ensure equal protein loading on
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the gel, Appendix 2). Results showed clear bands for E-cadherin in the AFM- 
grown VB6 lysate wells and no bands in the KGM-grown wells (Figure 3.11). 
This is indicative of some degree of E-cadherin upregulation when grown in 
additive and serum deprived media.
Indirect immunofluorescence studies were also performed targeting the (36 
integrin and E-cadherin on VB6 plated on coverslips grown in AFM and 
KGM. The (36 integrin staining intensity and distribution showed no 
difference between VB6 grown in KGM or AFM (Appendix 2). However, E- 
cadherin staining was more widespread and more intense in VB6 grown in 
AFM than those grown in KGM (Figure 3.12 and 3.13).
# i H
Figure 3.7 Two experiments showing VB6 grown in SFM, KGM and SFM with added 
EGF (A,B and C); and VB6 grown in AFM devoid of additives; in KGM and AFM with 
added EGF (D, E and F).
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Figure 3.11 Western blot analysis of 15ug total protein showing clear bands 
for E-cadherin in AFM-grown VB6.
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Figure 3.12 Indirect immunofluorescence staining of E-Cadherin (B) and actin (C) and 
a composite (D) showing obvious cell-cell adhesion in VB6 grown in AFM.
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Figure 3.13 Indirect immunofluorescence staining of E-Cadherin (B) and actin (C) 
and a composite (D) showing less cell-cell adhesion in VB6 grown in KGM.
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3.5 DISCUSSION
During wound healing and tumourigenesis cells exhibit an alteration in their 
cell adhesion molecule repertoire. Integrins and cadherins are among such 
molecules whose expression indicates the nature of the cells. Both cell lines 
used in this study express the a5p i integrin in similar amounts (Figure 3.5 
and 3.6) (Thomas et al. 2001a). FACS analysis of our cell lines revealed the 
expression the a5pi integrin to be similar in both VB6 and C l but low in 
NHK. Expression of av(36 was low in both NHK and C l and high in VB6. This 
concurred with previous studies (Thomas et al. 2001b; Ramos et al. 2002).
3.5.1 Medium m anipulation and cell morphology
Cells respond to environmental prompts and the smallest fluctuations in 
factors such as media content, homogeneity of the cell populations or seeding 
densities can lead to altered effects. Throughout this work a diverse number 
of parameters were tested including variations in cell seeding densities, 
growth media and mode of application of fragment, either as a coating or in 
suspension. In this section the homogeneity of the cell lines was assessed to 
ensure their expression of specific integrins. Furthermore, the effects of 
various media on the cells' essential characteristics was also assessed.
The ECM surrounding all living cells signals to them via its structural 
molecules or by harbouring growth factors or growth factor-binding proteins.
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Any alterations in the ECM structure or contents can therefore have profound 
effects on cells' differentiative and homeostatic mechanisms (Streuli 1999). 
Previous work by Altanov et al. (2001) showed that cells grown in serum-free 
medium (SFM) express reduced ability to organize a FN matrix. This group 
found that growing dermal keratinocytes in SFM changed their morphology 
to a smaller and less polarized one. Changing the medium reversed this and 
induced cells to grow in colonies. Medium manipulation therefore plays an 
important role in keratinocyte morphology and FN matrix assembly. SFM 
grown cells seem to exhibit a more stationary type and seem to adhere more 
strongly to the FN matrix. However, when switched to serum-containing 
medium such stationary cells seemed more likely to move along and degrade 
the FN. This group suggests that the way keratinocytes are cultured may 
affect not only their morphology but also their migratory potential and 
behaviour (Altanov et al. 2001).
While assessing the effect of medium-manipulation on our cells, a change in 
cell morphology was observed when the cells were starved of additives 
normally present in keratinocyte growth medium. Both VB6 and C l showed a 
change in morphology from rounded, evenly-growing, mostly single cells to 
epithelioid, island-growing cells, resembling normal hum an keratinocytes. 
Since both integrins and cadherins play pivotal roles in regulating diverse 
processes such as differentiation, morphology and cell migration, it is likely 
that these two cell adhesion molecules act co-ordinately to regulate such
1-4“
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processes. This has been shown in keratinocytes where cadherins down- 
regulate integrin expression during keratinocytes differentiation but not vice 
versa (Hodivala & Watt 1994). It seems likely that the missing additives 
somehow switched the cells to exhibit more E-cadherin, or that the E-cadherin 
already present was more active. A cell-adhesion molecule profile was run 
investigating a5pi, av(36 integrins and E-Cadherin expression in cells grown 
in KGM and in AFM. Both integrins' expression remained unchanged in VB6 
grown in KGM and AFM. However, our results suggest a slight upregulation 
of E-cadherin in cells grown in AFM. To confirm this, Western blot analysis of 
lysates of VB6 grown in KGM and AFM was carried out and showed E- 
cadherin expression in cells grown in AFM but not in those grown in KGM. 
Indirect immunofluorescence showed more intense E-cadherin staining in 
cells grown in AFM. Together the results observed suggest the presence of a 
"cadherin switch" brought about by manipulating the medium.
3.5,2 Integrin-cadherin switch
The change in morphology seen when growing cell in AFM could also be 
explained by an integrin-cadherin switch where the upregulation of one 
causes the down regulation of the other and vice versa. Weaver et al. (1997) 
showed that changes in tissue structure were critical for the expression of the 
malignant phenotype and ECM receptors are important modulators of these 
effects. An integrin switch where a cell may change its integrin expression 
pattern may enhance the survival of cancer cells in changing environments
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and encourage metastasis. Hodivala et al. (1994) suggested a likely cross-talk 
between cell adhesion molecules whereby cultured keratinocytes lacking 
cadherin adhesion showed decreased overall expression of integrins and de 
novo expression of some (such as av(36) while undergoing differentiation. 
Absence of E-cadherin was also found to correlate with extended filipodia 
processes joining other cells (Hodivala & Watt 1994; Chunthapong et al. 2004). 
Huttenlocher et al. (1998) elegantly proposed a synergistic dialogue between 
these two cell adhesion molecules stating that while cadherins are necessary 
for the termination of motility in a cell, they are not sufficient Their 
observation showed that alterations in integrin expression can result in 
changes in cadherin expression and changes in its function. Seeing that 
cadherins themselves may be involved in the down-regulation of integrin 
expression, a loop is formed linking the two molecules together in a "tug-of- 
war" (Hodivala & Watt 1994).
3.5.3 EGF and cell morphology
Systematic reintroduction of the various additives was carried out and images 
were taken under light microscopy (Appendix 2). When EGF was 
reintroduced in AFM, the cells reverted to their original tumour-like growth 
and morphology. This was irrespective of the presence or absence of serum in 
the medium (similar experiments were carried out with SFM, Appendix 2). 
Many reports have associated the EGF receptor (EGFR) to E-cadherin 
expression. Over-expression of the EGFR family members strongly correlates
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with poor prognosis in carcinomas (Hazan & Norton 1998; Al Moustafa et al. 
1999). This inverse relationship is in accord with the strong correlation 
between the loss of E-cadherin and enhanced cell invasiveness in vitro and 
tumour progression in vivo (Hazan & Norton 1998; Pece & Gutkind 2000). Al- 
Moustafa et al. (1999) observed an inverse relationship between EGFR 
activation and E-cadherin expression. Activation of EGFR was found to affect 
the adhesive function of E-cadherin via the p-catenin pathway. When EFGR 
inactivating antibodies were added to cultures, expression of E-cadherin was 
upregulated and the cells changed to a more epithelial phenotype as shown 
by indirect immunofluorescence and flow cytometry (Al Moustafa et al. 1999). 
This group further demonstrated that expression and modulation of EGFR is 
essential for phenotype conversion and proliferation of human epithelial-like 
lung cancer cells. Furthermore, in the same lung cancer cell line EGF was able 
to produce cell scattering possibly affecting motility; EGF-antibodies induced 
upregulation and re-localization of E-cadherin/catenin complex (Al Moustafa 
et al. 2002). This is likely considering that EGFR is co-localized to adhesive 
structures with E-cadherin even in the very early stages of cell-cell adhesion 
complex formation. Both E-cadherin and EGFR cooperate directly to activate 
signalling pathways (Pece & Gutkind 2000).
In onr work the cells reverted to their original phenotypic appearance by 
simply adding EGF back into the medium without carrying out any other 
manipulation; it seems that the mechanism involved could be very simple and
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basic. The reversion was observed to be irrespective of the cells' expression of 
the integrins associated with high motility and aggressiveness, portent of the 
secondary role played by such integrins in this situation. It has been reported 
that changes in cadherin expression alter integrin expression and therefore 
affect differentiation (Huttenlocher et al. 1998). Hodivala and Watt (1994) 
provided evidence that E-cadherin is upregulated during keratinocyte 
differentiation. Deugnier et al. (2002) showed that mammary basal epithelial 
cells, displaying phenotype plasticity, grown in EGF deficient medium had 
good cell-ECM contacts and lacked good cell-cell contacts. This was reversed 
by growing the cells in EGF containing medium for 8-10 days. It seems that 
EGF acts as a negative influence of basal keratinocyte phenotype and this 
appears to be a reversible effect. Treatment of mammary basal epithelial cells 
with EGF induced the production of MMP-2 and increased scattering and 
mobility on laminin-5 (Deugnier et al. 2002). This group grew cells with and 
without EGF and the former, while retaining the same integrin repertoire, 
showed an upregulated secretion of MMPs, particularly MMP-2. This was 
also reflected in the cells ability to migrate over laminin-5. Integrins and 
cadherins are both connected to the cell's cytoskeleton and the theory is that 
they may compete for some accessory cytoskeletal molecule that is required 
for stable expression during keratinocyte differentiation (Hodivala & Watt 
1994). Yet others have shown that squamous carcinoma cells, despite 
retaining E-cadherin expression differed from the non-malignant counterparts 
in their expression of integrins, intermediate filaments and protease secretion
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(Ghosh et al. 2002). This inverse relationship was not seen in normal 
keratinocytes (Gasparoni et al. 2004). Although links between E-cadherin and 
integrins have been previously shown, alterations in the level of E-cadherin 
induced by media components in our data did not result in changes in a5 and 
p6 integrin expression.
3.5.4 Conclusion
Loss of specific components of the ECM, changes in ECM receptors, growth of 
cells on different types of ECM and in different types of media have all been 
found to affect the differentiation of specific cell types (Bissell & Nelson 1999). 
Tumour cells thrive on the signals they receive from their surroundings and 
EGF is a major component of tumour microenvironment. E-cadherin and 
integrins are important determinants of cell behaviour and their expression 
was shown to be influenced by medium constituents. A loop seems to exist 
connecting integrins, E-cadherin and EGF, and is liable to include more 
molecules and signalling pathways as more associations are established.
Signalling events linked to the maintenance of normal tissue architecture are 
sufficient to abrogate malignancy and to repress the tumour phenotype 
(Weaver et al. 1997). The malignant cell's inherent ability to secrete and attract 
the molecules it needs to sustain it, enables it to become resistant to the body's 
natural defences and becomes immortalized. Adding or omitting additives in
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the medium sustaining cancer cells in vitro may therefore alter the cell's 
phenotype and characteristics.
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FIBRONECTIN FRAGMENTS AND CELL MOTILITY
4.1 INTRODUCTION
Cell motility is an essential step in cancer progression. In order for cancer cells 
to spread and metastasize they m ust first detach from the primary lesion, 
breach the basement membrane and remodel the surrounding extracellular 
matrix in order to reach distant loci. Cancer cells are able to alter their 
expression of cell adhesion molecules and production of proteases in order to 
enable them to accomplish such migration. This complex mechanism involves 
the interaction of tumour cells with a myriad of extracellular matrix molecules 
and their fragments and this is mainly mediated through integrins. Upon 
binding of integrins to various ligands a cascade of signalling is initiated that 
not only alters the gene expression but also initiates association with the cell 
cytoskeleton to promote cell motility and cell-attachment/detachment.
4.1.1 Integrins and cell motility
The role of integrins as bidirectional signal transducers makes them central to 
the search for therapies that target and alter their signals. Many studies have 
shown the altered expression of various integrins during tumour growth and 
progression (Clezardin 1998; Mizejewski 1999) in particular the integrins 
involved in cell motility; such integrins are either over-expressed or no longer 
expressed. Although most tumours retain normal expression of at least some
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of their integrins, some integrins may also be selectively activated/inactivated 
to avoid cell adhesion and extracellular matrix binding at inconvenient times 
and locations (Mizejewski 1999). Integrins are repeatedly implicated in 
malignant transformation, tum our progression and metastasis (Mizejewski 
1999). Of particular interest to our study are changes in the expression of FN- 
binding integrins, a5pi and avp6. Generally the a5pl integrin correlates with 
low level of transformation (Clezardin 1998; Mizejewski 1999) and its re­
expression has a negative effect on anchorage-independent growth (Clezardin
1998). The avp6 integrin is expressed de novo in tumours and during wound 
healing and is also thought to play a role in the transition to a malignant 
phenotype (Niu et al. 2001). The upregulation of the avp6 integrin by tumour 
cells makes it a potential marker of malignancy and aggressiveness.
4.1.2 Fibronectin Fragments and cell motility
The extracellular matrix is far from an inert unchanging scaffold, but rather is 
a rich dynamic information-rich source of inputs for cells (Hynes 1992; Hynes
1999). It seems probable that fragments of extracellular matrix molecules 
provide motility cues in the tumour microenvironment Digestion of these 
molecules by various proteases might expose otherwise hidden cryptic sites 
that possess activities quite different from the parent molecule (Yamada 2000). 
Fibronectin is an important extracellular matrix component that has been 
associated with normal cell phenotypes. Fibronectin-rich matrices provide 
substrates for cell adhesion and migration during development, wound
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healing and tumourigenesis (Hynes 1992; Hynes 1999). During tumour 
transformation, one of the first observations is the failure of tumour cells to 
deposit such a FN matrix (Colombi et al. 2003). It has been proposed that the 
fragmentation of FN is brought about by the up-regulation of protease 
secretion and down-regulation of FN-binding proteins in cancer cells 
(Colombi et al. 2003). Various FN fragments have been studied in relation to 
migration and protease secretion.
4.2 OBTECnVES
To assess the effect of FN fragments on migration, adhesion and the 
morphology of VB6 and C l cells when compared to the intact molecule.
Chapter 4
4.3 MATERIALS AND METHODS
Based on results from our previous chapter, defined SFM (Invitrogen 
Corporation, Gibco™) was our growth medium of choice during our 
experiments, unless otherwise stated.
4.3.1 Migration Assays
Haptotactic cell migration was measured using polycarbonate Trans well® 
inserts as described in section 2.2.1 (Coming Costar). The underside was 
coated with pFN, 120 kDa FN fragment (Upstate®, Biotechnology, Botolph 
Clayden, UK), 30 kDa amino-terminal FN fragment (Sigma-Aldrich Company 
Ltd.) and PHSRN peptide (Upstate®, Biotechnology) diluted in PBS to give a 
final concentration of lpM /m l, and the cells were allowed to migrate over a 
period of 4 hours (Figure 4.1).
Figure 4.1 High power microscope image of a field from a Transwell® membrane 
mounted on a slide. Cell (arrow) were counted per field.
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In the blocking experiments, mouse anti-human a5pl monoclonal antibody 
P1D6 and mouse anti-human avp6 monoclonal antibody 10D5 (Chemicon 
International, Chandler7 s ford, UK) were used at a concentration of lOpg/ml.
4.3.2 Adhesion Assays
Using a 96 well plate triplicate wells were coated with lOOpl of pFN, 120 kDa 
fragment and 30 kDa fragment, diluted in PBS to give a final concentration of 
IpM /m l, for one hour at 37°C, as previously described (section 2.2.3). 
Doubling standard dilution of cells was set up in SFM. 20pl of MTS (Cell Titer 
96® Aqueous One Solution Cell proliferation Assay, Promega UK) was added 
to both plates and following one hour incubation at 37°C in the dark, the 
absorbance was measured at 490nm by using Plate Reader 340 ATTC (SLT 
Labinstruments, Austria).
4.3.3 W ound Assays
VB6 and C l cells were grown to just below full confluence, trypsinized and 
seeded at 105 in 24 well plates. In one set of triplicate experiments the wells 
were coated with 250pl of pFN or 120 kDa FN fragment in PBS to give a final 
concentration of IpM /m l. In another set of triplicate experiments, rather than 
coating the wells, the cells were seeded in uncoated wells but were incubated 
with defined SFM (Invitrogen Corporation, Gibco™) containing the various 
matrix proteins at dilutions that gave the same final concentration as
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mentioned previously. The experiment was carried out as previously 
described in section 2.2.2 (Figure 4.2).
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Figure 4.2 High power images of a wound assay at To and Ti. A t To various random 
measurements are taken at various points. At Ti the same area is visualized and 
random measurements are taken again. Means are then calculated for both A and B 
and die mean for Ti is subtracted from To. The result is an indication of the average 
distance migrated by the cells over time to close the wound.
4.3.4 Proliferation Assays
To establish the optimal cell density to seed in each proliferation assay 
experiment, a pilot experiment was carried out using C l and VB6 at two 
densities, (15x104 and 30 xlO4) and using two time points, To and Ti (after 24 
hours). We established 30 xlO4 to be the optimum to use in all the following 
experiments (Appendix 2). Triplicate wells in a 96 well plate were coated with
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pFN and 120 kDa fragment diluted in PBS at a final concentration of lpM /m l 
and the control being PBS. One plate was set with standards of cell densities 
starting from 6X104. Four plates were set up; To being 6 hours, Ti 24 hours, T2 
48 hours and T3 76 hours. At each specified time point the wells were washed 
with PBS and blocked by adding lOOpl of SFM and incubated at 37°C for 1 
hour. Twenty pi of MTS (Promega UK) was then added to each well and the 
plate was again incubated at 37°C for 1 hour. Absorbance was measured at 
490nm by using Reader 340 ATTC (SLT Labinstruments). The number of 
adherent cells was calculated by comparison to the standard curve.
4.3.5 Indirect Immunofluorescence
A set of two experiments were set up, one for E-cadherin staining and one for 
avp6 integrin staining, both concomitant with actin and nuclei staining. VB6 
cells were seeded in defined keratinocyte SFM (Invitrogen Corporation, 
Gibco™) at a concentration of 104 on glass cover slips in a 24-well plate, cells 
to be stained for avp6 integrin were left overnight at 37°C and those to be 
stained for E-cadherin for 48hrs at 37°C.
Cells were rinsed and washed using 0.1/0.1 solution of 0.1% azide, 0.1% BSA 
in PBS and primary antibodies added, R6G9 monoclonal mouse anti-(36 at a 
concentration of lOpg/ml in 0.1/0.1 solution, and anti-E-Cad (Clone F1ECD-1, 
Abeam Ltd.) at a concentration of 1.8pg/ml and incubated for 1 hour at room 
temperature. Negative controls were left in PBS devoid of primary antibody.
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Following rinsing and washing off the primary antibodies, the cells were 
incubated with the secondary antibody for 30 minutes at room temperature 
and in a dark environment. Actin was stained using phalloidin-TRITC 
(Sigma-Aldrich Company Ltd.), and nuclei were stained with DAPI (Sigma- 
Aldrich Company Ltd.). After mounting the cover slips face down onto glass 
slides, images were captured using a Confocal Inverted Laser Scanning 
microscope (Zeiss Axiovert 200M, Welwyn Garden City, UK).
Chapter 4
4.4 RESULTS
4.4.1 VB6 migration towards fragments: Up-regulation towards the 120kDa 
FN fragment
Beta 6 expressing cells were found to migrate at approximately twice the rate 
towards the 120 kDa fragment as compared to the intact pFN, and the 30 kDa 
FN fragment (Figure 4.3 and Figure 4.4). Migration of these cells towards pFN 
was also three-fold higher than for the C l towards the same molecule. This 
confirms the importance of the avp6 integrin in the mediation of such 
migration despite the presence and known function of the a5pl integrin in 
both cell lines. Furthermore, blocking experiments with anti-a5pi antibody 
P1D6 and anti-avp6 antibody 10D5 showed a significant reduction in 
migration when the avp6 integrin is blocked (Figure 4.5). Blocking both 
integrins by using both antibodies showed an additive effect and lowered 
migration further. This clearly outlines the importance of both integrins in cell 
migration towards FN and in particular the avp6 integrin towards the 120kDa 
FN fragment.
Wound assays showed no significant differences in migration whether the 
fragments and the parent molecule were coated on the wells or incubated 
within the culture medium (Figure 4.6 and 4.7), and no significant difference 
between the VB6 and C l cell lines.
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Figure 4.3 Migration of Cl and VB6 towards pFN, 120 kDa FN fragment and 
control (PBS).VB6 cells showed a significant increase in migration towards the 120kDa 
FN fragment compared to pFN (p value=0.001), and overall increased migration 
towards both the fragment and intact molecule compared to Cl.
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Figure 4.4 Migration of Cl and VB6 towards pFN, 30 kDa FN fragment and 
control (PBS). VB6 cells showed increased migration towards the intact pFN 
molecule but failed to show any difference from the Cl in migration towards 
the 30 kDa FN fragment.
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Figure 4.5 Migration of VB6 cell line on 120kDa FN fragment using no antibody, 
anti-a5pl antibody (P1D6), anti-avp6 antibody (10D5), both antibodies and 
IgG control. A significant reduction in migration was observed using P1D6, 
10D5 and both antibodies together (p value=0.001).
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Figure 4.6 Wound assay on plate coated with 120 kDa FN fragment and pFN.
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Figure 4.7 Assay showing wound closure of Cl and VB6 incubated with 120kDa 
FN fragment and pFN.
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4.4.2 Increased migration towards the 120kDa FN fragment is independent 
of attachment and proliferation
In our study we have found no apparent difference in proliferation rate 
among both C l and VB6 on pFN and the various fragments (Appendix 2). 
This indicates that the increased migration is not due to increased 
proliferation resulting in increased cell number. The similarity in adhesion of 
the two cell lines indicates that the increased migration is independent of 
increased initial adhesion (Figure 4.8).
Having established that there was a difference in migration on the various 
substrates a comparison of the results was carried out with normal primary 
human keratinocytes (NHK). Migration assays, proliferation assays and 
adhesion assays were carried out using the same parameters used for the C l 
and VB6. The up-regulated migration observed in the VB6 on the 120kDa was 
absent in the normal cell lines, pFN was in fact more pro-migratory than the 
fragment (Figure 4.9). Proliferation assays showed no apparent difference 
among the various substrates (Figure 4.10).
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Figure 4.8 Adhesion assay showing adhesion of VB6 and Cl on pFN, 
120kDa FN fragment and control.
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Figure 4.9 Migration of NHK on pFN and 120kDa FN fragment; control was 
omitted on account of the absence of migration without a substrate. NHK 
cells showed a significant increase in migration towards the pFN rather than 
the 120kDa FN fragment (p value= 0.001)
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Figure 4.10 Proliferation assay of NHK on pFN and 120kDa FN fragment.
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4.4.3 Morphology studies by indirect immunofluorescence of cells plated 
on various substrates
In order to investigate the effect of the 120kDa FN fragment on cell 
morphology and compare it to the effect of the intact molecule, indirect 
staining by immunofluorescence was carried out. Both actin and the avp6 
integrin of VB6 plated on the two substrates were stained and observed. 
There is little evidence of any changes in distribution pattern of the avp6 
integrin, however, there is an indication of increased filopodia and 
lamellipodia in the cells seeded on the 120kDa FN fragment as opposed to the 
ones seeded on the pFN (Figure 4.11 and 4.12). Negative controls for these 
experiments involved the omission of the primary antibodies (Appendix 2).
Immunofluorescent analysis of the cell-adhesion molecule E-cadherin was 
also carried out to complete the morphologic characterization of the cells on 
account of its importance in cell morphology and close association to the actin 
cytoskeleton. No apparent difference in stain intensity was observed (Figure 
4.13 and 4.14).
Figure 4.11 Staining of the nuclei (A), avf*6 integrin (B), actin cytoskeleton (Q  and a 
com posite of the three (D) of VB6 plated on the 120kDa FN fragment. Lamellopodia 
and filipodia are apparent (arrows).
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Figure 4.12 Staining of the nuclei (A), avf>6 integrin (B), actin cytoskeleton (C) and a 
composite of the three (D) of VB6 plated on pFN.
Figure 4.13 Staining of the nuclei (A), E-cadherin (B), actin cytoskeleton (C) and a 
composite of the three (D) of VB6 plated on 120kDa FN fragment.
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Figure 4.14 Staining of the nuclei (A), E-cadherin (B), actin cytoskeleton (Q and a 
composite of the three (D) of VB6 plated on pFN.
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4.5 DISCUSSION
Paradoxically, the feature of epithelial cells that enables w ounds to heal is also 
the one that facilitates the spread  of cancer: enhanced motility. Tight 
regulation of such m otility is w h at differentiates the tw o conditions from each 
other and renders one "benign" and  one "m alignant". D uring w ound healing, 
keratinocytes become activated and  start m igrating into the wound. Such 
m igration involves the coordinated expression of extracellular matrix 
proteins, their receptors and  proteinases (Larjava et al. 2002). W hen there is 
im pairm ent of the regulatory process and loss of its coordination, 
tum ourigenesis m ay occur. W hether in w ound healing or in tum our invasion 
and  m etastasis, the result is due to cell responses to microenvironmental 
motility cues (Q uaranta 2002). M igrating keratinocytes change morphology 
from a polarized basal keratinocyte to an elongated and flattened one with 
cytoplasm ic processes and ruffled edges, resembling a mesenchymal 
phenotype (M ercurio & Rabinovitz 2001; Larjava et al. 2002). An additional 
characteristic is a change in their expression pattern of integrins, namely a5p i 
and avp6. These integrins are typically expressed at low levels in normal, 
healthy, adu lt epithelium  (H aapasalm i et al. 19%; Hakkinen et al. 2000; 
Koivisto et al. 2000). W hile expression of the a 5 p l integrin is high during 
initial m igration, the avp6 integrin expression is maximal when migration is 
well established (H aapasalm i et al. 1996).
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Proteolytic fragm ents of ECM have a w ide range of activities including 
chem oattraction. A m ong the various effects such fragments have been found 
to exhibit are: enhanced derm al fibroblast chemotaxis, keratinocytes 
m igration and  induction of hum an  platelet aggregation (Pilcher et al. 1997; 
M essent et al. 1998; Stringa et al. 2000). FN, collagen IV and laminin are 
pow erful sim ulators of m igration of tum our cells and non-transform ed cells. 
Studies on extracellular fragm ents have already been carried ou t on several 
extracellular molecules. D egradation products of collagens are involved in a 
variety of processes such as endothelial and  blood cell chemotaxis (Ortega & 
W erb 2002), chondrocyte M MP secretion and dow nregulation of collagen 
secretion (M essent et al. 1998), anti-angiogenesis and m igration of neural and 
non-neural cells (Ortega & W erb 2002). Break-down products of collagen IV 
w ith exposed cryptic sites have been show n to prom ote cell migration in 
carcinoma cells (Xu et al. 2001). Laminin fragm ents have been implicated in 
rem odelling m ouse tissue (Koshikawa et al. 2000), rodent skin carcinoma 
(Koshikawa et al. 2000) and rem odelling m am m ary glands (Koshikawa et al.
2000). Cleavage of laminin-5 by MMPs has been observed to increase motility 
m arkedly in carcinom a cells (Giannelli et al. 1997).
M igrating keratinocytes express alternatively spliced EDA FN whose RGD 
sequence is recognized by both a 5 p l and  avp6 integrins (Larjava et al. 2002) 
and  it is thought tha t FN m ay participate in the induction of its ow n receptor 
(Larouche et al. 2000). Studies have established the pivotal role played by FN
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in both w ound  healing and  tum ourigenesis and the ability to migrate over FN 
may be a crucial step  in tum our invasion and m etastasis (Koivisto et al. 2000). 
O n account of the m odular nature  of the inform ation provided to the cell by 
the different dom ains of FN, different proteolytic fragments evoke cellular 
responses that are distinctly different from those provoked by the intact 
molecule. Cell-binding fragm ents, and  not heparin- or collagen/gelatin- 
binding dom ain of FN or intact FN, m odulate the expression of proteinases 
(Hu et al. 2000). FN fragm ents induce proMMPs, uPA and decrease TIMP-1 
and TIMP-2 (Hu et al. 2000). Some have suggested that the distinct differences 
in cellular response to the 120 kDa FN fragm ent and the intact molecule may 
reside in the EUCS site of FN (Hu et al. 2000).
45.1 Fragm ents an d  m igration
The m igration assays that w ere carried ou t m easure the fragments' 
chemotactic properties by a concentration grad ien t An apparent increase in 
m igration of p6 expressing cells tow ards the 120kDa cell-binding FN fragment 
w as observed. Binding to this fragm ent is through the avp6 integrin by 
recognition of the RGD sequence. It also binds the a5 p i integrin and in this 
case the PHSRN sequence acts as a synergistic site. O ur results show not only 
greater m igratory stim ulation by the cell-binding fragment, but also found the 
VB6 cells to be m ore m igratory com pared to the (J6 null transfectant parent 
cells, C l. This confirm s previous experim ents perform ed in our laboratories 
(Thomas et al. 2001a). The m ore m alignant phenotype associated w ith the
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expression of the p6 integrin has been show n by others to be over-expressed 
in colon carcinom a cells and involved in the prom otion of tumourogenicity 
(Varner & Cheresh 1996; Agrez et al. 1999). O ur results not only depict the 
cell-binding fragm ent as an  active m ediator of m igration but also establish the 
im portant role played by the avp6  integrin. O ther groups have observed that 
enhanced expression of various extracellular m atrix proteins w as found 
maxim al underneath  keratinocytes expressing this integrin (Clark et al. 1988; 
Clark et al. 19%; H aapasalm i et al. 19%). A lthough Liu et al. (1998) have 
show n the heparin-binding 30kDa FN fragm ent to be im portant in increased 
m igration of cells in soft tissue sarcomas, our experim ents showed no effect 
w ith this fragm ent nor w ith  the peptide. This suggests the presence of other 
sites w ithin the 120kDa FN fragm ent, no t present in the other two fragments, 
w hich are responsible for the increased migration. Furthermore, the av^6 
integrin doesn 't bind to either the 30kDa FN fragm ent or the PHSRN peptide.
Cultures of SCC cells have show n that the deposited FN matrix was m ade up 
of truncated and less organized fibres and the addition of anti-avp6 antibody 
restored the deposition to an organized FN matrix (Ramos et al. 2002). Liu et 
al. (1998) have show n that the conditioned m edium  from oral squamous 
carcinom a cells is rich in prom igratory FN fragments. Kapila et al. (19%) have 
show n that the 120 kDa FN fragm ent possesses activities not found in the 
parent molecule w hich affects proliferation, and  stimulates migration. Active 
proteolysis of FN m ay occur close to cells undergoing neoplastic
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transform ation. Such fragm ents can  induce the generation of plasmin by 
cancer cells and  can lead to the activation of MMPs which not only break 
dow n extra cellular m atrix barriers, but also degrade FN further and release 
pro-m igratory fragm ents thus form ing a loop (G rant et al. 1998).
O ur w ound assay experim ents show ed no difference in m igration between 
the fragm ent and the intact molecule. This could be on account of the 
different environm ent of the w ound  assay. In this assay the cells were either 
seeded on the m atrix protein, or incubated w ith  it, and left overn ight Cells 
produce their ow n m atrix proteins and  therefore receive signals in a different 
m anner from the grad ien t of m igration assays. In m igration assays we are 
seeing the isolated effect of the fragm ent's exposed cryptic sites on the cells 
w ithout the involvem ent of any  other factor. Moreover, w hen keratinocytes 
m igrate laterally from  a cell cluster m igration seems to be m ediated mainly by 
the p i  integrins rather than  the p6 integrins (Larjava et al. 2002). O ur findings 
suggest that p6 integrins are active in  the presence o f migration gradients but 
play a lesser role in  m ore complex environm ent w hen more that one ECM 
molecule may be p re se n t C ultured keratinocytes and keratinocytes in vivo 
during  w ound heading show the  ability to  switch from  one integrin to another 
indicating a level of integrin redundancy (Larjava et al. 2002).
M easurem ent of m igration of NHK on the same matrix proteins showed 
increased m igration tow ards the intact molecule or just lower migration
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tow ards the fragm ent. Norm al hum an keratinocytes express lower levels of 
the av  (46 integrin than their m alignant counterpart and activated 
keratinocytes in w ound  healing (Thomas et al. 2001b) and are generally less 
m igratory expressing higher levels of E-cadherin. Growth in culture 
stim ulates re-expression of the av(46 integrin, however, it is still considerably 
less than the VB6 cells (Figure 3.7). It is reasonable to conclude that the ov(46 
integrin m ay be pivotal to the cells7 response to the fragm ent
45.2 The a v (36 integrin and m igration
The a5 p i integrin is seen as a prototype FN receptor since it is specialized for 
b inding to this ligand and  is expressed by many cell types for which it is the 
major FN receptor p re se n t The RGD loop in IIIio is the critical recognition site 
for a 5 p i bu t the synergy site PHSRN is required for high affinity binding 
(Livant et al. 2000). The avp6 integrin is expressed by epithelial cells during 
developm ent and  w ound  healing and by m any tum our cells. Agrez et al. 
(1994) have show n that the re-expression of the crvp6 integrin has been 
implicated to increase proliferation of epithelial cells. However, this effect was 
show n to be absent w hen plating the cells on matrix proteins such as collagen 
or FN. The effect w as nonetheless pronounced in three-dimensional culture 
environm ents. This fits w ith the observed increased migration of p6 
expressing cells on FN fragm ent and  suggests a more motile phenotype. 
Fibronectin is av(46 integrin7 s m ain ligand to which it also binds via the RGD 
sequence, bu t does no t require the synergy site. It is the only integrin
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expressed exclusively by epithelial cells (Johansson et al. 1997). This de novo 
expression suggests that its presence may m odify the cells phenotypic 
activities. O thers have show n that increased expression of this integrin was 
found to be the m ain individual m ediator of cell m ovem ent in migration 
assays (H uang et al. 1998).
Blocking experim ents w ere carried ou t to determ ine the importance of each 
integrin in this m igration. G roups w orking on breast tum our cells showed 
that anti-a5 antibodies reduced FN-induced m igratory properties and FN- 
m ediated adhesion (Bartsch et al. 2003). Others have show n that blocking the 
a 5 p i integrin by the addition  of a function-blocking antibody (P1D6) greatly 
reduced fragm ent-m ediated m igration in keratinocytes and fibroblasts 
(Livant et al. 2000). This is consistent w ith our findings. M igration of VB6 was 
reduced w hen both integrins w ere blocked separately; however, maximal 
inhibition of m igration was show n w hen both integrins were blocked, 
suggesting an additive effect
4.5.3 Fragm ents, adhesion  and  pro liferation
Inhibition of tum our cell adhesion is no t always associated with reduced 
m igration and this can be explained by adhesion being primarily related to 
the binding of integrins to ECM w hereas m igration is more complex and 
involves cycles of adhesion and  de-adhesion as well as the activation of 
intracellular signalling pathw ays w hich in tu rn  lead to varying cellular
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activities. M any have show n tha t no single integrin antagonist could totally 
abolish breast cancer cell adhesion and m igration on FN, and it can be 
concluded that m ore than  one integrin is involved in the process. M alignant 
tum ours express great degrees of heterogeneity in integrin expression in 
breast cancer cells (Bartsch et al. 2003).
H aving establishing the pro-m igratory properties of the cell-binding 
fragm ent, proliferation and  adhesion assays were carried o u t  The aim  was to 
ascertain w hether the increase in m igration was a result of an increase in the 
cells' proliferative activities. O thers have show n that the 120kDa FN fragm ent 
reduces proliferative activity and  enhances apoptosis in m am m ary epithelial 
cells (Schedin et al. 2000). O ur assays show ed no increase in proliferation of 
VB6 plated on fragm ent or whole molecule and this is inconsistent w ith 
findings of others (Agrez et al. 1994). Therefore it seems that these fragments 
exhibit their effect via p6 integrin alone and are independent of alterations in 
cell grow th and proliferation.
The m igration process involves the recognition and attachm ent of the cell to 
ECM molecules, followed by the detachm ent of the trailing edge and bodily 
translocation in the direction of the chemotactic stimuli (Mercurio & 
Rabinovitz 2001). H aving established that cells in our studies recognized the 
cell-binding FN fragm ent via their integrin receptors, adhesion assays were 
carried ou t to establish w hether the increased m igration was dependent on
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any changes in adhesion. Results show ed no difference between the matrix 
molecules tested, indicating that, rattier than decreasing the adhesion (with 
subsequent increase in migration), the fragm ent acts as a signal, independent 
of a quantitative change in a ttachm en t It seems that the role of the cell- 
binding fragm ent is in the stim ulation of single cell m igration via the av(36 
integrin (as opposed to the a 5 p l integrin). The avp6 integrin has been 
im plicated in this m igration by several studies (Larjava et al. 2002) and has 
been show n to play an im portan t role in the m igration studies described in 
this thesis.
45 .4  M igration an d  m orphology
W hen a keratinocyte changes from  a stationary cell to a m igratory one, its 
m orphology changes accordingly. Am ong the changes is the appearance of 
lam ellipodia and  filipodia (Kassis et al. 2001; M ercurio & Rabinovitz 2001). 
O ne of the m ost im portant functions of FN is maintenance of cell morphology 
via organization of cell attachm ent to ECM. After plating VB6 on various 
matrices, the cells exhibited varying degrees of spreading and morphologies. 
A m ore m igratory phenotype was seen in cells plated on the fragment as 
com pared to the intact molecule. However, no evidence of a down-regulation 
of E-cadherin in cells plated on the fragm ent w as observed. There exists an 
inverse relationship betw een the expression of E-cadherin and the migratory 
potential of the cell (W heelock & Johnson 2003). We could assume a reverse 
relationship betw een the (36 integrin and  E-cadherin, and the fragm ent may
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possibly influence the cells to have a m ore active p6 integrin and a more 
quiescent E-cadherin. A lthough others have show n a down-regulated 
expression of this cell-adhesion molecule in invasive cancer cells (Margulis et 
al. 2003) there w as no evidence of a difference in E-cadherin expression of 
cells plated  on plasm a FN and the 120 kDa FN fragm ent The reasons for our 
findings could be that staining experim ents, while detecting the presence of 
the antigen, do no t give any inform ation on the activity of the molecule.
4 5 5  C onclusion
It seems likely that the intact FN molecule, found in copious am ounts in 
active w ound healing and  tum ourigenesis, is cleaved by cellular proteases to 
yield fragm ents that possess different properties from  the parent molecule. In 
this work we studied  both the heparin-binding dom ain 30 kDa FN fragment 
and the 120kDa cell-binding fragm ent and found the latter to upregulate 
m igration of p6 expressing cells. This increase in locomotion is not 
accom panied by increased proliferation or adhesion, and is blocked by anti-(16 
antibodies. We have also show n that the a5 p l integrin plays a role but believe 
it to be secondary. M orphologically, cells exhibit a m igratory phenotype when 
plated on the fragm ent.
In theory, blocking the action of this FN fragm ent should inhibit or block 
invasion. Bartsch et al. (2003) synthesized an antagonist peptide to block the 
binding of a 5 p i integrin and  consequently block or alter the effects of ligand
binding. A lthough this was successful in vitro, cancer cells have shown a 
cunning ability to ad ap t and utilise other integrins to bypass such blockades. 
This reaffirms the complexity of the m echanisms involved and indicates that 
other molecules such as MMPs and  proteases m ay also play a role in this 
increased m igration.
CHAPTER 5
FIBRONECTIN FRAGM ENTS A N D  PROTEASE SECRETION
5.1 IN TR O D U CTIO N
Tum our invasion and  m etastasis depend on the ability of the tum our cells to 
co-ordinate a series of biological events implicated in the formation and 
degradation of structural m atrix proteins (Reuning et al. 1998). Tumour 
invasion and  w ound  healing are both processes that involve the active 
m igration of cells. Cell m igration into the surrounding ECM is inherently 
linked to a localized cell surface proteolytic activity which favours the cell 
detachm ent from the ECM and invasion into the surrounding degraded 
matrix. This m echanism  is brought about by the interaction of integrins and 
proteases, nam ely uPA and MMPs. Tumourigenesis differs from normal 
w ound healing in that cancer cells use uPA or MMPs in conjunction with 
some integrins a t tim es or places that is incompatible with normal cell 
behaviour (Clezardin 1998). U pregulation of the avp6 integrin in SCC 
suggests a role in tum our progression and possible role in the upregulation of 
such proteases (Thomas et al. 2001a).
5.1.1 F ibronectin an d  M M Ps
Matrix m etalloproteinases play an  im portant role in tum our grow th and 
m etastasis by degrading  m atrix barriers and by enhancing angiogenesis 
(W estermarck & Kahari 1999). Furtherm ore they can release growth factors
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and angiogenic factors from  the cell surface and ECM (Suzuki et al. 1997). A 
great deal of evidence implicates MMPs in cancer spread (Westermarck & 
Kahari 1999) and  it seems that the interaction occurring between integrins and 
MMPs is the general m echanism  commonly em ployed during tissue 
rem odelling and  tum ourigenesis (Clezardin 1998).
5.2 OBJECTIVES
To assess the effect of the FN fragm ents on the production of the serine 
protease uPA and  die effect of the 120kDa FN fragm ent on matrix 
m etalloproteinases MMP-2 and -9 production in both (C6 expressing cell line 
(VB6) and the null transfectant (Cl).
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5.3 MATERIALS AND METHODS
Protease expression can be m easured by different techniques that assess the 
production of proteases either directly or indirectly. They either m easure the 
actual presence of the proteins (W estern Blots) or m easure their activities 
(plasm inogen activator assays and  zym ography).
5.3.1 P lasm inogen A ctivator A ssay
Six-well plates (Nunc™, VWR International) were coated w ith pFN, 120kDa 
FN fragm ent, 30kDa FN fragm ent and PHSRN peptide in PBS at a 
concentration of lp M /m l. Cells w ere seeded at a concentration of 3x10s in 
defined SFM and left o v ern ig h t The following day the supernatant was 
collected and assayed by plasm inogen activator assay as described in section 
2.3.1. In another set of experim ents the matrix proteins were added to the 
m edium  (in solution) at the same concentrations, rather than coating.
5.3.2 Zymography
Cells were grow n on wells coated w ith  pFN, 120FN fragm ent in PBS and PBS 
alone at a concentration of lp M /m l overnight in Defined Keratinocyte 
m edium  a t a seeding density of 10s. The following day the supernatant was 
collected, centrifuged to rem ove cells and debris and  loaded with non­
reducing sam ple buffer (A ppendix 1) into a 10% SDS PAGE containing gelatin 
and  electrophoresed for 1 hour (see section 2.3.3). Following electrophoresis
C h a p U T :>
the gels w ere w ashed and placed in Developing Buffer overnight (see section 
2.3.3) The following day the gels were stained w ith Commassie blue, 
destained and im ages w ere taken w ith  Alpha im ager 1220 version 5.5 (Alpha 
Innotech Corp™ , USA). The data  w as then analyzed using Scion Image (Scion 
Corporation).
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5.4 RESULTS
5.4.1 The 120kDa FN fragm ent does no t influence the production of uPA
Experim ents w ere set u p  in order to assess the effect of the various FN 
fragm ents on the secretion of proteases. The fragm ents used include the 
30kDa am ino-term inal fragm ent and  the 120kDa cell-binding fragm ent The 
first set of experim ents checked for the uPA levels. We observed that the a v (56 
expressing cell line, VB6, produced m ore uPA than their negative counterpart, 
C l. Two sets of experim ents w ere ru n  in duplicate examining the effects of 
the fragm ents, one by coating the fragm ents in the wells and then seeding the 
cells therein, and  the other by seeding the cells in uncoated wells and adding 
the fragm ents in solution, ie . in the m edium . O ur data shows that both the 
30kDa and the 120kDa FN fragm ent d id  not upregulate the production of 
uPA in either cell line w hether seeded on fragm ent coated wells or w ith the 
fragm ents added  to the m edium  (Figure 5.1, 5.2, 5.3 and 5.4). The PHSRN 
peptide show ed sim ilar results (Appendix 2). There was however, a 
difference betw een VB6 and C l and this was seen consistently throughout the 
experim ents.
tooc
30
25
20
15
10
5
0
X.
T
1 T L .
□ ci
□ VB6
pFn 120frg
substrates
control
Figure 5.1 PAA of cells seeded on wells coated with pFN, 120kDa FN 
fragment and PBS. There is no difference in uPA production between pFN, the 
120 kDa FN fragment and the control in both cell lines. The difference observed 
here is in the higher baseline production of uPA in VB6 compared to Cl.
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Figure 5.2 PAA assay of cells incubated with pFN, 120kDa FN fragment 
and PBS. Similarly, no observed difference in uPA production in each cell line 
plated on the various matrices, but again, higher baseline production in VB6 cells.
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5.4.2 The 120kDa FN fragm ent up-regulates the expression of both pro- 
MMP-2 an d  pro-M M P-9 in  avp6 expressing cell lines
Zym ogram s w ere carried ou t using supernatants from NHK, C l and VB6 
seeded on 24 well plates coated w ith  pFN, 120kDa FN fragm ent and PBS. Our 
results show ed an increase in pro-MMP-2 production in both cancer cell lines, 
bu t a m ore pronounced difference betw een die pFN and the 120kDa FN 
fragm ent in the (J6 expressing cell lines (Figure 5.5, 5.6, 5.7 and 5.8). The 
norm al hum an keratinocytes exhibited no difference in production when 
plated on the various substrates (Figure 5.9 and 5.10).
Since the avp6 integrin has been implicated in the upregulation of MMPs 
(Thomas et al. 2001a), we ran experim ents w ith p6-blocking antibodies to 
check if blocking this integrin w ould down-regulate the production of the 
MMPs. O ur results show ed no difference between the cells w ith and the cells 
w ithout the anti-p6 antibody (Figure 5.11 and 5.12).
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Figure 5.5 Gelatin lysis bands on Zymogram gel of VB6 plated on pFN and 
120kDa FN fragment.
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Figure 5.6 Graphic representation of Zymogram carried out on the supernatants 
of VB6 exposed to wells coated with pFN, 120kDa FN fragment and PBS. Both 
Pro-MMP-2 and pro-MMP-9 are significantly upregulated when plated on the 
120kDa FN fragment (p value= 0.001).
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Figure 5.7 Gelatin lysis bands on Zymogram gel of C l plated on pFN and 
120kDa FN fragment. Figure
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Figure 5.8 Graphic representation of Zymogram carried out on the supernatants 
of Cl exposed to wells coated with pFN, 120kDa FN fragment and PBS.
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Figure 5.9 Gelatin lysis bands on Zymogram gel of NHK plated on pFN and 
120kDa FN fragment.
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Figure 5.10 Graphic representation of Zymogram carried out on the 
supernatants of NHK exposed to wells coated with pFN, 120kDa FN fragment 
and PBS.
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5 3  DISCUSSION
W hen discussing cell motility, one envisions a pathw ay through which the 
cells move. This pathw ay is created by the cells to either encourage the 
closure of a w ound, or as an  erratic and self-propagating means in 
tum ourigenesis. W hatever the reason, the result is a remodelling of the 
extracellular m atrix that renders it m ore penetrable and that presents novel 
molecules, or fragm ents of original molecules, that enhance and encourage 
further motility. It has been observed by m any that a cell not only changes in 
m orphology w hen it receives m otility cues, bu t also starts to secrete proteases 
and rearrange its cell-adhesion molecules and receptors to adapt to the new 
surroundings. In m igrating keratinocytes particularly, upregulated protease 
secretion seems to occur on the leading edge of the moving cell (Shapiro 1998; 
M urphy & Gavrilovic 1999).
53.1 The 120kPa FN fragm ent an d  uPA
There is a large body of evidence suggesting the involvement of uPA in 
cancer metastasis. It has been established that the high levels of uPA, PAI-1 
and uPAR correlate w ith  poor prognosis and the level of uPA was found to 
regulate the rate of cell m igration (Andreasen et al. 1997; Decock et al. 2005). 
PAI-1 seems to prom ote cancer form ation by regulating cell adhesion and 
m igration (Sakakibara et al. 2005). Such motility is inhibited by antibodies 
against uPA (A ndreasen et al. 1997). uPA is able to digest FN independently
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of plasm in and  also activates other matrix degrading enzymes such as MMP-2 
and MMP-9 (Reuning et al. 1998). Proteolysis of FN by uPA yields two large 
polypeptide chains, and this digestion seems to be efficient at a relatively high 
enzyme: substrate ratio, as opposed to plasmin. It could be possible that uPA 
causes an  initial cleavage of FN reducing it to its monomeric form and this 
form  is in tu rn  m ore susceptible to further degradation by other proteolytic 
enzym es (Gold et al. 1992).
A lthough the focus of our s tudy  w as on two families of proteases, the 
urokinase plasm inogen activator serine protease, and the matrix 
m etalloproteinases, MMP-2 and MMP-9, w e started by running several assays 
to assess the production of uPA by both, beta-6 transfected cells, VB6 and the 
null transfectant, C l. UPa (and its receptor uPAR) plays an im portant role in 
the tissue processes of localized and  directional proteolysis, and has been 
found to stim ulate the m igration and  proliferation of a variety of tum our and 
norm al cells (De et al. 2002). H igh levels of uPA mRNA has been found to be 
indicative of poor prognosis (Gold et al. 1992; De et al. 2002). O ur assays failed 
to show an upregulation  of uPA w hen the cells were plated on the 120kDa FN 
fragm ent as com pared to pFN, bu t did confirm previous data showing 
elevated secretion of uPA by beta-6 expressing cell lines (Kapila et al. 1996; Hu 
et al. 2000; A hm ed et al. 2002b). This fits the phenotype of VB6 as they are 
m ore aggressive and  m ore m igratory on account of their expression of the 
avp6 integrin (Thomas et al. 2001b; Ramos et al. 2002). The same experiment
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was carried out incubating pFN and the 120kDa FN fragment in the medium 
rather than coating on the wells. It is possible that suspension in medium 
exposes cryptic sites that are hidden when the fragment is attached to a 
surface. W hen FN is adsorbed to surfaces it undergoes conformational 
changes that could affect its activity (Hynes 1999). Since the nature of FN is 
elastic, FN exists in the pericellular matrix in a stretched form which could 
lead to differences in integrin receptor binding (Garcia et al. 1999). Work by 
Hu et al. (2000) showed an increased production of uPA by fibrocartilagenous 
cells w hen exposed to the 120kDa FN fragm ent Upregulation of uPA, 
collagenases and stromelysin was observed in periodontal ligament cells in 
response to the cell-binding fragment (Kapila et al. 19%). However, uPA 
assays failed to show differences in uPA production regardless whether the 
cells were seeded on the substrates or incubated with them. This was also the 
case for the 30kDa FN fragm ent and the PHSRN synergy peptide. Another 
reason could be that the cells were already producing uPA in maximal 
amounts and plating or incubating with fragments was therefore not inducing 
any difference.
5.5.2 The 120kDa FN fragm ent and  MMPs
Both MMP-2 and MMP-9 have been investigated thoroughly in cancers. 
MMP-2, for example, has been implicated as a marker for malignant 
transformation of cervical epithelial cells (Davidson et al. 1999; Talvensaari- 
Mattila et al. 1999). MMPs are mainly secreted by non-malignant stromal cells
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in malignant tumours. Integrins induce the expression of different ECM 
degrading proteases especially MMPs and the interplay between them could 
be one of the key phenom ena in the invasion process (Koistinen & Heino 
2002). For example, integrin avp6 has been shown to increase the expression 
of MMP-1, MMP-3 and MMP-9 (Werb et al. 1989). It has been suggested that 
FN fragments may be inducers of MMP activity and mediators of tissue 
remodelling in  w ound healing (Schedin et al. 2000).
We assessed MMP activity by the same cell lines, again running a comparison 
between the 120kDa FN fragment and the intact pFN. We found an 
upregulation of pro-MMP-2 and -9 by the VB6 which may at least in part 
explain the increase in migration noted in previous experiments (see chapter 
4). Integrins have been found to induce the expression of different ECM 
degrading proteases, especially members of the MMP family. Studies by 
Schedin et al. (2000) have show n that mammary epithelial cells upregulated 
their expression of MMPs w hen exposed to FN and its fragments. It has been 
reported that the induction of MMP peaks with the peak in FN fragmentation, 
and that the use of an MMP inhibitor suppressed this finding (Schedin et al. 
2000). The 120kDa FN fragm ent has been shown to induce expression of pro- 
MMP1 and pro-MMP-3 in cynoviocytes but not the intact molecule (Werb et 
al. 1989). In fibroblasts, signalling by FN and its fragment occur via the a5pi 
integrin and adding functional blocking antibodies to this integrin reduced 
dramatically the MMP-9 induction by the fragment (Schedin et al. 2000). Our
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study shows that this effect is further synergized by the av(36 integrin since 
both VB6 and C l exhibit similar expression patterns of a5|31. The production 
of pro-MMP-9 m ight be already at maximal levels in both cell lines plated on 
the cell-binding fragment, bu t the presence of the av{36 integrin further 
upregulates i t  This finding is shared by others. Esparza et al. (1999) has 
shown that lymphocytes exposed to FN produced increased amounts of 
MMP-2 and MMP-9 over time. Werb et al. (1989) have found that FN increases 
the expression of MMP-1, MMP-3 and MMP-9 in rabbit synoviocytes via the 
a5p l integrin. Kapila et al. (19%) have shown the effect of intact and the 
120kDa FN fragm ent on periodontal cells. Both ligands are able to stimulate 
the expression of different proteases. In the case of the 120kDa FN fragment 
not only were MMPs upregulated but also uPA which may be responsible for 
the activation of several MMPs. In colon cancer, the aggressiveness of the 
tum our has been linked to its expression of MMP-9 and TTMP-l. Again, the 
a5p l integrin has been shown to induce collagenases and stromelysin 
expression. Since the avp6 integrin is expressed de novo and has been found 
to be concentrated at the leading edge, it has been postulated that it plays a 
role in the upregulation of proteases since that is where proteolysis takes 
place. In colon cancer cell lines, like in our transfected keratinocytes, there is 
an increase in expression of MMP-9 in beta-6 expressing cells as opposed to 
null transfectant (Agrez et al. 1999).
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5.5.3 MMP-uPA-stroma cross-talk
Despite identifying MMP-2 and MMP-9 as the upregulated proteases in the 
presence of the 120kDa FN fragment, this does not exclude the involvement of 
uPA from in the increased motility seen in our work. Studies by many have 
provided us w ith the basic information that uPA is capable of cleaving FN 
near the C-terminus proximal to the disulfide bridges linking the two 
monomers w ith the release of two 230-250kDa FN fragments (Gold et al. 1992; 
De et al. 2002). Therefore, not only is uPA capable of stimulating the 
expression of FN, bu t it can also then cleave the secreted glycoprotein (De et 
al. 2002). The cleaved FN is then prone to further breakdown (Gold et al. 
1992). Such degradation and release of FN occurs at the cell-substratum 
contact sites, the same place where cell-bound uPA has been localized. It 
seems that such a location for uPA concentrates the enzyme at the surface of 
proteolytically active cells although a study by Dalvi et al. (2004) has found 
the avp6 expressing cells downregulate the expression of uPA receptor uPAR. 
UPa not only activates plasminogen into plasmin, responsible for the 
degradation of the ECM, bu t it also independently cleaves FN into more 
degradation-susceptible fragments that may possess innate biologic activities 
(Gold et al. 1992). This has provided part of the loop we observe in 
tumourigenesis and w ound healing. For example, it has been estimated that 
up  to 50% of the FN in  arthritic synovial fluids has been proteolytically 
fragmented. FN fragments, including the collagen-binding domain and the 
cell-binding dom ain have been shown to promote loss of cartilage
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proteoglycans in vitro. It is reported that the FN fragment induced cartilage 
degradation is due to increases in metalloproteinases expression and activity 
(Huhtala et al. 1995). Fibronectin fragments exhibiting the RGD integrin- 
binding site regulate the synthesis of MMPs via an Interleukin-l autocrine 
loop. MMPs then act on FN to release FN fragments (Stanton et al. 2002). This 
could be seen as part two of die loop (Figure 7.1)
Cellular invasion of the surrounding matrix involves the interaction of 
different proteases; the MMPs appear to be involved in the initial step in this 
process. In many tum ours there is varied expression of MMPs both in tumour 
cells and in the surrounding reactive tum our stroma (Davidson et al. 1999; 
Talvensaari-Mattila et al.1999; Reunanen & Kahari 2002). In many cases the 
level of expression of different MMPs has been correlated with tumour 
grading and clinical staging. However, no overall pattern of MMP expression 
in different types of hum an cancers has been developed (Stetler-Stevenson & 
Yu 2001). In order for MMP proteolysis not to lead to widespread destruction 
of the ECM, activation is closely regulated and maintained next to the cell 
surface. A consequence of such ECM remodelling is that changes within this 
three-dimensional structure may reveal cryptic sites in its components (FN 
being one of the more im portant ones) previously unrecognizable by the cell- 
surface receptors (Streuli 1999). A variety of MMPs are expressed both during 
normal physiological processes and dining tumourigenesis, and this is 
perhaps to compensate for potential loss of an individual MMP. Such
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diversity explains why MMP-mutant mice are only mildly affected with 
respect to development and other physiological processes (Shapiro 1998).
5.5.4 Conclusion
There is continuous talk between cancer cells, stromal cells and inflammatory 
cells dining invasion. O ur results show an upregulation of MMP-2 and MMP- 
9 by (36 expressing cells w hen plated on the 120kDa FN fragment, which 
suggests their involvement in the increased migration observed in chapter 4. 
The upregulated MMPs are in their zymogen states, and in fact, most MMPs 
are secreted as zymogens and are proteolytically activated in the ECM space. 
Plasmin and stromelysin are possible candidates for the activation of pro- 
MMPs into active enzymes. Beta-6 expressing cell lines and not the null 
transfectant produce more uPA and this is responsible for the activation of 
plasmin from plasminogen. This in turn  could be responsible for the 
activation of MMPs. It was found that recombinant PAI-2 and aprotonin (anti- 
plasmin) inhibited the enhanced degradation of plasmin by beta-6 
transfectants (Agrez et al. 1994). This could be the link tying the observed 
increased production of uPA by VB6 and their then upregulated expression of 
pro-MMP-2 and -9. This argum ent is tackled in further depth in the following 
chapter.
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CHAPTER 6
ROLE OF MATRIX METALLOPROTEINASES IN FIBRONECTIN 
FRAGMENT MEDIATED MOTILITY
6.1 INTRODUCTION
Extracellular matrix remodelling forms an essential step in both wound 
healing and cancer progression. Many tum ours in their advanced stages show 
a high expression of a variety of proteases (Streuli 1999). Such proteases may 
not only be involved in remodelling but also in the fragmentation of 
molecules w ithin the matrix forming potentially bioactive components 
(Streuli 1999).
There is a large body of evidence closely associating integrins and MMPs as 
collaborators in such processes as cancer progression and wound healing. 
Some integrins may m odulate the action of MMPs by binding directly to 
them  Such interaction may enable the cell to direct proteolytic activity in the 
desired manner at the migrating front. After cleaving the ECM components 
the migrating cell can further use the integrins for attachm ent Such binding 
of MMPs to the cells' integrins makes the latter both the activators and the 
targets of such pericellular proteolysis (Koistinen & Heino 2002). A positive 
correlation between MMPs and malignant tumours such as colon, lung, head 
and neck, breast and basal cell has been established (Westermarck & Kahari 
1999). Recent evidence has expanded the role of MMPs from simply
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degrading surrounding extracellular matrix to creating and maintaining a 
microenvironment that facilitates the growth and angiogenesis of tumours 
(Nelson et al. 2000). Being wide spectrum proteases, matrix metalloproteinases 
are able to break FN into smaller fragments (Reunanen & Kahari 2002). 
Ligation between integrins and FN activate MAPK pathways via Ras/Raf-1 
and p38 (Esparza et al. 1999) and inhibition of the MAPK pathways leads to a 
reduced expression of MMP-2 and MMP-9 in lymphocytes (Esparza et al. 
1999).
6.2 OBTECTIVES
O ur aim was to assess the influence of inhibitors of MMPs on the migration of 
cells on the 120kDa FN fragment, and the ability of MMPs to digest FN. 
Furthermore, to asses the effect of MAP Kinase and p38 pathways inhibitors 
and to co-localize the presence of these MMPs with FN and the av(36 integrin 
in the invading front of tum our islands in an in vivo situation.
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6.3 MATERIALS AND METHODS
6.3.1 M igration Assays w ith  TIMPs
Haptotactic cell migration was measured as previously described in chapter 2, 
using polycarbonate Transwell® inserts (Coming Costar). Inserts were coated 
the 120kDa FN fragment in PBS at a concentration of lp M /m l and VB6 cells 
were seeded at a seeding density of HP/well. The cells were seeded in SFM 
containing either matrix metalloproteinase inhibitor TIMP-l (Oncogene 
Research Products, Nottingham, UK) or a chemical MMPs inhibitor, Roche 
Inhibitor (Roche Diagnostics GmbH, Pharma Research, Lewes, UK). Cells 
were allowed to migrate as described in section 2.2.1.
6.3.2 Im m unohistochem istrv
Oral squamous cell carcinoma cases were obtained from the archives of the 
Oral Pathology departm ent at UCH (Table 6.1) ensuring that each showed an 
area of squamous cell carcinoma invading front (Ethics Approval reference 
number 02/E013). Each case was stained for:
• Cytokeratin: Monoclonal Mouse Anti-Human Cytokeratin EA1/EA3 
(Dako Cytomation, Ely, UK).
• MMP-9: Rabbit Anti-Human MMP-9 polyclonal antibody (Dako 
Cytomation).
• MMP-2; Rabbit Anti-Human MMP-2 polyclonal antibody (Dako 
Cytomation).
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• Cellular Fibronectin: Mouse Anti-Human cellular FN (ED-A domain) 
(Oxford Biotechnology®, Kidlington, UK).
• p6 integrin: Mouse Anti-Human monoclonal av|36 integrin 10D5 
(Chemicon International, Chandler's ford, UK).
CASES: Location of lesion
A Buccal Mucosa
B Lateral border of tongue
C Lateral border of tongue
D Lower lip
E Lower alveolus
F Tongue
G Mandible/Lip
Table 6.1 OSCC cases. Represented in this chapter are cases A and B.
Negative controls were left w ithout primary antibodies. The procedure for 
MMP-2, MMP-9, cytokeratin and cFN was carried out as previously described 
in section 2.4.2.
The slides to be stained for beta-6 integrin were dewaxed as previously 
described (section 2.4.2). Endogenous peroxidase was blocked using 30% 
H2O2 in methanol (Appendix 1) and antigen retrieval was carried out using 
Pepsin (Zymed® Laboratories Inc., Cambridge, UK). In order to amplify the 
staining, b io tin /avidin  blocking was carried out using Vector SP-2001 (Vector 
Laboratories, Peterborough, UK). Avidin was applied for 10 minutes, slides
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were washed twice in PBS, Biotin was applied for 10 more minutes and slides 
were washed again twice with PBS. To block non-specific binding 
0.5% C asein/0.05 %NaN3 was added for 10 minutes (Appendix 1). The 
primary antibody was added to 0.1%BSA 0.1%NaN3 in PBS on the slides and 
incubated overnight at 4°C.
The following day the slides were washed twice with PBS. The secondary 
antibody kit used was the Elite ABC reagents Vector kit PK-6102 (Vector 
Laboratories) and slides were washed twice in PBS between each step. The 
anti-mouse biotinylated secondary antibody Alexa Fluor® 488 goat anti­
mouse IgG (Molecular Probes, Invitrogen Detection Technologies, Paisley, 
UK) was applied for 30 minutes at room temperature. Slides were stained 
using the DAB substrate kit Vector SK-4100 (Vector Laboratories) for 5 
minutes. Slides were rinsed under running water for 2 minutes, stained with 
Mayer's haematoxylin for 1 minute, rehydrated and mounted as described in 
section 2.4.2.
6.2.3 D igestion of pFN
Pro-MMP-2 and pro-MMP-9 were obtained from Calbiochem® (VWR 
International Ltd., Poole, UK). Prior to running the digestion experiments the 
pro-MMPs were activated using organomercurial stock solution. P-amino 
phenylmercuric acetate solution was added to 0.1M NaOH solution just prior 
to incubation with the pro-MMPs. Pro-MMPs were added to this stock
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solution at a ratio of 10:1 and incubated at 37°C for 2-3 hours. Following 
activation, MMP-2 and MMP-9 were incubated with pFN (lOpg/ml) at a ratio 
of 1:25 (MMP-2) and 1:10 (MMP-9) (varying concentrations of both MMP-2 
and MMP-9 to pFN were tested to decide the optimal ratio to use in our work, 
(Appendix 2). The pFN /M M P mixtures were incubated at 37°C for 2 hours, 6 
hours, 24 hours and 48 hours, after which 20pl was removed from the mixture 
and added to non-reducing buffer X2 (Appendix 1) to immediately stop the 
reaction.
The samples were loaded on an SDS 10% Acrylamide Gel and n m  as 
previously described in section 2.3.2. The gels were then stained with 
commassie blue and an image taken with Alpha imager 1220 version 5.5 
(Alpha Innotech Corp™).
6.2.4 Intracellular signalling pathways
Experiments were performed to block two intracellular signalling pathways 
implicated in tumourigenesis, in order to investigate their role in modulating 
MMP production by VB6 cells. U0126 inhibits MEK1 and MEK2 of the MAP 
kinase pathway, and SB 203580 inhibits the SAPK2 (p38) cascade (Sigma- 
Aldrich Company Ltd.). Dose response curves were carried out to determine 
optimal concentrations w ithout detrimentally damaging the cells as 
previously reported by Dalvi et al. (unpublished data).
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Cells were seeded in 24-well plates (Nunc™, VWR International) previously 
coated w ith pFN and 120kDa FN fragment in Defined Keratinocyte SFM 
(Invitrogen Corporation, Gibco™) for 4 hours. The cells were then washed 
twice with PBS, and m edium  containing lOOpM U0126 and 20pM SB 203580 
was added to the different samples. Cells were incubated overnight at 37°C. 
The following day zymograms were run  of the supernatants as previously 
described (section 2.3.3) and the data collected was analysed with Scion Image 
(Scion Corporation).
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6.4 RESULTS
6.4.1 M ira tio n  on the 120kDa FN fragm ent is not reduced by adding MMP 
blockers
We have previously described in chapter 4 the upregulated migration of beta- 
6 expressing cells on the 120kDa FN fragm ent We have also shown evidence 
of increased MMP expression by cells seeded on the fragment in chapter 5. 
Having established the importance of the FN-binding integrins in the 
upregulated migration towards the 120kDa FN fragment, we attempted to 
inhibit such migration using matrix metalloproteinase inhibitor TIMP-1 
(Oncogene Research Products) and a chemical MMPs inhibitor, Roche 
Inhibitor (Roche Diagnostics GmbH) (Figure 6.1 and 6.2).
Both TIMP-1 and the Roche inhibitor showed a trend towards lower 
migration of VB6 and C l migration on the 120kDa FN, but this was not 
statistically significant (p value= 0.1 for C l and 0.7 for VB6+TIMP-1, Mann- 
Whitney test, and p  value= 0.2 for C l and 0.1 for VB6+RO, Mann-Whitney 
test).
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Figure 6.1 Migration assay of Cl and VB6 on 120kDa FN fragment and on the 
fragment plus TIMP-1.
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Figure 6.2 Migration assay of Cl and VB6 on 120kDa FN fragment and with 
MMP Roche Inhibitor.
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6.4.2 MMP-2 and MMP-9 co-localize w ith  beta-6 integrin and cellular FN 
around the invasive front of SCC lesions
In our work, we showed that the cell-binding FN fragment enhances 
migration of beta-6 expressing cells and upregulates the expression of MMP-2 
and MMP-9. In order to assess the localization of these factors in vivo, we 
randomly selected oral squamous carcinoma tum our cases and carried out 
immunohistochemistry analysis. The paraffin embedded sections were 
stained for cytokeratin, beta-6 integrin, cFN, MMP-2 and MMP-9 as described 
in section 2.4.1.
Positive cytokeratin staining was obtained in all sections and was specific to 
keratinocytes (Figure 6.3 and 6.5 (A)). Cellular FN staining was observed in 
the stroma surrounding the epithelial tum our island in a fibrous form (Figure
6.3 and 6.5 (B)). MMP-2 and MMP-9 were observed both within the tumour 
island as well as in the surrounding stroma, MMP-2 staining being more 
intense (Figure 6.3 and 6.5 (C) and (D)). Beta-6 integrin was seen to be 
expressed on the cell membrane of epithelial cells (Figure 6.4 and 6.6 (A)). The 
negative control w ith the omitted antibody was devoid of any staining 
(Figure 6.4 and 6.6 (B)).
Figure 6.3 Epithelial tumour island showing intense staining for cytokeratin (A), light staining fc
cellular fibronectin, in the tumour stroma (B), intense MMP-2 staining
within the tumour cells and the surrounding stroma indicative of a progressive and
highly invasive tumour (C), and MMP-9 staining, not as intense as MMP-2 but can also
be seen in and around the tumour island (D) (Magnification x200).
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Figure 6.4 Section (A) viewed under high power shows beta-6 integrin staining 
along the invading front of the epithelial tumour cells (Magnification x 400 ; 
section (B) is of the negative control showing haematoxylin staining devoid of any 
other staining (Magnification x 200)
215
Figure 6.5 Another case of epithelial tumour island showing intense staining for
cytokeratin (A), light staining for cellular Fibronectin, in the tumour stroma (B),
intense MMP-2 staining within the tumour cells and the surrounding stroma
indicative of a progressive and highly invasive tumour (C), and MMP-9 staining,
not as intense as MMP-2 but can also be seen in and around the tumour island (D) (Magnificat
x200).
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Figure 6.6 Section (A) viewed under high power shows beta-6 integrin staining 
along the invading front of the epithelial tumour cells (Magnification x 400); 
section (B) is of the negative control showing haematoxylin staining devoid of 
any other staining (Magnification x200).
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6.4.3 MMPs are able to degrade pFN into various size fragments in a time- 
dependent m anner
Active MMP-2 and MMP-9 were incubated with plasma FN and analysed 
over time to assess proteolytic degradation. Fibronectin is a known substrate 
of many proteases and in this particular case we tried to assess the various 
molecular weight fragments generated. At and after 24 hrs there is a clear 
band forming at the level of the 120kDa FN fragment, suggesting that at this 
time point the fragments generated by MMP-9 include the cell-binding FN 
fragment. The initial attack on pFN may simply divide the diameric protein 
into its two principal 200-220kDa fragments. Following this initial breakdown 
the two fragments may then be digested more thoroughly to yield smaller 
fragments. In our result it is noticeable that MMP-9 degrades FN to a higher 
degree than MMP-2 (Figure 6.7 and 6.8) and the generation of fragments in 
this case is more evident.
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Figure 6.7 Digestion of pFN by MMP-9 over a period of over 24 hours. The gel 
clearly shows progressive degradation of pFN over time producing more and 
more fragments. At 24hrs and above the cell-binding fragment is clearly visible.
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6.4.4 Blocking MEK1 and MEK2 of the MAP kinase and SAPK2 (p38) 
reduces the expression of MMPs by cells plated on the fragment
Inhibitors to the MEK1 and MEK2 of the MAP kinases pathways, and SAPK2 
(p38) were added to cells plated in SFM. MAP kinase and p38 are triggered by 
the binding of integrins to FN (Esparza et al. 1999) and this leads to signalling 
which triggers the expression of MMPs (Figure 6.9).
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Figure 6.9 Diagrammatic representation of various MAPK intracellular signalling 
pathways (Sigma Cell Signalling catalogue).
The inhibitors were added to VB6 cells plated on pFN and the 120kDa FN 
fragment for 24 hours and the conditioned medium was then collected and 
subjected to zymography. Our results have shown a downregulation of
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MMP-2 and MMP-9 produced by VB6s exposed to these inhibitors as opposed 
to the control. The down regulation of MMP-9 is apparent when blocking 
MEK whereas MMP-2 does not seem to be affected (Figure 6.10). However, 
blocking p38 seems to have an effect on both MMP-9 and MMP-2 on both the 
intact pFN and the fragment (Figure 6.11).
This is indicative of the importance played by these two signalling pathways 
in the upregulation of MMPs by beta-6 expressing cells plated on FN and its 
fragment.
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Figure 6.10 Bar chart clearly shows a down-regulation of pro-MMP-9 in the 
Presence of SB203580, the p38 inhibitor.
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Figure 6.11 Bar chart showing a down-regulation of pro-MMP-9 and MMP-2 
in thepresence of U-0126, a MEK1 inhibitor.
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6.5 DISCUSSION
6.5.1 M atrix m etalloproteinases and their inhibitors
Matrix metalloproteinases have been at the centre of attention for a long time 
and many reviews and studies have been carried out to elucidate their 
importance in both w ound healing and tumourigenesis (Chang & Werb 2001; 
Liotta & Kohn 2001; Mueller & Fusenig 2002). Having established the 
importance of the avp6 integrin in the interaction of tumour cells with the 
intact FN molecule and the FN fragment, we investigated the effects of 
various MMP inhibitors in the upregulated migration of VB6 cells towards the 
120kDa FN fragm ent
TIMPs expression has been observed in the tumour stroma and their over­
expression can be viewed as the cells7 attempt to regulate the MMP over 
expression. However, although many have found that increased TIMP 
expression is indicative of a lower grade tum our (Polette et al. 1991; Tsuchiya 
et al. 1993), some have shown the opposite (Visscher et al. 1994). Whatever the 
prognosis, there is general consensus that TIMP expression increases in 
tum ours as opposed to non-tum our sites (Yoshiji et al. 1996). But, the 
determining factor seems to be the ratio of MMPiTIMP expressed by tumours 
(Yoshiji et al. 1996). TIMPs appear to have ambiguous effects on tumour cells 
and this could be explained by the fact that as well as inhibiting MMPs they 
serve as activators of MMP pathways (Gomez et al. 1997). Our studies failed
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to show a down-regulation of migration in the presence of MMP inhibitors 
and this could reflect the fact that the MMPs produced by tumour cells may 
be evading otherwise common regulatory signals. Alternatively, lacking other 
im portant cues TIMPs may be simply acting by activating MMPs. However, it 
could also be that MMPs in their zymogen form are not inhibited by TIMPS.
6.5.2 MMP-2, MMP-9, the av(36 integrin and fibronectin in  the invading 
front of tum ours
The interaction between integrins and the MMPs may be one of the key 
phenomena in the invasion process (Koistinen & Heino 2002). The importance 
of the crv|36 integrin in the expression of MMP-9 by tumour cells has been 
previously described and was found to co-localize with the invading front of 
tumours concurrently where the MMPs are concentrated (Thomas et ah 
2001b). Thomas et al. (2001b) showed increased expression of MMP-2 and 
MMP-9 by cells expressing the av(36 integrins when plated on FN. This group 
also showed that adding blocking antibodies to the av|36 integrin greatly 
reduced expression of MMP-9 in normal hum an keratinocytes. Gu et ah (2002) 
have shown that colon cancer cells transfected with the (36 integrin expressed 
higher am ounts of MMP-9 as compared to the same cells transfected with the 
null transfectant This was further investigated by Morgan et ah (2004) who 
identified the cytoplasmic-tail motif EKQKVDLSTDC of the av(36 integrin as 
being responsible for this integrin's invasive potential through the 
upregulation of MMPs. Monsky et ah (1993) provided evidence that suggests
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MMP-2 production by stromal cells that then become attached to the invading 
front. Vaisanen et al. (1998) also reports an increased expression of MMP-2 
w ith increasing tum our grade whereas in melanomas MacDougall et al. (1995) 
show that the expression of MMP-9 is associated with metastasis.
We were able to show the presence of the av(36 integrin in tumour sections 
and by locating MMP-2, MMP-9 and cFN in the stroma of the tumour island 
we can suggest the hypothesis that these molecules are interacting with each 
other in vivo. The MMPs produced in and around tumour lesions may be 
proteolytically degrading the extracellular matrix generating proteolytic 
fragments. This firstly promotes degradation of the extracellular matrix that 
facilitates the tum our cells physical invasion and metastasis. Secondly, the 
resultant proteolytic fragments may in turn  give further "malignant" signals 
and stimulate cell migration and invasion. Such stimulation is in many cases 
confined to the invading front at the forward edge of invading cells, where an 
array of enzymes, inhibitors and receptor molecules go through cycles of 
activation, deactivation and so on (Liotta & Kohn 2001).
6.5.3 Tum our stroma and MMPs
In our immunohistochemistry analysis of tumour lesions we have described 
the distribution of MMPs both in the tumour islands and in their surrounding 
stroma. This is in agreement with previous findings that indicate that MMPs 
and proteases involved in tum our progression may be secreted by stroma
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cells rather than the tum our cells themselves. Thomas et al. (2002) have shown 
that tum our cells are able to utilize MMPs produced by stromal cells. Shapiro 
et al. (1998) has shown that MMP-2 is often produced by tumour cells but 
other MMPs and proteases involved in invasion are more likely secreted by 
stromal and inflammatory cells. Mueller et al. (2002) have shown that the 
increased expression of MMP-9 comes from stromal cells surrounding the 
tum our and this may in turn  upregulate the expression of MMPs in the 
tum our cells too. MMP-2 has been correlated with malignant transformation 
of epithelial cells (Davidson et al. 1999; Talvensaari-Mattila et al. 1999) and is 
expressed by many normal as well as transformed cells, whereas MMP-9 is 
expressed by keratinocytes, monocytes, alveolar macrophages, PMN 
leukocytes and many m alignant cells. Basset et al. (1997) have pu t forward a 
simple model of malignant cells-stromal cells interactions by describing 
MMP-2. This protease has been found to be secreted copiously by tumour 
cells; however, its activator, MT-MMP is expressed solely by stromal cells. 
Therefore, MT-MMP attached to stromal cells attracts the secreted MMP-2 
and activate it forming a synergistic interaction with the invading tumour 
cells. Similarly the uPA system follows a comparable pattern where the 
urokinase is secreted by stromal cells and its receptor uPAR is secreted by 
tum our cells (Basset et al. 1997).
MMPs are activated in the extracellular space and their expression in tumours 
is tightly regulated. It has been suggested that there is a continuous cross-talk
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between tum our cells, stromal cells and inflammatory cells during active 
invasion. It has been shown that the MMPs involved in a particular tumour 
are produced by stromal cells such as fibroblasts and inflammatory cells 
rather than tum our cells (Nelson et al. 2000). Therefore, stromal cells may 
participate in the tumourigenic conversion of epithelial cells. Such evidence is 
further confirmed by the localization of MMPs at the invading front both in 
tum our cells and stromal cells. It is in fact this cross-talk that may play a 
potentially vital role in the activation of MMPs (Westermarck & Kahari 1999).
Evidence now points to the importance of the tumour cell-stroma interaction 
in the regulation and maintenance of the invasion and progression of the 
tumours (Mueller & Fusenig 2002). Previous studies have shown the presence 
of MMPs in the stroma immediately surrounding tumour islands, in 
particular around the invading front (Kikuchi et al. 2000; Gu et al. 2002). 
Tumour cells may induce a specific "malignant" type of stroma around the 
lesion which has lost controlling functions and gives cues to enhance the 
proliferation and invasion capabilities of malignant cells (Mueller & Fusenig 
2002). The stroma surrounding the tumour cells may in effect be the 
conductor in an "orchestra" of invasion and progression. Local attractants 
derived from the stroma include degraded matrix proteins.
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6.5.4 Role of uPA
In chapter 5 our results showed an upregulation in MMP production but 
failed to show the same for uPA. However, it would be prem ature to exclude 
this serine protease from the fragment-MMP cascade. It may in fact be that the 
serine protease, though not upregulated in presence of the fragment, acts to 
activate the MMP and thus be playing a secondary, albeit important, role. 
This w as show n by studies that found the activation of pro-MMP-9 to active 
MMP-9 being regulated by plasm in and stromelysin, both found abundantly 
in tum ours. It w as found that PAI-2, a uPA inhibitor w hen added to colon 
cancer cells reduced collagenases degradation by such p6-expressing cells; 
this can be explained by the need for uPA to convert plasminogen into 
plasm in which then converts pro-MMP-9 into active MMP-9 (Thomas et al. 
2002). Such data no t only confirms that tumour-associated proteolysis is a cell 
surface event and  may be im portant in the generation of an invasive 
phenotype (Agrez et al. 1999), bu t further confirms the synergy between 
different proteases. While tum our cells may be only expressing specific 
proteases, in our case, MMPs, the surrounding stroma cells may in fact be 
secreting the proteases that enable the former to act. This is reaffirmed by the 
fact that plasm in mediates MMP activation (Shapiro 1998), and that Thomas et 
al. (2001a) have show n inhibition of MMPs when adding a uPA inhibitor.
The urokinase plasm inogen activator role in the activation of MMPs doesn't 
have to be a direct one but could be working in a more indirect fashion
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through the activation of plasminogen. The conversion of plasminogen to 
plasm in may in itself activate MMPs that in turn  activate the main MMPs 
involved in the extracellular matrix degradation. This example has been 
illustrated by Ramos-DeSimone et al. (1999) who showed a link whereby pro- 
MMP3 w as activated by plasm in and active MMP-3 then activated pro-MMP- 
9. In this case uPA was necessary to convert plasminogen into plasmin. 
Furthermore, they speculated that pro-MMP-3 was likely to be secreted by 
stromal cells surrounding die tum our rather than the tum our cells 
themselves.
A lthough we have suggested a role played by uPA in the activation of MMPs, 
other proteases m ay also be playing a p a r t  Esparza et al. (1999) showed 
evidence that MT-MMP is an im portant activator of MMPs, and in hum an 
lymphocytes they showed that FN was able to induce MMP-9 and MMP-2 as 
well as prom oting MMP-2 activation by upregulating MT-MMPs. 
Imm unohistochemical studies have found that increased expression of MT- 
MMP and MMP-2 correlates w ith invasion-positive cases in colorectal 
carcinoma. This supports, along w ith the localization of MMP-2 around 
cancer cells, die suggestion that MT-MMP is essential in the activation of 
MMP-2 (Kikuchi et al. 2000). The activation of pro-MMP-2 may be brought 
about by MT-1MMP whereas the activation of pro-MMP-9 requires MMP-3.
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6.5.5 F ibronectin as a substrate for MMP-2 and MMP-9
Having co-localized FN, the avp6 integrin, MMP-2 and MMP-9 to the 
invading front of tum ours, and having postulated the proteolytic action of 
these MMPs on the intact FN, we assessed this by carrying out digestion 
experiments. Evidence of the proteolytic action of MMPs on other 
extracellular matrix molecules has already been investigated. Giannelli et al. 
(1997) reported that laminin-5 cleavage by MMP-2 caused increased 
m igration of epithelial breast cells. It seems that cleavage of this substrate by 
MMP-2 exposes pro-m igratory cryptic sites within the molecule. Fukai et al. 
(1995) have show n that digestion of FN by MMPs in particular MMP-2 
releases various fragm ents that possess strong chemotactic properties. Our 
digestion experim ents have shown that MMP-9 in particular can degrade FN 
to produce fragm ents including the pro-migratory 120kDa fragment in a time 
dependent manner. MMP-9 can cleave FN and gelatin to expose the RGD site 
which is then recognized by the avp6 integrin and this seems to be pivotal for 
the progression of the tum our (Agrez et al. 1994).
6.5.6 M M Ps and  intracellular signalling pathways
Finally, attem pts were m ade to extend the studies described above to include 
prelim inary signalling pathw ays data. Ligation between integrin and FN 
activate MAPK pathw ays via Ras/Raf-1 and p38. Esparza et al. (1999) have 
show n that inhibition of the MAPK pathways leads to a reduced expression of 
MMP-2 and MMP-9 in lymphocytes. Their findings suggest a signalling
______________________________    C h a p t e r s
pathw ay w ithin the cell by which MMPs regulate tight ECM degradation 
around the cells upon  contacting FN. O ur study has shown a down- 
regulation of both MMPs w hen blocking the p38 pathway, showing that it is 
common to both proteases. However, blocking the MAPK pathway at the 
level of M EK1/2 dow nregulated MMP-9 but not MMP-2. It seems that this 
pathw ay is not shared and MMP-2 signalling follows another route. This was 
show n by W ang et al. w ho treated neuronal cultures w ith both SB203580 and 
U0126 to assess their effects on MMP-2 and -9 production and found that 
w hen both inhibitors worked together there was significant reduction in 
MMP-9 production. Using either inhibitor alone there was little effect. This 
shows the presence of possible redundancy in either pathway in respect with 
MMP-9 production (W ang et al. 2002). Cho et al. (2000) showed the same 
results w hen using the same inhibitors on MMP-9 expression by vascular 
smooth muscle cells.
6.5.7 Conclusion
Previous studies along with our findings have brought together enough 
evidence to suggest that integrins, MMPs and FN fragment act in synchrony 
to m aintain a milieu that enables malignant cells to survive and enables 
w ounds to heal. It is this intricate highway of cues and signals that turns on 
and off the switches needed to effectively allow degradation of the 
extracellular matrix, detachm ent of cells and migration. In tumourigenesis
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this is coupled w ith the im pedim ent of normal regulatory mechanisms from 
restraining and placing order to a somewhat chaotic scenario.
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DISCUSSION
During both w ound healing and tumourigenesis epithelial cells acquire a 
more m esenchym al phenotype. This enables them to move freely and change 
in function as the situation necessitates. They can breach barriers, secrete 
proteases w hen needed and  escape regulatory mechanisms such as apoptosis. 
During tum ourigenesis, cancer cells exist under a new law and act 
independently of protective mechanisms. Epithelial cells interact with 
surrounding strom a cells and induce them into promoting a suitable 
environm ent that induces further invasion. It is such interactions w ith the 
extracellular m atrix that ensures the immortality of the tumour. Changes in 
strom al behaviour can influence epithelial transformation and phenotype. 
Activation of local stroma is parallel w ith the shift from normal to invasive 
carcinoma and an environm ent that stimulates cancer invasion is created. The 
enzym e cascade of m alignant cells is confined to the leading edge of the 
tum our cell (Liotta & Kohn 2001).
Tum our cells secrete proteases that breakdown the surrounding extracellular 
matrix. It is now  well proven that this isrit just a structural breakdown that 
creates "pathw ays" for tum our cell to migrate through, but rather, it is a 
dynam ic process whereby bioactive molecules are released. Extracellular
matrix molecules can gain new  biological functions w hen partially degraded 
due to their m odular make u p  (Hynes 1992) and therefore possess functions 
that are absent in the parent molecules. Extracellular matrix molecules such as 
collagens and laminins and their respective fragments have already been 
extensively investigated as m entioned in section 1.3, and although FN 
fragm ents have no t received similar attention, they are found in abundance in 
the ECM and their correlation w ith tumourigenesis has been suggested 
(Schedin et al. 2000). A n example of such a fragment is migration stimulating 
factor (MSF), a 70kDa FN fragm ent containing of the peptide sequence of the 
gelatin-binding dom ain that has been shown to be produced only in foetal, 
cancer and activated keratinocytes. This fragment is not generated in normal 
adu lt hum an cells and its effects range from inducing migration, angiogenesis 
and  hyaluronan a d d  synthesis (Schor et al. 2003). In our work we chose to 
investigate the 120kDa cell-binding FN fragm ent The relationship between (36 
expressing cells and FN fragments was of particular interest to us. Although 
tum ours express a num ber of FN binding integrins including a5pi, the data 
presented in this thesis indicates that the 120kDa cell-binding FN fragment 
only exhibits its effects on cells expressing (36 via the RGD sequence. We 
believe such interaction is responsible for the increased migration we have 
observed over the fragm ent Therefore, since this integrin is expressed de novo 
in  cancer (and w ound healing), the effect is specific to the integrin.
In our study we have found av(36 expressing cells to be more migratory over 
the 120kDa cell-binding FN fragment than the intact plasma FN. The 
proposed m echanism  behind this increase in migration is an increased 
production of proteases. While increased production of the urokinase type 
plasm inogen activator was not observed, increased production of MMPs -2 
and -9 was. Both MMPs are know n to degrade extracellular matrix molecules. 
Furthermore, FN is a know n substrate of matrix metalloproteinases and it 
seems likely that a loop exists that is initiated when the tum our violates 
regulatory m echanisms and assumes an invasive state. We believe that such 
tum our cells under the effect of extracellular matrix by-products (which 
include FN fragments) produce more MMPs which breakdown surrounding 
extracellular m atrix and generate FN fragments which, via the (36 integrin, not 
only degrade the surroundings, bu t also continue the degradation of FN and 
the generation of more bioactive fragments (Figure 7.1). Our 
im m unohistochem istry experiments showed the co-localization of FN, the 
av  (36 integrin, MMP-2 and MMP-9, and give further credence to the 
suggested loop occurring in in vim  situations.
In our w ork the urokinase-type plasminogen does not appear to be 
upregulated w hen the FN cell-binding fragment interacts with (36 expressing 
cells. However, this does not exclude its well established importance in 
tum ourigenesis (Andreasen et al. 1997; Reuning et al.1998; Stoppelli 2005). In 
fact, the MMPs secreted are in an inactive state and are activated by plasmin.
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Figure 7.1 Diagrammatic representation of the positive feedback loop; p6 expressing 
cells when exposed to breakdown products of the ECM secrete pro-MMPs and uPA. 
The latter converts plasminogen into plasmin which in turn activates pro-MMPs. 
Activated matrix metalloproteinases then further breakdown ECM molecules 
(such as fibronectin) to generate more bioactive bi-products.
Plasmin is formed from plasminogen under the effect of uPA. Beta-6 
transfected cells have been found to produce more uPA which may be vital 
for the conversion of MMPs into active enzymes. However, although this 
upregulation is not affected by the fragment or whole molecule, the uPA 
produced by such cells may play an active role in their migration by 
activating MMPs.
A lot of attention has been recently given to the relationship between the 
various cell adhesion molecules. In our work, w hen establishing the optimal 
conditions in which to carry out the various functional assays we noticed an 
alteration in the cell morphology w hen such cells were starved of certain 
nutrients. W hen investigated further there was a suggestion of a link between 
the expression of E-cadherin and the presence of EGF. It is easy to assume an 
inverse relationship between the presence of E-cadherin and the (36 integrin. 
While the former is common in the less aggressive lesions, the latter is a 
m arker of aggressive tumours. Could there be cues in the tissue 
m icroenvironm ent that promote one over the other? In the absence of EGF 
cells seem ed to revert to a more epithelioid appearance and there is a 
suggestion of E-cadherin upregulation. Cell-to-cell contact seemed to mimic 
normal epithelia and there were less signs of migratory armamentaria such as 
lamellopodia and filipodia. Interestingly, work by Chunthapong et al. (2004) 
showed that E-cadherin is broken dow n to smaller fragments by the action of 
MMPs in prostate cancer cell lines. Such fragments have been found to
promote a more aggressive phenotype as opposed to the intact E-cadherin. If 
added to the m odel we have proposed for our work, the MMPs produced by 
our (36 cells can not only breakdown the surrounding ECM molecules, but 
also breakdow n the E-cadherin present on the cells to: 1) decrease the 
expression of E-cadherin and 2) to form bioactive by-products that further 
reinforce the aggressive nature of the cells. It is clear that complex processes 
such as cell m igration and differentiation need an integrated response to 
m ultiple external stim uli an example being the cross regulation among cell 
adhesion molecules. This could create a paradigm  shift; instead of 
m anipulating cells to revert back to their original state we could manipulate 
the environm ent to swing the balance and encourage the reversal to more 
benign phenotypes.
W ound healing and tumourigenesis are complex mechanisms; while the 
former is under strict regulatory mechanisms that ensure its commencement 
and conclusion, the latter is, in many aspects, w ound healing gone awry. It is 
such intricate mechanism that renders cancer therapy so difficult to achieve. 
Although cancer is multifaceted, the role of FN fragments may be central and, 
being indicative of a num ber of tumourigenic processes, may be a useful 
marker of aggressive disease or therapeutic target.
FUTURE WORK
The work in this thesis has show n the cell-binding FN fragment to promote 
m igration and MMP production in (56 expressing cells. Further studies will 
include localizing the exposed epitope present in the 120kDa cell-binding FN 
fragm ent (but not in the intact molecule). This will enable us to locate the 
fragm ent during immunohistochemistry, study in more detail its association 
w ith other cancer-promoting molecules and assess its localization in the lesion 
(for example, at the invading front). It may also be possible to study the 
prevalence of this fragm ent w ith various carcinoma types, such as verrucous 
or ulcerative lesions, early lesions or advanced ones.
Further m apping experiments to determine the active part of the 120kDa FN 
fragment, and the signaling pathways initiated by it will be carried out. 
Inhibitors of various signaling pathways may be used to determine ways to 
inhibit the actions evoked by this fragm ent
Using the work presented in this thesis as a model, more experiments may be 
carried ou t to determ ine whether integrin specific effects of matrix fragments 
occur in other systems such as a9 integrin and Tenascin C.
Future w ork will also aim at assessing the relationship between EGF, cell 
morphology and cell behaviour. More experiments such as indirect 
immunofluorescence in the presence and absence of EGF may be carried out 
looking in particular at the distribution of E-cadherin and the appearance of 
the actin cytoskeleton. M igration assays may be used to assess the motility of 
cells grown in m edium  containing EGF and m edium  devoid of i t  Time-lapse 
movies can provide further assessment of both morphology and motility of 
cells in the presence or absence of EGF. E-cadherin positive cell lines may be 
used as com parison to assess if (36 cells grown in the absence of EGF behave 
similarly.
APPENDIX 1
MEDIA, SOLUTIONS AND BUFFERS
A 1 Culture media and solutions 
A 1.1 Keratinocvte growth m edium
• 3 parts Dulbecco's modified Eagle's m edium  (DMEM) with sodium 
pyruvate and lOOOmg/L glucose (Gibco Invitrogen, Paisley, UK)
• 1 part nutrient mixture F-12 (HAM) with L-glutamine (Gibco 
Invitrogen)
• 10% Foetal calf serum  (PAA Laboratories, Yeovil, UK)
• lO ng/m l epiderm al growth factor (Sigma-Aldrich Company Ltd., 
Dorset, UK)
• 0 .5pg/m l hydrocortisone (Sigma-Aldrich Ltd.)
• 5 p g /m l Insulin (Sigma-Aldrich Ltd.)
• 1.8xl014M Adenine (Sigma-Aldrich Ltd.)
• 10-10M Cholera Toxin (Sigma-Aldrich Ltd.)
• lOOIU/ml Penicillin (Gibco Invitrogen)
• 100pg/m l Streptomycin (Gibco Invitrogen)
• 2 .5pg/m l Fungizone (Amphotericin B) (Gibco Invitrogen)
A 1.2 W ashing medium
PBS w ithout calcium and magnesium (Gibco Invitrogen)
A 1.3 Migration
Dulbecco's modified Eagle's m edium  (DMEM, Gibco Invitrogen) with sodium 
pyruvate and 1000m g/l glucose 
0.5% heat-inactivated BSA
A 1.4 Adhesion Assay 
Im M  CaCh 
0.23mM MgCh 
in PBS at pH  7.4
A 2 Immunohistochemistry
A 2.1 H arris' haematoxvlin 
lm g  of haematoxylin 
10ml of alcohol
20g of alum inium  potassium  sulphate 
0.5g of mercuric oxide 
8ml glacial acetic acid
A 2.2 Citrate buffer
0.02M Sodium  Citrate
3.4mM H Q
A 2.3 Tris Buffer Saline (TBS1 
1.4M N aQ  
0.05M Tris 
4.4mM H Q
adjust pH  to 7.4 w ith 1M H a
A 3 Im m unofluorescence 
A 3.1 Paraform aldehyde 4%
4g of paraform aldehyde 
50ml dHzO 
A pellet of NaOH
The solution was placed in a water-bath a t 60°C until dissolved, then 50ml 2X 
PBS was added.
A 3.2 Blocking solution (0.1/0.1 solution!
0.1% N aN 3 
0.1% BSA 
in PBS
A 4 Electrophoresis gels, solutions and  buffers 
A 4.1 Lysis buffer
1% SDS
lOmM Tris pH  7.4 
up  to 50ml w ith CIH2O
A 4.210% Acrvlamide separating gel
30% Acrylamide solution (Flowgen Bioscience Ltd., Nottingham, UK) 
1.5 M Tris-base pH  8.8 
10% SDS 
dH 20
10% am m onium  persulphate 
1 % TEMED
A 4.3 4% Acrvlamide stacking gel
30% Acrylamide solution
0.5 M Tris- HCL pH  6.8
10% SDS
dHzO
10% am m onium  persulphate 
5% TEMED
A 4.4 Sample buffer 
0.5M Tris pH  6.8 
50% glycerol
10% SDS
0.4% bromophenol blue 
dH  2O
A 4.5 Reducing sample buffer 
Sample buffer (above)
10% p-mercaptoethanol
A 4.6 Running buffer 
0.025M Tris, pH  8.3 
0.192M glycine 
0.1% SDS 
dl-bO
A 4.7 Transfer buffer 
0.025M Tris pH  8.3 
0.2M Glycine 
dH 20
A 4.8 W ashing Buffer (PBS-T) 
PBS
0.05% Tween 20
A 4.9 Blocking Solution 
5% skimmed milk pow der 
PBS-T
A 4.10 Coomassie Blue Stain 
30% Methanol 
10% Acetic acid 
2.5g Commassie Brilliant Blue 
Make up  to 500ml w ith dl-hO
A 4.11 Commassie Destain
30% M ethanol
10% Acetic a d d
Make u p  to 500ml w ith dIHhO
A 5 Zvm ographv buffers and  solutions
A 5.112% Gelatin-substrate Acrvlamide resolving gel
dl-hO
30% Acrylamide mix 
1.5M Tris (pH 8.8)
10% SDS 
10% Gelatin
10% A m m onium  persulphate
1% TEMED
A 5.2 Stacking gel 
dThO
30% Acrylamide mix 
0.5M Tris (pH 6.8)
10% SDS
10% Am m onium  persulfate 
5% TEMED
A 5.3 Running buffer 
0.25M Tris base 
0.52M Glycine 
1% SDS
dH 2 0  up  to 1 litre
A 5.4 Renaturing Buffer 
25% Triton X-100 
dH 20
A 5.5 Developing buffer 
1M Tris (pH 7.5)
5M NaCl
lM C aC k  
2.5% Triton X-100
Adjust to pH  7.5 with 0.1M HC1 and make up  to 200ml with dH20
A 6 Plasm inogen Activator Activity Assay 
A 6.1 T ris/N aC l buffer 
lOOmMNaCl 
50mM Tris pH  7.4
A 6.2 Tris/Tween80 buffer 
10 ml T ris/N aC l buffer 
10% Tween 80
APPENDIX 2
CHAPTER 3
Integrin profile (a5pi and avp6) of Cl cell line.
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Integrin profile of 3 cell lines (Figure 3.4).
mean Stdev
NHK a501 4.635 1.746554
crv/36 7.355 3.514321
C1 14.94 14.41084
1.14 0.622254
j VB6 2.69 1.088944
178.78 22.20315
Protein analysis of KGM and AFM-grown VB6 (Figure 3.11)
Means
of
samples
KGMVB6 0.363 0.425 0.087681
0.487
AFMVB6 0.375 0.3825 0.010607
0.39
Means of 
standards:
Omg/ml 0.14
2.5mg/ml 0.5
5mg/ml 0.613
7.5mg/ml 0.78
10mg/ml 0.9
y = 0.18x + 0.0466 
R2 = 0.94390.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
♦ Series 1 
 Linear (Seriesl)
FACS analysis of E-cadherin in KGM and AFM-grown VB6 and C l (Figure 3.11).
E-cad mean Stdev
C1-AFM 8.62 9.36 1.046518
10.1
VB6-
AFM 11.505 11.1125 0.555079
10.72
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VB6 grow n in various m edias w ithout serum:
A- SFM+ insulin B-SFM+EGF
C-SFM+ cholera toxin D-SFM+adenine
B- SFM+HC KGM
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C l grown in various medias: 
A- AFM+insulin B-AFM+EGF
C-AFM+cholera toxin D-AFM+adenine
E- AFM+HC
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Negative control of Figure 3.12
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Negative control of Figure 3.13
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CHAPTER 4
Proliferation assay of C l and VB6 seeded at different densities
C1 TO 
30,000
ID mean stdev
PFN 1.456 1.329 0.110177
1.272
1.259
120 1.7 1.75 0.050507
1.801
1.749
control 1.902 1.8885 0.019092
1.875
C1 T1 
30,000
ID mean st dev
pFN 1.328 1.467333 0.13706
1.602
1.472
120 1.175 1.275333 0.097172
1.282
1.369
control 1.072 1.355333 0.245895
1.481
1.513
VB6 TO 
30,000
ID mean stdev
pFN 0.862 0.893667 0.10321
1.009
0.81
120 1.55 1.444 0.094884
1.367
1.415
control 1.5 2.078333 0.502407
2.328
2.407
VB6 T1 
30,000
PFN 1.31 1.254667 0.107296
1.323
1.131
120 1.22 1.106 0.104747
1.014
1.084
control 1.119 1.114333 0.054151
1.166
1.058
C1 TO 
15,000
ID Mean stdev
pFN 0.702 0.836333 0.126429
0.854
0.953
120 0.905 0.925667 0.094707
1.029
0.843
control 0.759 0.7785 0.027577
0.798
C1 T1 
15,000
pFN 0.844 0.829667 0.036665
0.857
0.788
120 0.938 0.812667 0.12079
0.803
0.697
control 0.795 0.772667 0.104309
0.659
0.864
VB6T0
15,000
pFN 0.742 0.794 0.093552
0.902
0.738
120 1.05 0.985 0.101533
0.868
1.037
control 0.809 1.089 0.404692
0.905
1.553
VB6T1
15,000
pFN 0.611 0.603333 0.110699
0.489
0.71
120 0.65 0.792 0.149492
0.948
0.778
control 0.607 0.629 0.057263
0.694
0.586
Proliferation data of C l and VB6 on pFN, 120 FN fragment and control
Day1 Day2
C1: OD
Ceil
number Mean Stdev OD
Ceil
number Mean Stdev
pFN 0.876 125142.5 118666.3 7058.55 pFN 1.071 152999.6 183285.3 26259.69
0.838 119713.9 1.398 199713.9
0.778 111142.5 1.38 197142.5
120FNfrg 0.913 130428.2 133332.9 14575.86 120FNfrg 1.145 163571 161809.1 5707.734
0.843 120428.2 1.165 166428.2
1.044 149142.5 1.088 155428.2
control 0.894 127713.9 119428.2 7316.462 control 1.165 166428.2 163142.5 4510.758
0.797 113856.7 1.106 157999.6
0.817 116713.9 1.155 164999.6
Day3 Day4
OD
Cell
number Mean Stdev OD
Ceil
number Mean Stdev
pFN 1.145 163571 185428.2 23003.55 pFN 1.138 162571 156809.1 13991.49
1.466 209428.2 0.986 140856.7
1.283 183285.3 1.169 166999.6
120FNfrg 1.886 269428.2 270904.4 15837.4 120FNfrg 0.946 135142.5 141428.2 5473.498
2.012 287428.2 1.016 145142.5
1.791 255856.7 1.008 143999.6
control 1.886 269428.2 252904.4 15230.43 control 0.952 135999.6 134952 9614.332
1.676 239428.2 1.008 143999.6
1.749 249856.7 0.874 124856.7
Day1 Day2
VB6: OD
Cell
number Mean Stdev OD
Cell
number Mean Stdev
pFN 0.843 168599 169532.3 2722.744 pFN 1.757 351399 331332.3 34929.83
0.837 167399 1.758 351599
0.863 172599 1.455 290999
120FNfrg 0.891 178199 159599 17296.24 120FNfrg 1.809 361799 263799 86365.5
0.72 143999 1.154 230799
0.783 156599 0.994 198799
control 0.72 143999 138265.7 8259.136 control 0.918 183599 196799 18074.29
0.71 141999 1.087 217399
0.644 128799 0.947 189399
Day3 Day4
OD
Cell
number Mean Stdev OD
Cell
number Mean Stdev
pFN 1.437 287399 297265.7 73101.12 pFN 1.868 373599 347665.7 35505.68
1.148 229599 1.811 362199
1.874 374799 1.536 307199
i20FNfra 1.017 203399 298132.3 100530.7 120FNfrg 1.634 326799 372399 40292.93
2.018 403599 1.936 387199
1.437 287399 2.016 403199
control 1.211 242199 314799 72901.85 control 1.598 319599 329599 53110.83
1.571 314199 1.935 386999
1.94 387999 1.411 282199
Data of m igration assay on 120kDa FN fragment (Figure 4.3)
C1: pFN
C1:
120ffr.
C l:
control
VB6:
pFN
VB6:
120fr.
VB6:
control
Memb.1 Memb.1 Memb.1 Memb.1 Memb.1 Memb.1
16 23 13 107 153 7
41 30 8 85 138 2
45 24 10 82 125 8
15 21 16 63 136 0
19 15 5 52 130 3
22 25 12 74 161 9
13 14 3 85 159 6
34 26 11 69 148 9
20 18 3 74 119 5
Average: 25 21.77778 9 76.77778 141 5.444444
Memb.2 Memb.2 Memb.2 Memb.2 Memb.2 Memb.2
9 15 4 88 160 20
12 15 3 92 161 4
25 22 12 91 141 4
32 12 4 76 164 21
12 9 24 42 152 1
20 14 10 78 121 5
10 15 6 91 133 4
18 23 3 79 136 12
11 25 10 48 156 2
Average: 16.55556 16.66667 8.444444 76.11111 147.1111 8.111111
Memb.3 Memb.3 Memb.3 Memb.3 Memb.3 Memb.3
10 5 12 71 124 18
13 34 5 65 134 3
24 8 8 80 121 6
24 10 10 86 157 18
9 14 9 96 129 16
15 13 9 67 152 11
10 18 9 43 131 14
14 32 5 53 138 4
6 18 6 54 136 3
Average: 13 88889 16.88889 8.111111 68.33333 135.7778 10.33333
M igration assay data on 30kDa FN fragment (Figure 4.4)
C1: pFN Mean St Dev VB6: pFN Mean St Dev
27 25 2.645751 82 84.33333 4.041452
22 82
26 89
C1: 30fr. Mean St Dev VB6: 30fr. Mean St Dev
13 13.33333 0.57735 9 8.666667 2.516611
14 6
13 11
C1:
control Mean St Dev
VB6:
control Mean St Dev
2 4.666667 2.516611 1 3.333333 2.081666
5 5
7 4
M igration assay data of VB6 on 120FN fragment with various antibodies (Figure 4.5)
VB6:120frg VB6+P1D6 VB6+10D5 VB6+both VB6+lgG
Membl 89.77778 43 34 19.33333 69.11111
Memb2 94.22222 82.33333 30.77778 20 67.44444
Memb3 131.3333 66 20.44444 16 53.11111
Mean 105.1111 63.77778 28.40741 18.44444 63.22222
St Dev 22.81756 19.7606 7.081829 2.143033 8.796042
W ound assay data of C l and VB6 cells on wells coated w ith pFN, 120 FN fragment
and control (Figure 4.6)
TO Averages Mean Stdev
Cl pFN 310.4 103.2376
387 401 371 385 373 383.4
248 219 241 224 255 237.4
Cl 120frg 325 296 326 326 304 315.4 355.2667 37.80441
404 377 397 390 385 390.6
347 368 353 352 379 359.8
Cl control 382 384 392 391 377 385.2 397.8 10.96722
399 395 385 412 424 403
379 382 406 431 428 405.2
VB6 pFN 429 439 399 415 416 419.6 415.6 28.21347
422 406 392 307 401 385.6
424 430 438 460 456 441.6
VB6
120frg 440 418 420 445 415 427.6 412.9333 38.3637
391 363 344 397 352 369.4
440 435 445 450 439 441.8
VB6
control 383 361 384 379 373 376 397.4667 18.60036
409 403 409 412 411 408.8
447 395 404 390 402 407.6
T1
Cl pFN 97 163 147 151 177 147 177.0667 53.46862
210 263 244 238 239 238.8
174 200 121 103 129 145.4
Cl 120frg 190 209 220 219 228 213.2 193.7333 17.52864
193 164 203 185 199 188.8
205 174 175 175 167 179.2
Cl control 183 201 206 245 247 216.4 298.1333 84.96619
294 307 281 292 286 292
415 399 372 377 367 386
VB6 pFN 336.9 34.93107
349 355 370 342 392 361.6
264 293 328 327 349 312.2
VB6 120 
frg 335 325 336 315 268 315.8 295.9333 55.53245
228 212 262 219 245 233.2
341 357 320 350 326 338.8
VB6
control 235 234 255 247 236 241.4 248.2 18.36954
270 232 208 247 214 234.2
286 276 239 258 286 269
W ound assay data of C l and VB6 cells incubated w ith pFN, 120 FN fragment
control (Figure 4.7)
Mean St Dev
TO C1 pFN 324.8667 335.6667 341 333.8444 8.219579
C1 120frg 296.8667 291.4 334.1333 307.4667 23.2552
C1
control 312.6667 285.3333 368.8 322.2667 42.55339
VB6 pFN 394.8667 428.6 420.6667 414.7111 17.63763
VB6
120frg 342.4667 374.5333 405.0667 374.0222 31.30313
VB6
control 414.7111 374.0222 380.0778 389.6037 21.95345
T1 C1 pFN 242.2667 255.2667 251.8 249.7778 6.731793
C1120frg 200.7333 192.0667 225.9333 206.2444 17.5931
C1
control 206.8667 194.2 260.6 220.5556 35.25307
VB6 pFN 280.6 313.4 298.7333 297.5778 16.4305
VB6
120frg 225.9333 191.4 272.5333 229.9556 40.71594
VB6
control 281.0667 276.8667 273.0667 277 4.001666
T0-T1 C1 pFN 84.06667 7.475686
C1 120frg 101.2222 20.42415
C1
control 101.7111 38.90323
VB6 pFN 117.1333 17.03407
VB6
120frg 144.0667 36.00954
VB6
control 112.6037 12.97756
W ound assay data of VB6 and C l cell lines on wells coated with pFN, 30kDa FN
fragm ent and control
Mean St Dev
TO Cl pFN 394.9333 459.0667 333.6 395.867 62.7385
Cl 3 0 ^ 385.9333 381.6667 421.9333 396.511 22.1194
Cl
control 317.8 422.2 246.4667 328.822 883836
VB6pFN 386 337.6 390.2 371.267 29.2317
VB6 30frg 362.4 386.7333 299.8 349.644 44.8484
VB6
control 311.6667 342.4 330.8667 328311 15.5252
T1 Cl pFN 258 312.7333 280.8667 283.867 27.4897
Cl 30frx 236.9333 216.8667 298.7333 250.844 42.6694
Cl
control 186.3333 288.2667 110.6667 195.089 89.1231
VB6pFN 285.7333 247 300.8 277.844 27.754
VB6 30frg 268.6 290.6667 215.9333 258.4 383966
VB6
control 211.6 262.6667 231.1333 235.133 25.7672
TO T1 T0-T1
T0-T1 Cl pFN 395.8667 283.8667 112
Cl 30frg 396.5111 250.8444 145.667
Cl
control 328.8222 195.0889 133.733
VB6pFN 371.2667 277.8444 93.4222
VB6 30/rfz 349.6444 258.4 91.2444
VB6
control 328.3111 235.1333 93.1778
W ound assay data of VB6 and C l cell lines incubated with pFN, 30kDa FN fragment
and control
Mean St Dev
TO Cl-pFN 216.9778 18.16619 14.31492
Cl-30 364.7111 7313903 71.04762
Cl control 290.3556 13.09736 27.30234
VB6-pFN 358.8 21.38161 12.69406
VB6-30 332.6 22.65774 8.366069
VB6
control 343.9333 23.14054 20.13569
T1 Cl-pFN 89.77778 14.31492
Cl-30 183.6 71.04762
Cl control 116.7333 27.30234
VB6-pFN 233.9111 12.69406
VB6-30 194.4 8.366069
VB6
control 182.6444 20.13569
T0-T1 Cl-pFN 127.2 16.24056
Cl-120 132.7333 19.84057
Cl-30 181.1111 39.18076
control 173.6222 20.19985
VB6-pFN 124.8889 17.03784
VB6-120 136.5111 8.417903
VB6-30 138.2 15.51191
control 161.2889 21.63811
Adhesion assay data for C l and VB6 cells on wells coated with pFN, 120 FN 
fragm ent and control (Figure 4.8)
Cl: pFN Mean St Dev VB6: pFN Mean St Dev
0.519 0.538 0.016523 0.536 0.540667 0.004509
0.546 0.541
0.549 0.545
Cl:
120frag. Mean St Dev
VB6:
120frag. Mean St Dev
0.572 0.561333333 0.018475 0.555 0.519333 0.030892
0.54 0.501
0.572 0.502
Cl:
control Mean St Dev
VB6:
control Mean St Dev
0.459 0.456666667 0.004041 0.408 0.401 0.013
0.452 0.386
0.459 0.409
M igration assay data of NHK on pFN and 120kDa FN fragment (Figure 4.9)
membl memt>2 memb3 membl memb2 memb3
pFN 72 62 60 120frg 47 52 45
69 77 61 44 56 43
72 64 59 43 43 39
Average 71 67.66667 60 Average 44.66667 50.33333 42.33333
Mean 66.22222 Mean 45.77778
St Dev 5.640462 St Dev 4.114113
Proliferation data of NHK grow n on  pFN, 120 FN fragment and control (Figure 4.10)
Mean St Dev
pFN 120FNfrg control
Day1 46382.83 2231.778 48366.17 660.1767 51599.5 3127.699
Day2 54416.17 5140.606 60366.17 5913.191 48332.83 3493.327
Day3 69816.17 11081.67 71499.5 5935.487 64016.17 14900.7
Day4 64999.5 7210.583 69732.83 7681.363 75832.83 9978.769
CHAPTERS
Plasminogen activator cell density data
C1: VB6:
250,000 ng/ml Mean St Dev 250,000 ng/ml Mean St Dev
0.132 2.4377 2.359425 0.078275 0.146 3.53355 3.794467 0.966097
0.13 2.28115 0.163 4.864225
0.131 2.359425 0.139 2.985625
300,000 ng/ml Mean St Dev 300,000 ng/ml Mean St Dev
0.133 2.515975 2.28115 0.207096 0.141 3.142175 3.298725 0.341193
0.128 2.1246 0.148 3.6901
0.129 2.202875 0.14 3.0639
350,000 ng/ml Mean St Dev 350,000 ng/ml Mean St Dev
0.141 3.142175 2.90735 0.406729 0.161 4.707675 4.342392 0.352962
0.141 3.142175 0.156 4.3163
0.132 2.4377 0.152 4.0032
C1
250,000 2.359425 0.078275
C1
300,000 2.28115 0.207096
C1
350,000 2.90735 0.406729
VB6
250,000 3.794467 0.966097
VB6
300,000 3.298725 0.341193
VB6
350,000 4.342392 0.352962
Plasminogen activator assay data of C l and VB6 seeded on wells coated with pFN,
120kDa FN fragment and control (Figure 5.1)
COATING
VB6
pFN ng/ml Mean St Dev 120fr ng/ml Mean St Dev
0.857 25.01185 21.92401 2.695743 0.854 24.90968 22.5711 2.350015
0.711 20.03953 0.716 20.20981
0.731 20.72067 0.786 22.5938
plastic ng/ml Mean St Dev
0.667 18.54102 17.13333 4.756573
0.74 21.02718
0.47 11.83179
COATING
Cl
pFN ng/ml Mean St Dev 120fr ng/ml Mean St Dev
0.208 2.908856 3.385654 0.446653 0.197 2.534229 3.011027 0.825838
0.224 3.453768 0.239 3.964623
0.234 3.794338 0.197 2.534229
plastic ng/ml Mean St Dev
0.176 1.819032 2.738571 0.810957
0.221 3.351597
0.212 3.045084
Plasminogen activator assay data of C l and VB6 incubated with pFN, 120kDa FN 
fragm ent and control (Figure 5.2)
INCUBATING
VB6
pFN ng/ml Mean St Dev 120fr ng/ml Mean St Dev
0.579 15.544 16.71329 2.668716 0.688 19.25622 19.19945 6.453989
0.558 14.82881 0.875 25.62488
0.703 19.76707 0.496 12.71727
plastic ng/ml Mean St Dev
0.749 21.33369 18.24586 2.675011
0.615 16.77006
0.611 16.63383
INCUBATING
Cl
pFN ng/ml Mean St Dev 120ft ng/ml Mean St Dev
0.189 2.261773 3.499177 1.140952 0.265 4.850105 5.746939 1.494762
0.255 4.509535 0.267 4.918219
0.232 3.726224 0.342 7.472494
plastic ng/ml Mean St Dev
0.187 2.193659 3.624053 1.742907
0.214 3.113198
0.286 5.565302
Plasminogena activator assay data of C l and VB6 seeded on wells coated w ith pFN,
30kDa FN fragment and control (Figure 5.3)
C1 COATING VB6: COATING
PFn ng/ml Mean St Dev PFn ng/ml Mean St Dev
0.134 4.6537 4.2429 0.4108 0.167 8.0428 8.590533 0.699064
0.126 3.8321 0.17 8.3509
0.13 4.2429 0.18 9.3779
30 frag. ng/ml Mean St Dev 30 frag. ng/ml Mean St Dev
0.132 4.4483 4.2429 0.177882 0.157 7.0158 7.974333 1.660228
0.129 4.1402 0.185 9.8914
0.129 4.1402 0.157 7.0158
control ng/ml Mean St Dev control ng/ml Mean St Dev
0.143 5.578 4.722167 0.74295 0.158 7.1185 7.392367 0.388816
0.13 4.2429 0.165 7.8374
0.131 4.3456 0.159 7.2212
Mean St Dev
C1 PFN 4.2429 0.4108
30kDa FN 
frg 4.2429 0.177882
control 4.722167 0.74295
VB6 pFN 8.590533 0.699064
30kDa FN 
frg 7.974333 1.660228
control 7.392367 0.388816
Plasminogen activator assay data of C l and VB6 incubated with pFN, 30kDa FN
fragment and control (Figure 5.4)
C1: ADDING VB6: ADDING
PFn ng/ml Mean St Dev PFn ng/ml Mean St Dev
0.134 4.6537 4.790633 1.749923 0.146 5.8861 7.152733 1.468047
0.119 3.1132 0.155 6.8104
0.153 6.605 0.174 8.7617
30 frag. ng/ml Mean St Dev 30 frag. ng/ml Mean St Dev
0.129 4.1402 3.797867 0.313754 0.162 7.5293 6.673467 0.757013
0.123 3.524 0.148 6.0915
0.125 3.7294 0.151 6.3996
control ng/ml Mean St Dev control ng/ml Mean St Dev
0.145 5.7834 4.893333 0.797717 0.166 7.9401 8.111267 1.803353
0.13 4.2429 0.186 9.9941
0.134 4.6537 0.151 6.3996
Mean St Dev
C1 pFN 4.790633 1.749923
30kDa FN 
frg 3.797867 0.313754
control 4.893333 0.797717
VB6 pFN 7.152733 1.468047
30kDa FN
frg 6.673467 0.757013
control 8.111267 1.803353
Plasminogen activator assay data of C l and VB6 seeded in wells coated with pFN,
PHSRN peptide and control.
C1
incubating
VB6
incubating
pFn ng/ml Mean St Dev pFn ng/ml Mean St Dev
0.222 3.199 3.76742 1.48821 0.315 6.23712 6.4462 0.55082
0.212 2.87232 0.323 6.49846
0.201 2.51297 0.342 7.11916
0.247 4.0157 0.297 5.6491
0.315 6.23712 0.33 6.72714
PHRSN. ng/ml Mean St Dev PHSRN ng/ml Mean St Dev
0.365 7.87052 6.39393 1.86771 0.469 11.268 11.7711 0.40776
0.281 5.12641 0.473 11.3987
0.284 5.22441 0.495 12.1174
0.397 8.9159 0.49 11.954
0.272 4.8324 0.495 12.1174
control ng/ml Mean St Dev control ng/ml Mean St Dev
0.235 3.62368 3.92423 0.5325 0.469 11.268 11.9606 1.86314
0.239 3.75435 0.434 10.1246
0.228 3.395 0.562 14.3061
0.27 4.76706 0.447 10.5493
0.249 4.08103 0.539 13.5548
C1 pFN 3.76742 1.48821
peptide 6.39393 1.86771
control 3.92423 0.5325
VB6 pFN 6.4462 0.55082
peptide 11.7711 0.40776
control 11.9606 1.86314
Plasm inogen activator assay data of C l and VB6 incubated with pFN, PHSRN
peptide and control.
ADDING:
Cl
ADDING:
VB6
pP'N ng/ml Mean St Dev pFN ng/ml Mean St Dev
0.662 19.81193 18.32279 1.679236 0.688 20.88742 22.07322 3.86189
0.634 18.65371 0.641 18.94327
0.582 16.50273 0.821 26.38897
PHSRN ng/ml Mean St Dev PHSRN ng/ml Mean St Dev
0.669 20.10149 20.915 0.806706 0.718 22.12837 24.72058 2.717001
0.708 21.71472 0.775 24.48618
0.689 20.92879 0.849 27.54719
control ng/ml Mean St Dev control ng/ml Mean St Dev
0.653 19.43965 21.63199 3.410794 0.731 22.66612 23.12113 0.788109
0.664 19.89466 0.764 24.03116
0.801 25.56167 0.731 22.66612
ADDING:
VB6pFN 22.07322 3.86189
VB6 Frg. 24.72058 2.717001
VB6
contr. 23.12113 0.788109
Cl pFN 18.32279 1.679236
Cl Frg. 20.915 0.806706
Cl contr. 21.63199 3.410794
Zymogram data of supernatants of VB6 and C l cells exposed to pFN, 120kDa FN
fragment and control (Figure 5.6 and 5.8)
MMP2 Mean /100000 Stdev MMP9 Mean /100000 Stdev
Cl pFN 98 108.6667 630.2667 13.61372 Cl pFN 853 685.3333 3974.933 148.3723
104 632
124 571
Cl 120 239 258.3333 1291.667 20.59935 Cl 120 679 761.3333 3806.667 88.54566
280 855
256 750
Cl control 159 179.6667 844.4333 32.39341 Cl control 643 639 3003.3 138.0435
163 499
217 775
VB6pFN 385 411.3333 2138.933 32.7465 VB6 pFN 1230 1169.667 6082.267 52.30997
401 1137
448 1142
VB6 120 1125 981.6667 5301 228.6314 VB6 120 1712 1727 9325.8 23.43075
1102 1754
718 1715
VB6
control 413 373.3333 1978.667 36.22614
VB6
control 1106 1125 5962.5 50.26927
342 1087
365 1182
Zymogram data of supernatants of NHK cells exposed to pFN, 120kDa FN fragment
and control (Figure 5.10)
Gel1
Lanel 2 3 4 5 6 7 8 9
396 664 656 625 633 635 533 544 412
768 971 1149 1147 1024 1055 1036 1035 963
Gel2
Lanel 2 3 4 5 6 7 8 9
406 712 622 626 656 675 521 583 454
777 1090 1125 1169 1070 1071 1075 1044 949
MMP-9 pFN 120frg control MMP-2 pFN 120frg control
664 633 544 971 1024 1035
712 656 583 1090 1070 1044
656 635 412 1149 1055 963
622 675 454 1125 1071 949
625 533 396 1147 1036 768
626 521 406 1169 1075 777
Mean 650.8333 608.8333 465.8333 1108.5 1055.167 922.6667
St Dev 34.80469 65.32508 79.16165 72.53068 20.98968 122.3122
M igration assay of C l and VB6 on 120kDa FN fragment and on the fragment plus
TIMP-1 (Figure 6.1)
C1 120
C1
120+TIMP VB6 120 VB6120+TIMP
membl Membl membl membl
12 18 44 14
3 18 61 10
7 21 70 23
4 9 63 13
15 3 69 8
4 9 85 14
11 12 67 13
6 8 46 8
7 11 55 8
7.666667 12.11111 62.22222 12.33333
memb2 Memb2 memb2 memb2
6 7 32 18
8 10 12 12
9 9 22 9
7 4 16 13
14 8 27 10
8 4 22 16
4 9 20 19
10 5 18 15
3 7 6 12
7.666667 7 19.44444 13.77778
memb3 Memb3 memb3 memb3
10 8 27 42
10 7 8 25
9 2 29 19
6 4 29 18
8 6 31 6
9 4 13 25
10 3 23 13
6 10 16 7
19 7 23 9
9.666667 5.666667 22.11111 18.22222
Migration assay of C l and VB6 on 120kDa FN fragment and on the fragment plus
Roche inhibitor (Figure 6.2)
C1 120 
frg.
C1
120+RI
VB6
120frg
VB6
120+RI
memb 1 memb 1 memb 1 memb 1
5 6 106 116
34 32 140 148
73 33 138 128
53 25 116 102
21 9 104 101
51 31 124 102
21 27 76 81
43 19 119 117
11 18 96 100
34.66667 22.22222 113.2222 110.5556
memb2 memb2 memb2 memb2
11 4 108 28
25 12 131 77
44 15 98 107
20 5 112 52
12 9 92 48
55 10 102 56
24 7 80 21
27 16 91 97
20 3 74 40
26.44444 9 98.66667 58.44444
memb3 memb3 memb3 memb3
10 5 152 22
32 5 157 88
42 37 139 93
41 10 86 46
11 5 75 11
37 10 94 44
10 5 80 29
17 2 151 63
15 5 110 13
23.88889 9.333333 116 45.44444
Zymogram data of VB6 cells plated on pFN, 120 FN fragment and control and in the
presence of S203580 inhibitor and U-0126 (Figures 6.10 and 6.11).
Gel1 SB203580
pFN++ pFN++ pFN— pFN— 120frg++ 120firg++ 120frg— 120frg—
565 666 1058 1064 618 484 554 773
pro-
MMP-9
173 119 155 166 251 264 249 277
pro-
MMP-2
617 803 692 852 672 612 615 626 MMP-2
Gel2 U-0126
pFN++ pFN++ pFN— pFN— 120firg++ 120firg++ 120frg— 120frg-
182 209 748 764 198 225 633 617
pro-
MMP-9
18 27 225 194 295 569 321 258
pro-
MMP-2
205 193 745 749 669 543 581 619 MMP-2
835 782
Gel3 SB203580 U-0126
contr++ contr++ contr- contr- contr++ Contr++ contr- contr-
616 535 1051 1044 245 201 1063 890
pro-
MMP-9
297 283 279 269 332 276 308 461
pro-
MMP-2
1009 859 802 910 673 681 883 2345 MMP-2
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